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Abstract 
 
Human malaria is caused by protozoan parasites of the genus Plasmodium and is a major 
contributor to global morbidity and mortality. Plasmodium falciparum is the most virulent of five 
Plasmodium species that infect human. As in the other species, P. falciparum develops and 
proliferates in the nutrient-rich anucleated erythrocyte, consuming glucose for energy and 
metabolizing haemoglobin as a source of amino acids. In the erythrocyte, the parasite is also able 
to avoid some of the host’s immune responses during infection. To support the high growth rate of 
the parasite during infection, glucose consumption in the infected erythrocytes increases by up to 
75-fold in comparison with uninfected erythrocytes. As a consequence, a high amount of the 2-
oxoaldehyde methylglyoxal, a toxic by-product of glycolysis, is spontaneously formed in the 
parasite. Methylglyoxal reacts with and damages nucleic acids and proteins leading to the 
formation of the so-called advanced glycation end-products (AGE) in the cell. Glyoxalases 1 and 
2 (Glo1 and Glo2) of the ubiquitous glyoxalase system catalyze the glutathione-dependent 
detoxification of methylglyoxal and other 2-oxoaldehydes to non-toxic 2-hydroxycarboxylic 
acids.  
In the P. falciparum infected erythrocyte, two functional glyoxalase systems operate; one in the 
cytosol of the erythrocyte (hGlo1 and hGlo2) and the other in the parasite cytosol (PfGlo1 and 
PfcGlo2). In addition to the cytosolic enzymes, P. falciparum also encodes a functional 
apicoplast-targeted Glo2 enzyme (PftGlo2), and an inactive Glo1-like protein (PfGILP) that also 
carries an apicoplast-targeting sequence. On account of the detoxification role the glyoxalase 
system plays during Plasmodium infection, there has been a long-standing hypothesis that 
inhibition or knockout of the Plasmodium glyoxalase-encoding genes would lead to an 
accumulation of methylglyoxal (2-oxoaldehydes) in the host-parasite unit and result in parasite 
death. And so, the glyoxalase system(s) of the host-parasite unit could be targeted for antimalarial 
drug development.  
This thesis investigated the relevance of the glyoxalase system to the blood-stage parasite survival 
by generating clonal PFGLO1 and PFcGLO2 knockout lines of P. falciparum 3D7 strain using 
the CRISPR-Cas9 system. SYBR green-based growth assays of the knockout clones showed that 
the 3D7Δglo1 knockout clones had an increased susceptibility to the external 2-oxoaldehyde 
glyoxal compared with the 3D7Δcglo2 knockout clone and the 3D7 wild-type strain. Western blot 
analyses also supported the accumulation of selected modified proteins in 3D7Δglo1 and 
3D7Δcglo2 knockout strains in comparison with the 3D7 wild-type strain. The 3D7Δglo1 and 
3D7Δcglo2 knockout lines were, however, viable and showed no significant morphological or 
growth phenotype under standard growth conditions. Furthermore, the lack of PfcGlo2, but not 
PfGlo1, resulted in increased gametocyte induction and gametocytogenesis in the knockout lines. 
PfGlo1 and PfcGlo2 are therefore dispensable during asexual blood-stage development and the 
loss of PfcGlo2 may actually contribute to the transmission of the malaria parasite. The results 
show that PfGlo1 and PfcGlo2 are non-essential and most likely not suitable for targeted 
antimalarial drug development.  
Several attempts to generate knockout clonal lines for the apicoplast targeted glyoxalase enzymes 
were unsuccessful. Transfectants resistant to both positive and negative selection were obtained in 
three knockout trials but were all confirmed to be false-positive transgenic parasites. The most 
vii 
 
probable explanation for this outcome is an off-target or unwanted integration of the positive 
selectable marker into the parasite genome. Methodological limitations, rather than the 
essentiality of the two enzymes, are therefore most likely the cause of the negative knockout 
results.  
The thesis also investigated the relevance of the hGlo1 enzyme to the survival of the parasite in 
the host-parasite unit using three tight-binding Glo1 inhibitors. Inhibitor treatments of uninfected 
erythrocytes showed an extremely slow inactivation of the host cell glyoxalase. Esteriﬁcation did 
not confer improved pharmacokinetics nor increased the potency of the inhibitors. Inhibition of 
the erythrocyte Glo1 enzyme did not affect parasite development in the host cell, pointing to a 
potential dispensability of the host cell enzyme for parasite survival in the host-parasite unit.  
Finally, as a way of addressing the relevance of the so-called oxidative stress on parasite 
development, the thesis investigated the effects of the prooxidant H2O2 and the so-called 
antioxidants NAc, ascorbate, and DTT on the survival of P. falciparum 3D7 strain. IC50 values for 
the redox agents were determined for ring-stage synchronized parasites using a SYBR green-
based growth assay. An IC50 value of 78 mM for H2O2 revealed the compound as a very poor 
prooxidant in parasite culture. The host-parasite unit appears to be very robust against challenges 
with H2O2 and parasite killing required extremely high concentrations with implications for host 
defence mechanisms. The reductants NAc, ascorbate and DTT also had antiproliferative instead of 
growth-promoting effects with IC50 values around 16, 4 and 0.3 mM, respectively. Taken 
together, the host-parasite unit appears more tolerant to high levels of H2O2, ascorbate and NAc, 
but is more susceptible to DTT. The inhibitory effect of the so-called antioxidants has 
implications for clinical trials and studies on oxidative stress. 
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Zusammenfassung 
 
Menschliche Malaria wird von Protozoenparasiten der Gattung Plasmodium verursacht und gehört 
zu den Hauptursachen der globalen Morbidität und Sterblichkeit. Plasmodium falciparum ist der 
virulenteste der fünf humanpathogenen Malaria-Arten. Wie auch die anderen Arten, entwickelt 
und vermehrt P. falciparum sich in nährstoffreichen zellkernlosen Erythrozyten, nutzt Glucose als 
Energiequelle und metabolisiert Hämoglobin als Aminosäurequelle. Innerhalb der roten 
Blutkörperchen ist der Parasit teilweise auch in der Lage, sich der Immunantwort des Wirts 
während der Infektion zu entziehen. Als Folge der hohen Wachstumsrate des Parasiten während 
der Infektion erhöht sich der Glucoseverbrauch des infizierten Erythrozyten um das bis zu 75-
fache im Vergleich zu nicht infizierten Erythrozyten. Als eine Konsequenz entsteht spontan eine 
große Menge des 2-Oxoaldehyds Methylglyoxal als toxisches Nebenprodukt der Glykolyse im 
Parasiten. Glyoxalase 1 und 2 (Glo1 und Glo2) des ubiquitären Glyoxalase Systems katalisieren 
die glutathionabhängige Entgiftung von Methylglyoxal und anderen 2-Oxoaldehyden zu 
ungiftigen 2-Hydroxycarbonsäuren. In mit P. falciparum infizierten Erythrozyten sind zwei 
funktionale Glyoxalase-Systeme tätig; eins im Zytosol des Erythrozyten (hGlo1 und hGlo2) und 
das andere im Zytosol des Parasiten (PfGlo1 und PfcGlo2). Zusätzlich zu den zytosolischen 
Enzymen, codiert P. falciparum für das funktionelle Glo2 Enzym (PftGlo2) mit Apicoplast-
Zielsequenz und ein inaktives Glo1-ähnliches Protein (PfGILP), welches auch eine Apicoplast-
Zielsequenz aufweist. Aufgrund der Entgiftungsrolle des Glyoxalase-Systems während einer 
Plasmodien-Infektion, gibt es seit langer Zeit die Hypothese, dass eine Inhibition oder das 
Ausschalten der Glyoxalasen in Plasmodium zu einer Anreicherung von 2-Oxoaldehyden in der 
Wirt-Parasiten-Einheit führen könnte, welche zum Tod des Parasiten führen könnte. Deshalb 
könnte das Glyoxalase-System der Wirt-Parasiten-Einheit ein mögliches Angriffsziel für die 
Entwicklung von Antimalariawirkstoffen sein. In dieser Arbeit wurde die Relevanz des 
Glyoxalase-Systems für das Überleben des Parasiten in Blutzellstadien untersucht, indem klonale 
P. falciparum 3D7 Knockout Stämme für PFGLO1 und PFcGLO2 mithilfe der CRISPR-Cas9 
Technologie erzeugt wurden. Auf SYBR-green basierte Wachstumsstudien der Knockout Klone 
zeigten, dass die 3D7Δglo1 Knockout Klone eine erhöhte Empfindlichkeit gegenüber externem 
Glyoxal im Vergleich zu den 3D7Δcglo2 Knockout Klonen und Wildtypparasiten zeigten.Western 
Blot Untersuchungen zeigten ebenfalls eine Anreicherung von ausgewählten modifizierten 
Proteinen in den 3D7Δglo1 and 3D7Δcglo2 Knockout Stämmen im Vergleich zum 3D7 
Wildtypstamm. Allerdings waren alle klonalen Linien des 3D7Δglo1 und 3D7Δcglo2 Knockouts 
überlebensfähig und zeigten keinen signifikanten morphologischen oder Wachstums-Phänotyp 
unter Standardwachstumsbedingungen. Außerdem resultierte das Fehlen von PfcGlo2, aber nicht 
das Fehlen von PfGlo1, überraschenderweise in einer erhöhten Gametozytenbildung in den 
Knockout-Stämmen. PfGlo1 und PfcGlo2 sind daher entbehrlich während der asexuellen 
Blutstadienentwicklung und der Verlust von PfcGlo2 könnte tatsächlich zur Übertragung des 
Malariaparasiten beitragen. Die Daten zeigen, dass PfGlo1 und PfcGlo2 nicht essentiell und daher 
höchstwahrscheinlich nicht für die zielgerichtete Entwicklung eines Malariamedikaments geeignet 
sind. Mehrere Versuche klonale Knockout-Stämme für die Glyoxalasen des Apicoplasten zu 
generieren waren erfolglos. Transfektanten, welche sowohl gegen positive als auch negative 
Selektion resistent waren, wurden in drei Knockout-Versuchen erzielt, wurden aber alle als falsch 
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positive transgene Parasiten identifiziert. Die wahrscheinlichste Erklärung für dieses Ergebnis 
sind unerwünschte Integrationen des positiven Selektionsmarkers in das Genom des Parasiten. 
Methodische Einschränkungen sind daher plausibler als Erklärung der negativen Knockout 
Ergebnisse als dass die zwei Enzyme essentiell sind. In diesem Projekt wurde außerdem die 
Relevanz des hGlo1 Enzyms auf das Überleben des Parasiten in der Wirt-Parsiten-Einheit 
untersucht, indem zwei Inhibitoren der Glyoxalase Glo1 und deren Carboxyl tert-butyl Ester 
Derivate eingesetzt wurden. Die Behandlung nicht-infizierter Erythrozyten mit Inhibitor zeigte 
eine extrem langsame Inaktivierung der Wirtszellglyoxalase. Eine Veresterung führte weder zu 
verbesserter Pharmocokinetik noch erhöhte sich die Wirksamkeit des Inhibitors. Die Inhibition 
des Glo1-Enzyms des Erythrozyten hatte keinen Effekt auf die Entwicklung des Parasiten was auf 
eine mögliche Entbehrlichkeit des Wirtsenzyms für das Überleben des Parasiten in der Wirt-
Parasiten-Einheit deutet. Schließlich wurde in dieser Arbeit der Effekt des Prooxidants H2O2 und 
der  sogenannten Antioxidantien NAc, Ascorbat und DTT auf das Überleben des 3D7-Stamms 
von P. falciparum untersucht, um Einblicke in die Relevanz von sogenanntem oxidativem Stress 
auf die Entwicklung des Parasiten zu gewinnen. Für die Redoxmittel wurden IC50-Werte mit 
synchronisierten Parasiten im Ringstadium mittels SYBR-green basierten Wachstumskurven 
bestimmt. Ein IC50-Wert von 78 mM für H2O2 zeigte, dass H2O2 ein sehr schwaches Prooxidants 
in der Parasitenkultur ist. Die Einheit aus Wirt und Parasit scheint sehr widerstandsfähig gegen 
die Behandlung mit H2O2 zu sein, und um den Parasiten zu töten waren extrem hohe 
Konzentrationen nötig, die auch Auswirkungen auf den Verteidigungsmechanismus des Wirts 
haben. Die Reduktionsmittel NAc, Ascorbat und DTT hatten auch einen antiproliferativen anstatt 
wachstumsfördernden Effekt mit entsprechenden IC50-Werten von 12, 3 und 0,4 mM. 
Zusammengefasst scheint die Einheit aus Wirt und Parasit toleranter gegen hohe Konzentrationen 
von H2O2, Ascorbat und NAc zu sein, aber anfälliger für DTT. Der hemmende Effekt der 
sogenannten Antioxidantien hat Auswirkungen für klinische Versuche und Studien zum 
oxidativen Stress. 
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1. INTRODUCTION 
 
           
1.1.  Introduction to malaria and Plasmodium species 
 
1.1.1.  Malaria – a brief history 
 
Malaria is a major parasitic protozoan disease of humans that is transmitted by the bite of an 
infected female Anopheles mosquito (Cox, 2010; Neghina et al., 2010; Webb, 2010; 
Kamareddine, 2012). The characteristic symptoms of the disease are rhythmic or fluctuating 
fevers, splenomegaly, malaise and anaemia, which when untreated can lead to a varied box of 
life-threatening complications such as coma (Webb, 2010; Clark et al., 2004; Bartoloni & 
Zammarchi, 2012). The incubation period of the disease, depending on the parasite 
transmitted and status of the host, ranges from seven to fifteen days after a bite by the infected 
vector (Bartoloni & Zammarchi, 2012; WHO, 2017a; Kim et al., 2013). 
Earliest description of human infections similar to malaria can be traced back to Chinese 
documents around 2700 BC, and to records of Mesopotamia and ancient Egypt around 1500 
BC. Hippocrates (400 BC), the famous early Greek physician, and his compatriots observed 
and associated poor health, fevers and enlarged spleens (which are malaria-like symptoms) to 
individuals living in marshy places (Cox, 2010; Neghina et al., 2010). Thus, for over 2500 
years after this initial association, miasmas emanating from swampy areas were connected 
with and thought to be the cause of poor health among people living in these areas. The name 
malaria was later adopted to describe the condition of poor health common among people 
living in marshy areas and is widely believed to have originated from the Italian phrase 
mal’aria, which means spoiled air (Cox, 2010; Neghina et al., 2010; Webb, 2010). With the 
advancement of science, the miasma theory lost favour and in 1880, C. L. Alphonse Laveran 
discovered that the actual causative agent of malaria was a parasitic protozoan (Cox, 2010). 
The role of the Anopheles mosquito as the transmitting vector of Plasmodium parasites was 
subsequently discovered by Ronald Ross seventeen (17) years later (Cox, 2010; Neghina et 
al., 2010). Despite the long history and many years of dedicated scientific research to control 
Plasmodium infection, malaria still remains one of the most dilapidating diseases in the 
history of mankind. In the past, malaria had played its part in the rise and decline of nations 
and helped model civilizations (Neghina et al., 2010; Webb, 2010). At the present, although 
some important advances have been made, malaria still remains a huge socio-economic and 
health issue in many countries especially those in sub-Saharan Africa (Neghina et al., 2010; 
Webb, 2010; WHO, 2016b). An estimated 297 million new malaria cases were recorded in 
2015 with 731 000 fatal consequences (Vos et al., 2016; Wang et al., 2016). Of all deaths 
caused by malaria globally, 90% occur in sub-Saharan Africa alone. The reason for this is 
partly due to the warm and conducive climate for vector development in this region, and also 
as a result of the continuous sustenance of the disease by poverty (Webb, 2010; WHO, 2016b; 
Vos et al., 2016; WHO, 2016a; Cruz et al., 2013). High rates of malaria infections are also 
recorded in the South-East Asian, the Eastern Mediterranean and the South American regions 
of the world (WHO, 2017a; Cruz et al., 2013). A majority of malaria deaths are among 
pregnant women and children under the age of five (5) years (Webb, 2010; WHO, 2016b; Vos 
et al., 2016; WHO, 2016a). In 2015 alone, 2.9 billion US$ was allocated to the fight against 
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malaria but the disease remains endemic in 91 countries putting nearly half of the world’s 
population at risk (WHO, 2017a, 2016a). An upsurge in malaria research and the sequencing 
of the complete Plasmodium falciparum genome has helped in better understanding the 
transmission of the disease and the biology of the parasite. By combined efforts of donors, 
researchers and governments, the European region has been declared free of locally acquired 
malaria infections for many years now (WHO, 2016b). Several other countries are winning 
their fight against malaria and are now declared non-endemic to the disease (Figure 1.1) 
(WHO, 2016b). Nevertheless, the eradication and total control of the disease through new 
drugs and potential vaccines have so far been daunting to achieve in many parts of the world. 
Considering the challenging effects of drug resistance, climate change, global warming and a 
rise in international travel, chances are high for malaria transmission to increase or re-emerge 
even in areas now known to be free of the disease (Lee et al., 2013; Mirski et al., 2011; Bai et 
al., 2013; Hurd et al., 2005). 
 
 
 
 
Figure 1.1. Global status of malaria in 2016. Taken from (WHO, 2017b). 
  
 
1.1.2.  Insect vector 
 
To date, over 460 mosquito species of the genus Anopheles have been identified, 100 of 
which can act as potential vectors and definitive hosts for the malaria parasite (Webb, 2010; 
Kamareddine, 2012; Arrow et al., 2004; Pimenta et al., 2015; Sinka et al., 2012). Of these 
potential vectors, 30-40 species are of major public health importance because of the 
efficiency of which they transmit the disease worldwide (Kamareddine, 2012; Arrow et al., 
2004; Sinka et al., 2012). In sub-Saharan Africa where most of the world’s transmission of 
the disease occurs, A. gambiae, A. arabiensis and A. funestus co-dominate as vectors (Arrow 
et al., 2004; Sinka et al., 2012). Only female Anopheles mosquitoes are known to transmit 
Plasmodium species to their intermediate host (Webb, 2010; Kamareddine, 2012; Arrow et 
al., 2004). The life cycle of the mosquito comprises four developmental stages; egg, larva, 
pupa and adult (imago) (Arrow et al., 2004). The adult female mosquito would normally bite 
an intermediate host for a blood meal. The mosquito needs blood to nurture its developing 
eggs to maturity. In the process of feeding, the mosquito may also suck up parasite 
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gametocytes from an infected host along with the blood, or introduce parasite sporozoites 
from its salivary glands into the host skin (WHO, 2017a; Arrow et al., 2004; Pimenta et al., 
2015). Apart from a human intermediate host, Anopheles mosquitoes also feed on other 
warm-blooded animal such as other mammals. If the mosquito species prefers a human host, 
the species is termed anthropophagic or anthropophilic. If the species prefers to feed on other 
animals, it is termed zoophagic or zoophilic (Arrow et al., 2004). The A. gambiae mosquito is 
particularly responsible for most cases of malaria in the African region because of its strong 
preference for human blood and its relatively longer lifespan compared to other species 
(WHO, 2017a; Arrow et al., 2004; Cohuet et al., 2010). 
 
 
1.1.3.  Plasmodium species – the complex life cycle 
 
Malaria parasites are Apicomplexan protozoan belonging to the genus Plasmodium (Rich & 
Ayala, 2006). Presently, there are over 200 known Plasmodium species that infect and cause 
malaria in various vertebrates including humans, other mammals, birds and reptiles (Rich & 
Ayala, 2006; Perkins & Austin, 2009; Ramasamy, 2014; Lee & Vythilingam, 2013). 
Plasmodium species that infect other animals may be transmitted by different insect species 
apart from mosquitoes (or Anopheles species) (Sinden, 2002). In humans, malaria is caused 
by five morphologically and immunologically different Plasmodium species: P. falciparum, 
P. vivax, P. malariae, and P. ovale and the relatively new zoonotic addition, P. knowlesi 
(Cox, 2010; WHO, 2017a; Tuteja, 2007). The classical symptoms of the disease mentioned 
above are common to all five Plasmodium species even though their severity, manifestations 
and possible relapse pattern vary from species to species (Tuteja, 2007). 
P. falciparum is the most virulent human malaria parasite, accounting for more than 85% of 
global malaria cases and deaths (Lee & Vythilingam, 2013; Tuteja, 2007; Rich & Ayala, 
2006). It is also the most prevalent Plasmodium species in the African region (WHO, 2017a; 
Bousema & Drakeley, 2011). Infections by this species are characterized by severe anemia 
caused by high parasitemia during infection and the fever presented is usually asynchronous. 
P. falciparum infections often lead to fatal organ complications and cerebral malaria in 
children (Tuteja, 2007). 
P. vivax causes a milder disease and is rarely fatal, similar to disease caused by P. malariae 
and P. ovale. This species is the most geographically widespread and infections cause the so-
called mild tertian malaria which is characterized by mild anemia and fevers that reoccur 
every 48 hours (Antinori et al., 2012). P. vivax typically forms hypnozoites, intrahepatic-stage 
parasites that are responsible for the relapse of the disease after many months of dormancy 
(Tuteja, 2007; Antinori et al., 2012; Bousema & Drakeley, 2011). P. vivax is prevalent 
throughout the tropics especially in South-East Asia and South America (WHO, 2017a; Rich 
& Ayala, 2006; Lee & Vythilingam, 2013; Bousema & Drakeley, 2011; Antinori et al., 2012). 
P. ovale is the least common malaria parasite and is present mostly in West Africa. Two 
morphologically indistinguishable genetic haplotypes (or species) of this species, P. ovale 
curtisi and P. ovale wallikeri, occur in sympatry (Tuteja, 2007; Antinori et al., 2012). 
Infections by this species cause mild and easily managed disease. Similar to P. vivax 
infection, P. ovale can also cause relapses in malaria infections from dormant hypnozoites 
(Antinori et al., 2012; Tuteja, 2007). 
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P. malariae is responsible for only a low frequency of human infections although it also has a 
worldwide distribution (Tuteja, 2007). The species is responsible for the so-called quartan 
malaria, the hallmark of which is 72 hours recurring fevers with a low grade parasitemia and 
mild anemia (Antinori et al., 2012; Rosenberg, 2008). Even though no hypnozoites have been 
identified for this parasite, blood-stage parasites are capable of surviving at low parasitemia 
for long periods with the potential of causing disease recrudescence (Antinori et al., 2012; 
Lee & Vythilingam, 2013; Garcia, 2010). 
P. knowlesi is naturally a simian malaria parasite infecting macaque monkeys but has now 
been confirmed to have the potential of crossing over the species barrier to infect humans 
(Lee & Vythilingam, 2013; Galinski & Barnwell, 2009; Cox-Singh et al., 2008; White, 2008). 
Records show that, due to the morphological similarities this species shares with P. malariae, 
many P. knowlesi infections have in the past been misdiagnosed as P. malariae infections. 
However, as a result of improved and more sensitive diagnostic methods, the species is now 
gaining grounds especially in South-East Asia as an important cause of malaria in humans 
(Lee & Vythilingam, 2013; Galinski & Barnwell, 2009; Cox-Singh et al., 2008). Human 
infections of P. knowlesi are characterized by severe anemia. Disease manifectations caused 
by high level parasitemia have also been reported similar to the infection pattern of P. 
falciparum (White, 2008; Antinori et al., 2012). Renal failure, jaundice and fevers that recur 
every 24 hr (quotidian cycle) are common symptoms of P. knowlesi infection (White, 2008). 
The life cycle of the malaria parasite is complex and involves several tissues and 
developmental forms in two different hosts, vertebrate and invertebrate (Fig.1.2). Asexual 
development takes places in the vertebrate (intermediate) host (Fig 1.3) while sexual 
development occurs in the invertebrate (definitive) host (Spinello, 2012). All the five human 
malaria parasites undergo a similar life cycle, sharing a human vertebrate host and female 
Anopheles as the intermediate host. In the exemplified life cycle of P. falciparum, the 
endogenous asexual phase, also called schizogony, commences when infective sporozoites 
(1n=haploid) from the salivary gland of the Anopheles mosquito are injected into the skin of 
the human host during a blood meal. The sporozoites will later find their way from the skin 
dermis through the capillaries into the host blood circulation (Antinori et al., 2012). 
Sporozoites are usually delivered along with mosquito saliva containing anticoagulant and 
anti-inflammatory enzymes. These components of saliva ensure an easy flowing blood meal 
and minimize the pain-reaction caused by the bite (Lee & Vythilingam, 2013; Tuteja, 2007; 
Garcia, 2010; Garcia et al., 2006). Around 20-200 sporozoites are transmitted in an infected 
bite, most of which are rapidly cleared from the blood circulation by the host’s immune 
system leaving only a few to find and infect the liver hepatocytes (Rosenberg, 2008; Garcia et 
al., 2006). The sporozoites are able to glide at considerable speed through the skin and into 
the blood vessels enabled by specialized parasite proteins (Boucher et al., 2018). Exhibiting 
the same gliding motility, the sporozoites are then able to traverse liver sinusoidal cell layer 
including the kuffer cells, some hepatocytes and finally invade the hepatocytes to establish an 
infection (Boucher et al., 2018). Parasite proteins such as thrombospondin-related anonymous 
protein (TRAP) are necessary for parasite active mobility and invasion, using power 
generated by an actomysin motor (Boucher et al., 2018). At the liver-stage, each sporozoite 
penetrates one hepatocyte, differentiates into a liver trophozoite (1n) and undergoes a phase of 
asexual reproduction (mitosis) called pre-erythrocytic schizogony resulting in the production 
of tissue schizonts (1n) containing up to 30000 (compared to about 10000 in P. vivax or P. 
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ovale) uninucleated motile merozoites (1n) (Lee & Vythilingam, 2013; Antinori et al., 2012; 
Rosenberg, 2008; Collins & Jeffery, 2007).  
 
 
 
 
Figure 1.2. The life cycle of P. falciparum. Infectious sporozoites are injected into the human skin through 
the bite of an infected female Anopheles mosquito. Sporozoites travel through the blood stream to the liver and 
develop in the liver hepatocytes to produce tens of thousands of merozoites (extra-erythrocytic schizogony) by 
asexual reproduction. Merozoites are released into the blood and invade red blood cells, undergoing repeated 
rounds of asexual multiplication (intra-erythrocytic schizogony). Parasite development in the erythrocyte 
progresses through ring, trophozoite- and schizont-stages in one cycle. After a number of cycles, a small 
proportion (<10%) of merozoites leave the regular asexual cycle and instead begin to develop into the male and 
female sexual gametocytes. After 10–12 days of gametocytosis, gametocytes are taken up by the mosquito 
during a blood meal to begin the sexual phase of the life cycle in the mid-gut. Gametocytes differentiate into 
male and female gametes and undergo fertilization to form a zygote, which develops through the motile 
ookinete-stage to form the oocyst. Upon rupture of the oocyst, haploid sporozoites are released which migrate to 
the salivary glands and can then be transmitted to humans. Taken and modified from (Josling & Llinás, 2015). 
 
 
At maturity, the liver schizont together with the infected hepatocyte burst to release packages 
of merozoites known as merosomes (through the liver) into the host blood stream (Tuteja, 
2007; Gerald et al., 2011). On average, the pre-erythrocytic phase takes between 5-6 days in 
P. falciparum (8-9 days for P. ovale, P. vivax and P. knowlesi, and 13-16 days for P. 
malariae) (Lee & Vythilingam, 2013; Antinori et al., 2012; Gerald et al., 2011). In the rodent 
Plasmodium species P. berghei, merosomes, which are membrane-bound vesicles derived 
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from hepatocyte material including membranes, are thought to protect the merozoites from 
the liver immune kupffer cells while they migrate to the host blood stream (Tuteja, 2007; 
Gerald et al., 2011; Sturm et al., 2006). The merosomes therefore ensure the direct release of 
the merozoites into the host bloodstream. In P. ovale and P. vivax liver infections, not all 
sporozoites that infect the hepatocytes maintain the developmental pattern and immediately 
progress through schizonts into merozoites. Some sporozoites remain dormant in the liver 
cells for a year or more in the form of hypnozoites. Hypnozoites are later reactivated to 
resume development and are responsible for malaria relapse many months after an apparent 
initial cure of the disease (Lee & Vythilingam, 2013; Tuteja, 2007; Antinori et al., 2012). 
Liver-stage infection is asymptomatic and produces no disease condition (Derbyshire et al., 
2011).  
 
 
 
 
Figure 1.3. Developmental stages of P. falciparum in the erythrocyte. The P. falciparum merozoite attaches 
to, reorientates and invades erythrocytes, and develops a parasitophorous vacuole (PV) around itself. Once 
inside, the parasite develops through the ring- (0–24 hours), trophozoite- (24–36 hours) and schizont-stages (40–
48 hours). In the mature forms of the parasite (>24 h), different proteins are produced and exported to the 
cytoplasm and membrane of the erythrocyte, causing knobby deformations to appear on the erythrocyte 
membrane. The infected erythrocyte and the mature schizont rupture after approximately 48 hours, releasing 16–
32 daughter merozoites into the blood. Hemozoin crystals, formed as a result of hemoglobin degradation, are 
deposited in a digestive vacuole. PfEMP1, Plasmodium falciparum erythrocyte membrane protein 1. Taken and 
modified from (Maier et al., 2009). 
 
 
While in the bloodstream, merosomes burst to release hepatic merozoites which use a 
complex acto-myosin motor system to invade erythrocytes and initiate a second phase of 
asexual multiplication called erythrocytic schizogony (Cox, 2010; Tuteja, 2007; Antinori et 
al., 2012; Collins & Jeffery, 2007; Gerald et al., 2011). Erythrocyte invasion is complex and 
involves several steps; i) initial recognition and reversible attachment of merozoite to the 
erythrocyte plasma membrane, ii) merozoite reorientation, irreversible attachment and the 
formation of the parasitophorous vacuole stimulated by the release of signal compounds from 
the rhoptry and the microneme organelles, iii) invagination of erythrocyte membrane around 
the attached merozoite with the loss of the merozoite surface coat and iv) closing of the 
parasitophorous vacuole and the erythrocyte membrane around the merozoite (Cowman et al., 
2012; Tuteja, 2007; Garcia et al., 2006). P. falciparum merozoites can infect all age classes of 
erythrocytes but P. vivax and P. ovale preferentially infect the recticulocytes while P. 
malariae prefers old erythrocytes (Kerlin & Gatton, 2013; McQueen & McKenzie, 2004 ). 
Once inside the erythrocyte, the merozoite goes through several different stages of 
development that includes the early trophozoite or ring (1n), trophozoite (1n) and the schizont 
(1n) (Figure 1.3). The early trophozoite is uninucleated and has a characteristic ring-shaped 
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morphology. A ring is small in size and grows by feeding on hemoglobin from the normal 
size host erythrocyte. The ring later differentiates into a mature trophozoite by increased 
metabolism through the glycolytic consumption of large amounts of imported glucose. The 
ring also digests hemoglobin into constituent amino acids for protein synthesis and detoxifies 
free heme as hemozoin (Tuteja, 2007; Garcia, 2010; Mohandas & An, 2012). The mature 
trophozoite subsequently increases in size and also modifies the infected erythrocyte in many 
ways. Consequently, the infected erythrocyte loses its normal discoid shape and its membrane 
becomes more rigid and more permeable. Numerous proteins are produced by the parasite at 
this stage and are exported into the cytoplasm or to the surface of the infected erythrocyte. 
Some of these proteins such as the P. falciparum erythrocyte membrane protein 1 (PfEMP1) 
and the knob-associated histidine-rich protein (KAHRP) play a central role in parasite 
cytoadhesion (Tuteja, 2007; Mohandas & An, 2012; Ganguly et al., 2015). The changes to the 
host cell also facilitate the survival of the parasite and are responsible for the severity of 
malaria (Mohandas & An, 2012). The period from the infective mosquito bite to the 
appearance of the first trophozoites in the erythrocytes is called the prepatent period. This 
period is about 8-25 days in P. falciparum (8-27 days in P. vivax, 15 days in P. malariae, 9-
17 days in P. ovale and 15-30 in P. knowlesi) (Tuteja, 2007; Antinori et al., 2012). 
The trophozoite-stage is completed with four to five asynchronous nuclear divisions without 
cytokinesis resulting in the formation of the multinucleate plasmodial schizont (Lee & 
Vythilingam, 2013; Tuteja, 2007; Gerald et al., 2011). Between 8 and 36 new merozoites are 
produced per erythrocytic schizont. The merozoites are released into the bloodstream upon 
rupture of the schizont and the infected red blood cell, thus completing one cycle of 
erythrocytic schizogony (Cox, 2010; Tuteja, 2007; Antinori et al., 2012; Gerald et al., 2011). 
The characteristic symptoms of malaria are all associated with blood-stage development of 
the parasite with the classical fevers coinciding with the release of merozoites (Cox, 2010; 
Lee & Vythilingam, 2013; Tuteja, 2007; Antinori et al., 2012; Gerald et al., 2011). Although 
some of the merozoites are arrested by the host immune system, others survive and 
immediately invade new healthy erythrocytes to begin another cycle of erythrocytic 
schizogony (Garcia, 2010; Garcia et al., 2006; Gerald et al., 2011). The time needed to 
complete one cycle of erythrocytic schizogony is 48 hours in P. falciparum, P. ovale and P. 
vivax (72 hours in P. malariae and 24 hours in P. knowlesi) (Lee & Vythilingam, 2013; 
Tuteja, 2007). After several recurrent cycles of erythrocytic schizogony, some young 
merozoites are stimulated to differentiate into micro- or macrogametocytes (haploid male and 
female sexual forms respectively) after infecting a new erythrocyte in a process called 
gametocytogenesis (Cox, 2010; Lee & Vythilingam, 2013; Antinori et al., 2012; Garcia, 
2010). The gametocytes are highly specialized cells, the development of which is controlled 
by over 250 genes (Bousema & Drakeley, 2011). Five morphologically distinguishable 
gametocyte developmental stages occur during which the cell enlarges and elongates to 
occupy most of the space in the infected erythrocyte (Fig 1.4). These stages, I-V, take 
between 10-12 days to complete development. Stage I gametocytes are indistinguishable from 
asexual trophozoites. At stage II, gametocytes begin to elongate and are D-shaped. The 
subpellicullar-microtubules, which are involved in gametocyte structure and motility, also 
begin to form. Stage III gametocytes are further elongated with rounded ends and also contain 
proliferating mitochondria and Golgi bodies. Stage IV gametocytes are more elongated but 
now have pointed ends. In the macrogametocytes, osmiophillic bodies and an extensive rough 
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endoplasmic reticulum develop. In stage V, gametocytes assume their characteristic crescent 
form and the macrogametocytes which are more elongated and curved with a prominent 
nucleolus are distinguishable from the thicker microgametocytes. Only the mature stage V 
gametocytes circulate in peripheral blood of the host because erythrocytes that contain the 
early-stage gametocytes are usually found sequestered (Dixon et al., 2012; Bousema & 
Drakeley, 2011; Schwank et al., 2010; Josling & Llinás, 2015 ). During P. falciparum 
infection, mostly ring stages and stage V gametocytes are normally detected in the peripheral 
blood circulatory system of the host.  
 
 
 
Figure 1.4. Schematic representation of the morphological stages of P. falciparum gametocytes. P. 
falciparum gametocytes develop through five distinct morphological stages. Early gametocytes (stage I and IIa) 
are almost indistinguishable from trophozoites. In stage IIb–III the parasite elongates and adopts a D-shaped 
morphology with rounded ends. Stage IV gametocytes are further elongated, have pointed ends adopting a 
curvature to conform to the confines of the host erythrocyte which is now reduced to a thin layer around the 
parasite. Hemozoin crystals are seen to be dispersed in the microgametocyte. In the final-stage (V), the ends of 
the gametocyte become more rounded. Hemozoin crystals in the macrogametocyte are seen to be partly 
aggregated. N, nucleus, Hz, hemozoin crystals, MC, the Maurer’s clefts, Ob, osmiophilic bodies, IMC, inner 
membrane complex, and MT, microtubules. A male-stage IV and a female-stage V gametocyte are depicted. 
Taken and modified from (Dixon et al., 2012). 
 
 
The highly modified erythrocytes that host the mature trophozoite or schizonts are sticky and 
adhere to the endothelial lining of the small capillaries of organs. Adhered erythrocytes 
normally do not appear in the host’s blood circulation (Cox, 2010; Bousema & Drakeley, 
2011; Garcia, 2010).  
Male and female gametocytes are ingested when the female Anopheles mosquito takes a 
blood meal from an infected person, an activity that is vital to the transmission of malaria 
(Cox, 2010; Lee & Vythilingam, 2013; Tuteja, 2007; Collins & Jeffery, 2007). Both physical 
(heat, moisture and visual) and chemical cues (characteristic odours) play an important role 
leading the mosquito to the vertebrate host (Antinori et al., 2012). It takes between 2-3 days 
for circulating mature gametocytes (still in the erythrocyte) to be infectious to the mosquito. If 
infectious gametocytes are not injested by the mosquito, they only survive for a short period 
(5-12 hours) in blood circulation before they are degraded (Tuteja, 2007; Bousema & 
Drakeley, 2011; Antinori et al., 2012). In the lumen of the mosquito mid-gut, the 
macrogametocytes are released by the rupture of the erythrocyte and mature within 5 min into 
mature macrogametes (1n) wheras the microgametocytes go through the process of 
exflagellation. This process involves division of the nucleus (20 min) of the microgametocyte 
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and subsequent differentiation of the cell into 8 haploid flagellated microgametes (1n) which 
are liberated from the erythrocyte to fertilize the macrogametes (Cox, 2010; Antinori et al., 
2012; Garcia, 2010; Garcia et al., 2006; Collins & Jeffery, 2007). Still in the lumen of midgut, 
a microgamete penetrates a macrogamete in the process of fertilization to form the diploid 
zygote (2n) which subsequently differentiates into a motile ookinete. Several parallel 
fertilizations can occur concurrently depending on the number of gamete pairs available in the 
midgut of the mosquito (Garcia et al., 2006). The ookinete (4n) is invasive and undergoes 
meiosis to generate a cell with four haploid nuclei (Garcia et al., 2006; Gerald et al., 2011). 
The okinete then actively penetrates the wall of the midgut, positioned under the basal 
membrane of the midgut and differentiates into the oocyst. An oocyst is capable of 
undergoing sporogony, generating thousands of sporozoites (1n) through the process of 
mitosis (Lee & Vythilingam, 2013; Garcia et al., 2006; Collins & Jeffery, 2007; Gerald et al., 
2011). When the mature oocyst ruptures, about a quarter of the sporozoites are released into 
the hemocoel of the mosquito. From there, they are able to actively migrate through the 
haemolymph to the salivary glands (Collins & Jeffery, 2007). After about a day of maturation 
in the salivary glands, sporozoites become highly infective to the vertebrate host when the 
mosquito takes the next blood meal (Antinori et al., 2012). Depending on the ambient 
temperature, mature sporozoites normally appear in the mosquito’s salivary glands between 
10-18 days after the mosquito acquired the male and female gametocytes. The mosquito 
remains infectious for 1-2 months (Lee & Vythilingam, 2013; Tuteja, 2007; Collins & Jeffery, 
2007). 
 
 
1.1.4. Morphology and metabolism of P. falciparum 
 
Morphologically, Plasmodium species share a variety of traits with other unicellular 
eukaryotes of the phylum Apicomplexa. Examples of these traits include an apicoplast and an 
apical complex comprising rhoptries, micronemes and the apical polar rings. The rhoptries 
and micronemes secrete proteins that are crucial in mobility, adhesion, host cell invasion and 
the formation of the parasitophorous vacuole. The apical polar rings are one of several 
microtubule-organizing centers in the parasites (Garcia et al., 2006; Morrissette & Sibley, 
2002; Aikawa, 1977; Preisera et al., 2000). The Plasmodium parasite is also surrounded by 
the pellicle, which is a structure formed from the plasma membrane and the closely apposed 
internal membrane complex. The pellicle is closely associated with a cytoskeletal complex 
made up of actin, myosin, microtubules and other filament-like elements (Morrissette & 
Sibley, 2002; Olshina et al., 2015; Cowman et al., 2012). Even though the different 
developmental stages of Plasmodium share morphological traits, substantial structural 
differences, both in architecture and number of organelles, are clearly evident when the 
erythrocytic, exoerythrocytic and mosquito stages of the malaria parasite are compared. These 
differences are an indication of the adaptation of the parasite to the different environments in 
which the parasite resides and develops. For instance, the food vacuole is very evident in the 
ring- and trophozoite-stages and inconspicuous in the sporozoite- and merozoite-stages 
(Dooren et al., 2005; Aikawa, 1977). The components of the apical complex along with the 
inner pelical membrane and associated subpellicular microtubules also disappear in the young 
trophozoites only to reappear later in the schizont-stage (Aikawa, 1977; Dooren et al., 2005). 
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Of particular interest is the apicoplast, a multi-membrane bound non-photosynthetic plastid 
organelle which is found in very close association with the mitochondrion in Plasmodium 
species (Sherman, 1979; Dooren et al., 2006; Aikawa, 1971; Lim & McFadden, 2010 ). This 
essential organelle is semi-autonomous with its own genome and gene expression machinery 
comparable to plant chloroplasts. It, however, also imports numerous nuclear-encoded 
proteins, which are usually tagged with apicoplast-targeting signal sequences (Tuteja, 2007; 
Sherman, 1979; Bannister et al., 2000; Gardner et al., 2002 ). The apicoplast is thought to be 
derived from a red algae that entered into a secondary endosymbiotic partnership with another 
eukaryotic host cell (Bannister et al., 2000; Lim & McFadden, 2010; Waller & McFadden, 
2005). Though the exact cellular role of the apicoplast is still elusive, it is known to play an 
important role in the synthesis of lipids, heme and isoprenoids (Yeh & DeRisi, 2011). Along 
with many other parasite biochemical pathways, the plant-like metabolic processes of this 
organelle are (potential) targets for drug discovery against malaria (Lim & McFadden, 2010; 
Bannister et al., 2000; Jomaa et al., 1999).  
Biochemical studies of the malaria parasite have generally been restricted to the asexual blood 
stages of the life cycle because of the challenges of obtaining workable quantities of material 
from the other stages. As mentioned above, the merozoite differentiates into the trophozoite, 
which lies in the parasitophorous vacuole and begins to ingest host cell cytoplasm through its 
cystostomes. As it develops, the trophozoite produces and exports different types of proteins 
into the parasitophorous vacuole and into the cytosol of the erythrocyte. Some of these 
proteins are incorporated into the host plasma membrane making it more permeable to sugars 
and other solutes from the external environment (Mohandas & An, 2012; Sherman, 1979; 
Bannister & Mitchel, 2003; Staines et al., 2006). The intraerythrocytic stages of the parasite 
possess no glycogen or other polysaccharides and therefore depend on the simple sugars for 
growth and development (Sherman, 1979). Glucose and sometimes maltose were identified to 
support parasite growth in cell culture (Sherman, 1979). Early biochemical studies on 
carbohydrate utilization by the malaria parasite established that, glucose is the preferred 
source of energy and that parasitized erythrocytes consume up to 75 times more glucose 
compared to uninfected erythrocytes (Sherman, 1979; Dooren et al., 2006 ). It is now known 
that the sustenance of this high glucose demand by parasitized erythrocytes is through an 
increased permeability of the infected erythrocyte, which is itself a consequence of parasite 
infection (Sherman, 1979). The transport of glucose from the cytosol of the infected 
erythrocyte into the cytosol of the parasite is mediated by the parasite hexose transporter 
(PfHT) (Tjhin et al., 2013). Once inside the cell, mechanisms for the breakdown of glucose in 
Plasmodium species are similar to those used by many other eukaryotic organisms. Among 
other products, it has also been established that the major end-product of glucose metabolism 
in the parasite is L-lactate, which is produced by the anaerobic glycolytic pathway (Sherman, 
1979; Dooren et al., 2006; Ginsburg, 2016). This pathway involves the initial hydrolysis of 
glucose to pyruvate and then the anaerobic conversion of pyruvate to lactate (Ginsburg, 2016; 
Gardner et al., 2002). All genes involved in the glycolytic pathway have been identified in the 
malaria parasite and it has also been suggested that, the parasite’s glycolytic pathway is up to 
100 times more active than that of the host erythrocyte (Gardner et al., 2002; Ginsburg, 
2016). Intense glycolytic metabolism leads to the spontaneous formation of toxic 
methylglyoxal from the 3-carbon intermediates of glycolysis. To prevent the accumulation of 
this toxic intermediate, methylglyoxal is detoxified by the glyoxalase system of the parasite 
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leading to the production of D-lactate. In most eukaryotes, pyruvate from glycolysis is 
metabolized aerobically in the mitochondria to store energy in the form of ATP, using 
tricarboxylic acid (TCA) cycle and a protein gradient that is formed by the electron protein 
chain. However, only an unconventional TCA cycle occurs in the asexual stages of 
Plasmodium species. Even though all the enzymes of the conventional TCA pathway have 
been identified in the parasite, the localization of major enzymes in the cell suggests that the 
pathway found in the parasite may play an alternative role rather than its usual role of full 
oxidation of products of glycolysis (Ke et al., 2015; Gardner et al., 2002). Pyruvate 
dehydrogenase and malate dehydrogenase identified in the parasite seem to localize to the 
apicoplast and cytosol respectively instead of the mitochondrion (Gardner et al., 2002).  
Malaria parasites acquire amino acids for protein bio-synthesis by degrading hemoglobin in 
the parasite food vacuole. The P. falciparum food vacuole is a lysosome-like organelle that is 
formed by fusion of small vesicles that pinched off from the base of the cystostome at the 
ring-stage of parasite development (Lamarque et al., 2008; Dluzewski et al., 2008). The 
parasite is able to degrade about 60 – 80% of the hemoglobin contained in the host cytoplasm 
as it grows. Proteolysis of hemoglobin in the parasite leads to the release of heme and amino 
acids (Francis et al., 1997; Liu et al., 2006). While the amino acids are incorporated into 
proteins or probably used in energy metabolism, the heme group is not metabolized further 
and is polymerized into hemozoin crystals and safely stored within the food vacuole (Liu et 
al., 2006; Francis et al., 1997; Garcia, 2010). Hemoglobin metabolism is an essential 
catabolic process in Plasmodium parasites and involves two families of proteolytic enzymes 
called plasmepsins and falcipains in P. falciparum (Liu et al., 2006). Most of the amino acid 
requirements of Plasmodium parasites are acquired from hemoglobin catabolism since the 
parasites have a limited ability to produce amino acids de novo. However, hemoglobin is a 
poor source of methionine, cysteine, glutamine and glutamate and contains no isoleucine at 
all. Thus, for normal healthy growth, the parasite also depends on exogenous acquisition of 
amino acids, most especially isoleucine, for growth (Liu et al., 2006; Francis et al., 1997). It 
has been reported that more amino acids are generated from breakdown of hemoglobin than is 
needed for protein synthesis, resulting in the diffusion of some hemoglobin-derived amino 
acids into the host cell. This phenomenon has lead to the suggestion that the catabolism of 
hemoglobin may also play other functions in the cell (Liu et al., 2006; Francis et al., 1997; 
Mohandas & An, 2012; Tuteja, 2007; Garcia, 2010).  
 
 
1.2. Control of malaria 
 
1.2.1. Prevention of transmission 
 
Control of malaria can be viewed as an attempt to control the proliferation of the malaria 
parasite in two moving organisms, man and mosquito. Humans and mosquitoes can host, 
multiply and distribute the parasite from place to place. Depending on the target of the 
specific method, malaria transmission can be controlled by employing one or a combination 
of three strategies: i) preventing the mosquitoes from biting humans through vector control, ii) 
administration of drugs to suppress infection and prevent disease through chemoprevention or 
chemoprophylaxis and, iii) the administration of antimalarial vaccines.  
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For vector control, the insecticide dichlorodiphenyltrichloroethane (DDT) has been a front-
liner in the fight against the mosquito vector for decades. DDT was very instrumental in 
achieving eradication of malaria in the United States of America and was also very important 
in the fight against the disease in many parts of the globe. For the past decades, however, 
there have been increasing reports of the emergence of DDT-resistant Anopheles mosquitoes 
in many parts of the world (WHO, 2006). The insecticide has also been implicated as a danger 
to both humans and environment (Bouwman et al., 2011). As a result, DDT use has been 
banned in many countries and is now only restrictedly used to fight malaria in regions where 
mosquitoes are still sensitive (Corin & Weaver, 2005; WHO, 2009). The use (sleeping under) 
of insecticide-treated mosquito nets (ITNs) is currently one common, easy and inexpensive 
way to prevent humans from being bitten by mosquitoes in many malaria endemic regions of 
the world. Among several insecticides used to impregnate mosquito nets, permethrin solution 
(or other pyrethroids) is now one of the most effective insecticides used in the field today 
(Garcia, 2010; Hemingway et al., 2016; WHO, 2016b). Indoor residual spraying (IRS) is the 
third strategy employed to control the insect vector. It involves the application of the effective 
insecticide on walls and surfaces of indoor human-dwelling places where mosquitoes would 
normally rest (WHO, 2016b; Hemingway et al., 2016; Shiff, 2002). As effective as ITNs and 
IRS may be, these methods only target mosquitoes that bite and settle indoors. Outdoor 
resting mosquito populations are also very significant in the transmission and spread of 
malaria. Personal protection by wearing protective cloths and application of mosquito 
repellent creams while outdoor is an effective method of controlling this form of parasite 
transmission (Gueye et al., 2016). Environmental management that involves drainage of water 
bodies that breed mosquitoes and improved house design to keep mosquitoes out are also 
important malaria control methods. In some places, larval source-management strategies have 
been adopted. The introduction of larvivorous fish or larviciding agents into water bodies to 
kill mosquito larvae has been a supplementary vector control strategy in many areas (WHO, 
2016b; Gueye et al., 2016).  
Strategies to suppress malaria infection and prevent disease before or after exposure to the 
parasite include the example of intermittent preventive treatment of malaria. This strategy is 
especially effective for vulnerable groups (pregnant women and children under 5 years) living 
in malaria endemic regions and has helped to reduce malaria cases and severity in these 
groups (WHO, 2016b). Chemoprevention also involves the monthly administration of malaria 
treatment to coincide with peaks of transmission. The target group is again children under 5 
years and pregnant women, and it has been shown to be an effective in some parts of Africa 
(Hemingway et al., 2016). A similar approach is chemoprophylaxis which involves the 
administration of antimalarial drugs every week or everyday to individuals traveling from 
malaria free zones to endemic areas. Mefloquine, doxycycline, atovaquone-proguanil 
(Malarone), and to some extent primaquine are principle drugs that are regularly used as 
chemoprophylaxis for P. falciparum malaria (Schwartz, 2012).  
The development of an effective vaccine against malaria has been a major research focus for 
many years. But so far, no vaccine candidate with a high efficacy has yet been produced 
(Hemingway et al., 2016; Shiff, 2002). RTS,S, a pre-erythrocytic vaccine that should prevent 
clinical P. falciparum malaria in children, is the only vaccine to successfully pass through 
phase III of clinical trials. The trials, performed on African children, however, protected only 
50% and 30% of children between 5-17 months and infants respectively from clinical malaria 
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(Hemingway et al., 2016; WHO, 2016b). Clearly, a better vaccine or a combination of 
vaccines (which ideally should produce a much higher efficacy, protect against disease and 
prevent transmission of several Plasmodium species) is vital to control malaria. 
 
 
1.2.2. Diagnosis of malaria 
 
Malaria is diagnosed using a combination of results from physical examinations, patient 
records and laboratory diagnostic tests (Amir et al., 2018). Detection of parasites in Giemsa-
stained thin and thick peripheral blood smears using light microscopy has been the gold 
standard for laboratory diagnosis of human malaria for many years (Garcia, 2010; Lee & 
Vythilingam, 2013). Performing blood smears is simple, rapid and cheap. For a thick blood 
smear, a drop of blood is dried, fixed in methanol and stained on a glass-slide for microscopic 
examination. Thin blood smears involve spreading the drop evenly on the slide before 
staining. Blood samples for blood smears are preferable taken when the patient’s temperature 
is rising using a syringe and needle or a finger prick. Stained smears are examined under the 
oil immersion 100x objective (Amir et al., 2018). Thick blood smears are about 10 times 
more sensitive than thin blood smears (Warhurst & Williams, 1996). For quicker malaria 
diagnosis, the rapid diagnostic kits (RDTs) are an excellent choice for testing persons already 
showing signs of malaria and therefore may have high levels of blood parasitemia. The 
development of molecular tools such as polymerase chain reaction (PCR) has revolutionized 
malaria diagnosis and is now routinely used to confirm diagnoses. Traditional PCR detects 
many more cases of malaria than do thick blood films, especially in situations when samples 
are of low parasitemia (Garcia, 2010; Tavares et al., 2011; Amir et al., 2018). PCR diagnosis 
is also very valuable in the determination of specific Plasmodium species causing infection 
especially in cases of mixed infections (Garcia, 2010; Lee & Vythilingam, 2013). Nested PCR 
and real-time PCR are improvements on traditional PCR methods and are more superior in 
both specificity and sensitivity compared to traditional PCR-based malaria diagnostic 
methods (Lee & Vythilingam, 2013; Amir et al., 2018).  
 
 
1.2.3. Drug treatment of malaria 
 
Malaria is generally curable if the appropriate treatment is given adequately and promptly, but 
most antimalarials are effective only against blood-stage parasites (Derbyshire et al., 2011; 
Winstanley, 2000; Cui et al., 2015). Quinine and its dextroisomer quinidine have been for a 
long time the first widely used antimalarial drug especially for the treatment of severe malaria 
(Petersen et al., 2011; Dronamraju & Arese, 2006; Sinha et al., 2014; Bloland, 2001). These 
drugs are extracted from the bark of the Andean Cinchona tree originally found in South 
America (Petersen et al., 2011; Tuteja, 2007; Dronamraju & Arese, 2006; Sinha et al., 2014). 
Chloroquine is the first synthetic quinoline-based drug that was found to be very effective in 
the treatment of malaria.  Following its first synthesises in 1934, chloroquine became one of 
the most commonly used and most affordable therapeutic drug against malaria for many 
decades (Petersen et al., 2011; Dronamraju & Arese, 2006). The drug acts by capping 
developing hemozoin crystals, preventing further biocrystallization of heme. It can also bind 
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heme forming a cytotoxic complex. This complex, together with toxic heme meioties, 
eventually causes autodigestion of the parasite (Petersen et al., 2011; Hempelmann, 2007). 
Unfortunately, extensive drug use has over time lead to the development and spread of 
resistance to quinine and chloroquine in P. falciparum and P. vivax, limiting the use of the 
drugs in many parts of the world (Tuteja, 2007; Winstanley, 2000; Sinha et al., 2014). 
Chloroquine is, however, still one of the few drugs used for the treatment of P. vivax malaria 
in some parts of Asia (Cui et al., 2015; Petersen et al., 2011). Other synthetic quinoline-based 
drugs that have been very effective in the treatment of malaria include amodiaquine, 
mefloquine and primaquine. These drugs all act as inhibitors of heme biocrystallization 
(Hempelmann, 2007; Petersen et al., 2011). Primaquine is one of the very few drugs that are 
also potent against liver-stage infection and is principally used to prevent disease relapse in P. 
ovale and P. vivax infections (Cui et al., 2015).  
Another group of drugs that are effective in the treatment of malaria include the antifolate 
drugs (Dronamraju & Arese, 2006). Pyrimethamine, proguanil, proguanil and sulfa drugs 
such as sulfadoxine and dapsone belong to this class of drugs. Antifolate drugs are generally 
dihydrofolate reductase (DHFR) or dihydropteroate synthase (DHPS) inhibitors that affect 
DNA and RNA synthesis during cell replication (Petersen et al., 2011; Dronamraju & Arese, 
2006; Garcia, 2010; Bloland, 2001). These drugs are usually administered in combinations to 
increase the synergistic effect on the parasite and also overcome the problem of drug 
resistances (Dronamraju & Arese, 2006). For instance, Fansidar is a combination drug of 
pyrimethamine and sulfadoxine.   
Lumefantrine, an aryl alcohol, and atovaquone, a hydroxynaphthoquinone, are also effectively 
used in Africa for the treatment of chloroquine-resistant malaria. Atovaquone acts through the 
inhibition of the electron transport chain at the cytochrome bc1 complex that indirectly affects 
pyrimidine bio-synthesis and replication (Painter et al., 2007; Petersen et al., 2011). To 
reduce the development of parasite resistance, atovaquone is now administered in 
combination with proguanil in an antimalarial called Malarone (Bloland, 2001; Garcia, 2010).  
Artemisinin and its analogues are currently compounds used as the first-line of defense 
against acute uncomplicated malaria around the world (Petersen et al., 2011; Dronamraju & 
Arese, 2006; Cui et al., 2015). These compounds that also include artesunate and artemether 
are extremely effective and rapid acting antimalarial drugs. They are also nontoxic and appear 
to be safe for treating all classes of patients (Dronamraju & Arese, 2006). Artemisinin is 
obtained from the Chinese herb Artemisia annua, which has been used for centuries for the 
treatment of parasitic diseases (Petersen et al., 2011; Dronamraju & Arese, 2006). The target 
of artemisinin is still not confirmed. This drug or its derivatives are commonly used in 
combination with several slow acting antimalarial drugs such as Fansidar, lumifantrine or 
mefloquine for the treatment of malaria in many parts of the world (Petersen et al., 2011; 
Tuteja, 2007; Derbyshire et al., 2011). ACTs are also first line drugs for the treatment of P. 
vivax malaria and for the treatment of chloroquine-resistant, chloroquine-sensitive or 
multidrug-resistant P. falciparum malaria (Dronamraju & Arese, 2006). Tetracyclin and its 
derivative doxycycline are a group of antibiotics that have proven to be very potent against 
Plasmodium species. These compounds can act as apicoplast protein synthesis inhibitors and 
are therefore potent as malaria chemoprophylaxis. They are also effective in combination with 
quinine for the treatment of severe malaria (Garcia, 2010; Bloland, 2001; Cui et al., 2015). In 
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the Sahel subregion of Africa, Fansidar and its combination with amodiaquine are advocated 
for use as an intermittent preventive therapy against malaria (Cui et al., 2015). 
 
 
1.2.4.  Emergence and implications of drug resistance 
 
Drug-resistant strains of Plasmodium species have over the last decades become prevalent for 
almost all of the few potent antimalarial drugs currently used (Petersen et al., 2011; Cui et al., 
2015; Winstanley, 2000). Among the five human Plasmodium species, antimalarial drug 
resistance has been registered mainly in P. falciparum, P. vivax and P. malariae (Dronamraju 
& Arese, 2006; Sinha et al., 2014). P. falciparum has developed resistance to almost all 
effective malaria drugs currently in use, even though the geographical distribution of 
resistance to each drug varies (Bloland, 2001). Quinine-resistant parasites have been reported 
for many years now in parts of East/South-East Asia and some few parts of South America 
(Dronamraju & Arese, 2006). Resistance to chloroquine, Fansidar, mefloquine and 
amodiaquine has also been reported in P. falciparum across the world. Chloroquine resistance 
is the most wide-spread, occurring in almost all regions were P. falciparum malaria is 
transmitted except in very few locations of Central America, the Middle East and Central 
Asia (Dronamraju & Arese, 2006; Bloland, 2001).  An increased dependence on Fansidar as a 
result of the spread of chloroquine resistance also led to the development of resistance to this 
drug in South-East Asia, South America and most recently in Africa (Dronamraju & Arese, 
2006; Bloland, 2001). Mefloquine resistance is also frequently reported in South-East Asia, 
some parts of Africa and the Amazon region of South America (Bloland, 2001; Sinha et al., 
2014). Resistance to amodiaquine, a drug also used (in combination with artesunate) to treat 
chloroquine-resistant malaria, has also been reported in Tanzania in Africa (Dronamraju & 
Arese, 2006; Sinha et al., 2014). Cases of resistance of P. falciparum to malarone have been 
reported in some parts of Africa (Dronamraju & Arese, 2006). Upon an official 
recommendation by the World Health Organization in 2001, artemisinin-based combination 
therapies (ACTs) are now the first-line treatment especially for P. falciparum malaria, and 
this has generally led to a substantial decline in global cases of malaria (Sinha et al., 2014). 
However, parasites showing first signs of resistance to artemisinin and its analogues have 
recently been detected in several parts of Cambodia, Thailand, Myanmar and Vietnam, all in 
South-East Asia (Petersen et al., 2011; Cui et al., 2015; Sinha et al., 2014).  
The mechanisms of parasite resistance are manifold and generally appear to develop through 
spontaneously occurrence and selection for mutations that lead to reduced sensitivity of the 
given antimalarial drug or a group of drugs (Dronamraju & Arese, 2006; Bloland, 2001). 
Resistant mutations may be single or multiple and can occur in a single gene or multiple 
genes (Dronamraju & Arese, 2006; Bloland, 2001). The mutation may introduce a 
polymorphism in genes leading to the reduction in drug import or in drug metabolism. 
Mutation may also alter the structure of a drug-associated enzyme causing drug binding 
defects (Dronamraju & Arese, 2006). P. falciparum resistance to chloroquine is reported to be 
mediated by a single nucleotide polymorphism (SNP) in the chloroquine resistance 
transporter gene (Pfcrt) that causes the increased efflux of the drug out of the food vacuole 
(Petersen et al., 2011; Bloland, 2001; Cui et al., 2015). SNPs in the autologue of the P. 
falciparum multidrug resistance protein-1 (Pfmdr1) gene are also linked to reduced sensitivity 
of P.vivax to chloroquine and quinine (Cui et al., 2015). P. falciparum and P. vivax resistance 
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to antifolate antimalarials have also been attributed to single and multiple mutations in the 
genes coding for DHFR and DHPS (Petersen et al., 2011; Dronamraju & Arese, 2006; 
Bloland, 2001; Cui et al., 2015). Recent cases of resistance to artemisinin have been attributed 
to mutations in the propeller domain of the P. falciparum kelch (K13) gene located on 
chromosome 13 (Cui et al., 2015) and resistance to atovaquone has been linked to single-
point mutations in the cytochrome b (Pfcytb) gene (Petersen et al., 2011; Bloland, 2001; Cui 
et al., 2015).  
Antimalarial drug resistance poses a serious threat to the global fight to control and eliminate 
malaria. The successes made so far in the fight against the disease are in fear of being 
reversed by continuous reports of drug resistance especially to ACTs. As the world continues 
to wait for the arrival of an effective malaria vaccine, the need for the development of novel 
potent medications and the appropriate use of current antimalarial drugs to prevent the 
development of parasite resistance remains the cornerstone to the fight against the disease. 
 
 
1.3. Molecular biology and genetic manipulation of P. falciparum 
 
1.3.1.  Historical and general aspects 
 
The sequencing and publication of the full P. faciparum genome in 2002 provided a good 
stimulus for increased research into understanding the cellular and molecular mechanisms of 
the malaria parasite. Over 5500 genes that control most aspects of the functioning of the 
parasite have been identified (Gardner et al., 2002; Conway, 2015). These genes are encoded 
by an approximately 23 Mb haploid genome on 14 different chromosomes, 81% of which is 
A-T in composition (Conway, 2015; Tuteja, 2007; Gardner et al., 2002). The parasite also 
contains a 35 kb circular apicoplast genome encoding about 57 genes and a 6 kb 
mitochondrial genome (Gardner et al., 2002; Tuteja, 2007; Wilson & Williamson, 1997). 
An improved understanding of the complex biology of the malaria parasite is necessary to 
facilitate the identification and characterization of new drug targets, strategies for vaccine 
development and the molecular basis of resistance to current drugs. Molecular manipulation 
of the parasite offers a major window to understanding parasite gene functions and usually 
involves genetic alteration of the parasite genome using gene knockout or editing strategies 
(Koning-Ward et al., 2015; Cowman & Crabb, 2005). The establishment of cell culture 
systems for some of the Plasmoium species including the asexual blood stages of P. 
falciparum (Trager & Jensen, 1976) has made genetic manipulation of the parasite genome 
more feasible and achievable. Customized vectors carrying foreign genetic material are more 
easily introduced into cultured parasites through the process of transfection, and can possibly 
lead to modification of the parasite genome. A major hindrance to genetic manipulation of 
Plasmodium species, however, is the inefficiency of the transfection process. This is 
particularly a problem in Plasmodium species because the parasites are intracellular for most 
of their life cycle and the introduced plasmid must cross multiple membrane barriers of the 
host-parasite unit before a successful transfection is achieved (Cowman & Crabb, 2005; 
Goonewardene et al., 1993). Electroporation greatly improves the transfection efficiency of 
Plasmodium parasites compared to the few others methods available for getting plasmids into 
the parasite nucleus (Lee et al., 2014; Waterkeyna et al., 1999). Infected erythrocytes 
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synchronized at ring- or schizont-stages of development are usually electroporated in P. 
falciparum transfection  (Koning-Ward et al., 2015; Lee et al., 2014). However, transfection 
efficiency is much more improved when uninfected erythrocytes are first electroporated 
(preloaded) with the transfection DNA before infection, usually by mixing with infected 
erythrocytes that are synchronized at the schizont-stage (Cowman & Crabb, 2005; Deitsch et 
al., 2001).  
Transfection vectors (plasmids) are usually generated through a series of cloning steps and 
routinely contain reporter or selectable marker genes to allow selection for transgenic 
parasites once a successful transfection is achieved. For studies that involve gene knockout or 
editing, the vectors also contain DNA sequences (homology regions) complementary to 
portions of the target gene on the parasite genome to allow for one or both forms of 
homologous recombination: single cross-over recombination and double crossover 
recombination (Cowman & Crabb, 2005). Single cross-over recombination results in plasmid 
DNA insertion into the native genome whereas double crossover recombination events result 
in the replacement of DNA sequences in the native genome by a template sequence from a 
donor DNA. 
The first report of genetic manipulation of Plasmodium parasites was in 1993 by 
Goodewardene et al. They described the successful transfection of gametes and zygotes of the 
avian malaria parasite P. gallinaceum with a transient vector and the expression of the firefly 
luciferase gene in transgenic parasites (Koning-Ward et al., 2015; Goonewardene et al., 
1993). Shortly after, transient and stable transfections were also achieved for the blood-stage 
forms of P. falciparum and P. berghei by several different groups (Koning-Ward et al., 2015; 
Cowman & Crabb, 2005; Carvalho & Ménard, 2005). Following these earlier reports, there 
has been a speedy progression of the development of other technologies including efficient 
gene knockout and genome editing approaches for P. falciparum, P. berghei and other 
Plasmodium species (Koning-Ward et al., 2015). Transient transfection has been a molecular 
tool for studying gene expression of Plasmodium species. Traditionally, this tool has been 
used to characterize DNA elements essential for gene expression in many eukaryotic cells 
(Cowman & Crabb, 2005; Morrissette & Sibley, 2002). Episomal plasmids used in transient 
transfection normally contain a reporter gene flanked by the DNA segments under study. 
Commonly used reporter genes include chloramphenicol acetyltransferase, firefly luciferase 
and green fluorescent protein (GFP) (Corin & Weaver, 2005). Stable transfection on the other 
hand is used for functional analysis of parasite genes as occurs in knockout or gene editing 
studies. It is also used for the expression of fluorescent chimeric transgenes allowing for 
direct visualization of protein trafficking to subcellualr and extracellular locations in the host-
parasite unit (Cowman & Crabb, 2005; Hempelmann, 2007; Ghorbal et al., 2014). Plasmid 
vectors used in stable transfections (or parts of them) ultimately get integrated into the 
parasite genome through one of the two forms of homologous recombination (Cowman & 
Crabb, 2005). The plasmids are also designed to carry positive and or negative drug-
selectable marker(s). Positive selection helps to select for parasites that pick up the episomal 
plasmid after transfection (and single cross over events) wheras negative selection selects for 
parasites that have lost a vector, for example because of a double crossover event after 
transfection. To facilitate a clean double crossover event in gene knockout or editing studies, 
transfection plasmids are designed so that the positive drug-selectable marker is flanked by 
two homology regions. Examples of commonly used positive drug-selectable markers in P. 
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falciparum and P. berghei are the mutated form of Toxoplasma gondii dihyrofolate reductase-
thymidylate synthase (dhfr-ts) and human DHFR which confer resistance to pyrimethamine 
and WR99210, respectively (Cowman & Crabb, 2005; Bousema & Drakeley, 2011; Crabb et 
al., 2004).  
An important prerequisite for genome editing strategies is the requirement of a double strand 
break (DSB) (Lee et al., 2014 ). In Plasmodium species, DSBs in DNA are naturally repaired 
by the precise homologous recombination because the parasite does not encode the more 
common alternative error-prone nonhomologous end-joining (NHEJ) pathway. An atypical 
Plasmodium specific NHEJ pathway is, however, identified and reported in Plasmodium 
parasites for the repair of DSBs (Singer et al., 2015; Singer & Frischknecht, 2017; Koning-
Ward et al., 2015 ; Lee et al., 2014 ; Reinke & Troemel, 2015; Crawford et al., 2017). The 
inclusion of homology regions on the episomal plasmid therefore facilitates repair of targeted 
DSBs on the parasite genome. 
Traditional stable transfections in P. falciparum take several months of cell culture for gene 
knockout or editing to occur through a random homologous recombination event (Lee & 
Fidock, 2014; Duraisingh et al., 2002). The culture process usually involves several weeks of 
positive selection to maintain the plasmid in the parasite, and then several months of drug on- 
and off-selection regimes to allow for the integration of the plasmid into the parasite genome 
and selection of integrants (Koning-Ward et al., 2015; Cowman & Crabb, 2005; Duraisingh et 
al., 2002; Maier et al., 2006). Unintegrated plasmids are rapidly lost in the absence of the 
drug but integrated plasmids persist (Koning-Ward et al., 2015; Cowman & Crabb, 2005; 
Maier et al., 2006). This chance-dependent strategy, though used successfully to manipulate 
some genes, was generally inefficient and time-consuming among other disadvantages 
(Cowman & Crabb, 2005; Duraisingh et al., 2002; Maier et al., 2006). The introduction of 
negative selection which selected for rare double-crossover homologous recombination events 
improved the process of genome editing a bit in P. falciparum (Cowman & Crabb, 2005). 
Negative selection helped remove circular episomal plasmids and the backbone of integrated 
plasmids. This decreases the time to obtain transgenic parasites during genome editing 
(Koning-Ward et al., 2015; Lee et al., 2014; Maier et al., 2006). Nevertheless, double 
crossover events, similar to single crossovers, depend on the rare stochastic strand breaks in 
genomic DNA and are therefore also time consuming and inefficient (Lee et al., 2014). 
Recently, more sophisticated stable transfection-based genome-editing tools have been 
developed for eukaryotic cells. These include zinc-finger nuclease (ZFNs)-mediated genome-
editing, transcription activator-like type II effector nucleases (TALENs) and the clustered 
regularly interspaced short palindromic repeats) (CRISPR) – CRISPR-associated protein 9 
(Cas9) (CRISPR-Cas9) systems (Singer et al., 2015; Lee et al., 2014). Specialized 
endonucleases incorporated in these systems are directed to cause the needed DSBs at specific 
target loci in the target genome. These enzymes include endonuclease FokI in ZFN-mediated 
genome-editing and TALENs systems, and Cas9 endonuclease of the CRISPR-Cas9 system. 
DSBs are then repaired by homologous recombination using the homologous regions (HR) 
which reside on the plasmid or linear DNA (Koning-Ward et al., 2015; Lee et al., 2014; Lee 
& Fidock, 2014; Crawford et al., 2017). The principle behind these strategies involves 
exploiting and directing the non-specific endonucleases to target sequences in the genome via 
asociation with protein or RNA (Lee et al., 2014). To date, only ZFNs and the CRISPR-Cas9 
system have been successfully used to achieve genome-editing in P. falciparum (Koning-
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Ward et al., 2015; Lee et al., 2014 ). Though both systems have been shown to generate 
transgenic parasites within a few weeks of transfection, the CRISPR-Cas9 system has recently 
been shown to be more workable with P. falciparum (Lee et al., 2014; Koning-Ward et al., 
2015; Lee & Fidock, 2014).  
 
 
1.3.2.  The CRISPR-Cas9 genome-editing strategy 
 
The CRISPR-Cas9 genome-editing strategy is based on the CRISPR-Cas system present in 
many bacteria and most archaea. In these organisms, the system plays the main role of 
providing adaptive immunity and confers protection against exogenous viruses and plasmids 
(Barrangou & Marraffini, 2014). CRISPR-mediated immunity is acquired when bacteria pick 
up DNA fragments from invading viruses and plasmids and orderly integrate the fragments 
into the genomic CRISPR loci (Barrangou & Marraffini, 2014; Westra et al., 2014). Upon 
subsequent reinfection, relevant complementary DNA portions (CRISPR spacers) of the 
CRISPR loci are transcribed and processed into small interfering crRNAs that guide 
endonucleases by complementary base-paring to cleave and destroy the invading elements 
(Barrangou & Marraffini, 2014; Westra et al., 2014). The CRISPR loci thus contain short 
partially palindromic DNA repeats that occur at regular intervals (CRISPR repeats) and 
alternate with the variable CRISPR spacers. Each locus is immediately flanked by a short 
‘leader’ DNA sequence and accompanying CRISPR associated (cas) genes (Barrangou & 
Marraffini, 2014; Westra et al., 2014). The DNA sequence of the invading element that is 
complementary to the unique CRISPR spacer sequence is called the protospacer. One to four 
nucleotides away, the protospacer is flanked by a system-specific highly conserved 2-5 
nucleotide CRISPR motif called protospacer adjacent motif (PAM) (Barrangou & Marraffini, 
2014). The PAM sequence of Streptococcus pyogenes protospacer is NGG where N can be 
any of the four nucleotides of the genetic code (Lee & Fidock, 2014; Zhang et al., 2014). 
PAM sequences can occur at the 3’ or 5’ end of the protospacer depending on the type of 
system (Barrangou & Marraffini, 2014) and have been implicated in both sampling for which 
exogenous DNA fragment is taking up as a spacer unit, and in directing for targeted strand 
cleavage (Barrangou & Marraffini, 2014; Barrangou, 2015b).  
CRISPR-Cas systems are diverse and are classified into three major types: type I, type II and 
type III mainly by the nature of the cas genes they encode (Barrangou & Marraffini, 2014; 
Barrangou, 2015b, 2015a). Among the three, the type II system (Fig 1.5) requires the least 
complex cas machinery for immunity and typically encodes the Cas9 gene (Barrangou & 
Marraffini, 2014; Barrangou, 2015a).  In the biogenesis of the interfering crRNAs, the type II 
system employs a trans-encoded CRISPR RNA (tracrRNA) which is a small RNA that shares 
partial complementarity with the CRISPR repeats and whose gene is also located in the 
CRISPR locus (Barrangou & Marraffini, 2014). Pairing between tracrRNA and processed 
crRNA (transcribed from relevant spacer) leads to recruitment of the Cas9 protein (Barrangou 
& Marraffini, 2014; Westra et al., 2014; Barrangou, 2015a; Zhang et al., 2014). The spacer 
sequence of the mature crRNA (CRISPR guide RNA) is also called the guide sequence and 
usually consists of the first 20 nucleotides at the 5’ end. The guide sequence determines the 
specificity of the system by being homologous to the target (Lee & Fidock, 2014). 
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Figure 1.5. Scheme of type II CRISPR-mediated DNA double-strand breaks. A typical type II 
CRISPR system occurs in Streptococcus pyogenes. The type II CRISPR locus of contains genes common to 
other CRISPR types such as Cas1and Cas2 as well as unique genes like the Cas9 gene. It also contains the two 
non-coding elements tracrRNA and the CRISPR repeats which alternate with variable CRISPR spacers. Each 
spacer is complementary to the protospacer on the foreign genetic material from which it (spacer) was acquired. 
The spacers together with the associated PAM direct the Cas9 protein to cleave the foreign genetic material upon 
subsequent encounter. In the Type II CRISPR system, the process of achieving a targeted double-strand break 
(DSB) is initiated by the transcription of the pre-crRNA array and tracrRNA. The pre-crRNA is transcribed from 
one of the CRISPR spacer sequences. The transcribed tracrRNA hybridizes with processed pre-crRNA (mature 
crRNA) and Cas9 protein. The mature crRNA also contains the guide sequence which gives specificity to Cas9 
endonuclease to incise the target DNA within the protospacer sequence of the target DNA sequence. An 
upstream PAM is required for the incision to occur. Taken and modified from (Cong et al., 2013). 
 
 
To initiate the cleavage step, the mature CRISPR guide RNA complexes with the tracrRNA 
and drives conformational changes in the single large multi-domain Cas9 protein leading to 
the incision of DNA in a gene sequence that must also contain an upstream PAM sequence. 
The Cas9 protein contains two independent nuclease domains, HNH and RuvC, each of which 
cleaves one strand of the DNA helix generating blunt ends (Barrangou & Marraffini, 2014; 
Barrangou, 2015a; Zhang et al., 2014).  
The engineered CRISPR-Cas9 genome editing strategy of P. falciparum is based on the type 
II CRISPR-Cas system of Streptococcus pyogenes (Barrangou & Marraffini, 2014; 
Barrangou, 2015a). In principle, the requirements for targeted DNA cleavage by Cas9 in the 
type II CRISPR-Cas system (tracrRNA and crRNA) are engineered into a chimeric RNA 
guide, also called single-guide RNA (sgRNA) (Koning-Ward et al., 2015 ). A guide sequence 
of 20 nucleotides can then be designed for each target using special molecular tools to 
generate a workable system. The first report of a CRISPR-Cas9 strategy for P. falciparum 
was by Ghorbal and colleagues in 2014 (Ghorbal et al., 2014). The group demonstrated in 
their ground-breaking study the versatility of the CRISPR-Cas9 approach for genetic 
manipulation of the parasite. In a record time of 3 weeks post-transfection, they were able to 
generate transgenic parasites with a gene disruption or single-nucleotide edited gene (Ghorbal 
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et al., 2014; Lee & Fidock, 2014). Ghorbal et al. used two plasmids (Fig 1.6) to express the 
Cas9 protein, transcribe the single-guide RNA (sgRNA) and to deliver the HR for 
homologous recombination (Ghorbal et al., 2014). The first was the pUF1-Cas9 episome that 
expressed the human codon-optimized S. pyogenes endonuclease Cas9 under the control of 
plasmodial regulatory elements. The Cas9 gene sequence used was engineered with nuclear 
localization signals and carried the yeast dihydroorotate dehydrogenase (ydhodh) for positive 
selection with DSM1, a P. falciparum dihydroorotate dehydrogenase inhibitor. The second is 
the pL7 episome for transcription of the sgRNA under the control of P. falciparum U6 small 
nuclear (sn) RNA regulatory elements dependent on RNA polymerase III. For positive 
selection, the pL7 episome carried the human dihydrofolate reductase (hdhfr) that confers 
resistance to WR99210. Flanking the drug-selectable marker were the homology regions of 
the target gene. The pL7 episome also carried the suicide fusion gene, yeast cytosine 
deaminase and uridyl phosphoribosyl transferase (yfcu), allowing for negative selection with 
5-fluorocytosine. Both plasmids were co-transfected and the Cas9 protein only transiently 
expressed (Ghorbal et al., 2014; Lee & Fidock, 2014; Lu et al., 2016). Even though the high 
A-T composition of the Plasmodium genome presents a peculiar possibility of off-target 
activity, Ghorbal and colleagues convincingly showed that the approach is highly efficient 
and can be used to target potentially every P. falciparum locus (with a nearby PAM sequence) 
for modification.  
 
            
 
Figure 1.6. Two plasmids for targeted P. falciparum genome editing using sgRNA:Cas9. The 
pUF1-Cas9 expresses the Cas9 endonuclease using plasmodial regulatory elements. The Cas9 protein also bears 
nuclear localization signals (NLS). The pL7 episome contains the sgRNA-expression cassette and 5’ and 3’ 
homologous regions (donor DNA). sgRNA is expressed from the P. falciparum U6 snRNA polymerase III 
promoter (5′ U6). The homologous region 1 (HR1) and homology region 2 (HR2) of the gene of interest (GOI) 
must surround a drug-selectable marker (hdhfr) to select for gene disruption. 5′ hsp, heat shock protein 86 
promoter region; 3′ Pb dhfr, 3′ region of P. berghei dhfr; ydhodh, yeast dihydroorotate dehydrogenase gene. 
Taken and modified from (Ghorbal et al., 2014). 
 
 
1.4. The gyoxalase system  
 
1.4.1. History and general aspects 
 
1.4.1.1.  History 
 
In 1913, Neuberg working alone and Dakin and Dudley independently discovered an 
enzymatic activity that converted the 2-oxoaldehyde methylglyoxal into the 
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hydroxycarboxylic acid lactic acid in a variety of tissues and cell extracts (Silva et al., 2013; 
Dakin & Dudley, 1913; Racker, 1951; Inoue et al., 2011; Urscher et al., 2011; Deponte, 
2013). This discovery laid the foundation for the elucidation of the glyoxalase sytem and the 
identification of its components. The key enzyme then, ketonaldehydemutase (now glyoxalase 
1) together with methylglyoxal became the focus of the then poorly understood biochemical 
pathway of glycolysis (Deponte, 2013; Racker, 1951). The accepted model of glycolysis at 
this time was the split of glucose into two three-carbon sugars that were converted to 
methylglyoxal and then to lactic acid through the action of glyoxalase 1 (Deponte, 2013). In 
1950, building on a previous work by Hopkins and Morgen, Crook and Law reported the 
presence of a second enzyme (glyoxalase 2) involved in methylglyoxal metabolism.  
 
 
 
 
Figure 1.7. The glyoxalase detoxification system. Glo1 isomerizes the spontaneously formed 
hemithioacetal between toxic dehydrated 2-oxoaldehydes and reduced glutathione (GSH) to the 2-hydroxy 
thioester. This product is then hydrolyzed by Glo2 to the corresponding less-harmful 2-hydroxycarboxylic acid 
and GSH. Taken from (Deponte, 2014). 
 
 
Eventually, a definition of the specific biochemical functions of glyoxalase (Glo1) and 
glyoxalase 2 (Glo2) were described by Racker who, after combining this new finding with 
earlier reports of the role of glutathione in methylglyoxal metabolism, attempted to spell out 
the pathway of present-day glyoxalase system (Racker, 1951; Urscher et al., 2011; 
Thornalley, 1993; Deponte, 2013). Racker did not only demonstrate the basis of the first 
enzymatic assay of glutathione but later also showed that the lactic acid produced from 
methylglyoxal metabolism was actually D-lactate (Deponte, 2013; Racker, 1951), a finding 
that dismissed the physiological role of methylglyoxal and the glyoxalase enzymes in the 
mainstream glycolytic pathway. Having been made orphan by this finding, it took almost 
another two decades for the physiological relevance of the glyoxalase system as a 
detoxification pathway for toxic dicarbonyls to be proposed by Mannervik in 1974 (Deponte, 
2013). The glyoxalase system is now accepted as a ubiquitous glutathione-dependent 
(trypanothione-dependent in rare cases) pathway that performs the main task of detoxifying 
harmful 2-oxoaldehydes to non-toxic 2-hydroxycarboxylic acids (Inoue et al., 2011; Cameron 
et al., 1997; Ariza et al., 2006; Urscher et al., 2012; Deponte, 2014, 2013). Renewed interest 
in the glyoxalases and the glyoxalase sytem has recently helped to identify other potential 
roles of the pathway, which include the regulation of cellular growth and spermatogenesis 
(Glo2), signal transduction and assembly of microtubules (Urscher et al., 2011; Thornalley, 
1993; Cameron et al., 1997; Urscher et al., 2012; Deponte, 2013). The glyoxalases are also 
thought to function in the regulation of osteoclastogenesis in mouse macrophages (Kawatani 
et al., 2008) and the intermediate of the glyoxalase sytem, S-D-lactyolglutathione (SLG), is 
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thought to regulate the efflux of potassium in Escherichia coli (E. coli) (Ferguson et al., 1993; 
Ozyamak et al., 2010). The generalized glyoxalase system comprises the isomerase Glo1, the 
thioesterase Glo2, and a catalytic amount of the reduced tripeptide glutathione (GSH) as co-
factor (Fig 1.7) (Urscher et al., 2012; Deponte, 2014; Thornalley, 1998). Glo1 catalyzes the 
virtually irreversible isomerization of the nonenzymatically formed hemithioacetal of GSH 
and a 2-oxoaldehyde to a 2-hydroxythioester. The latter is then hydrolyzed by glyoxalase 2 
(Glo2), with the release of GSH and the corresponding 2-hydroxycarboxylic acid (Deponte, 
2013; Thornalley, 1998; Silva et al., 2013; Urscher et al., 2011).  
 
 
1.4.1.2. Glo1 
 
Glo1 (also known as GloI or Glx1) has been characterized as a metalloenzyme in many 
organisms, from mammals to plants, yeast, bacteria and protozoan parasites (Deponte, 2013). 
The enzyme belongs to the vicinal oxygen chalate (VOC) metalloenzyme superfamily whose 
members contain a βαβββ-motif required for metal ion coordination (Deponte, 2013; Urscher 
et al., 2011). Studies in organisms expressing this enzyme show that it is localized mostly to 
the cytosol (Marasinghe et al., 2005; Urscher et al., 2010; Deponte, 2013). Structurally, most 
eukaryotic Glo1 enzymes and the Glo1 of some prokaryotes such as E. coli are homodimers 
with two subunits, each of which contain a pair of the βαβββ-motif thought to have originated 
from a gene duplication event (Iozef et al., 2003; Deponte, 2013; Thornalley, 2003). Each 
subunit contains two halves of two structurally identical active sites, each of which contains a 
zinc or nickel metal center necessary for catalysis, and a glutathione-binding pocket located at 
its interface (Inoue et al., 2011; Thornalley, 1993; Frickel et al., 2001; Deponte, 2013). Two 
essential glutamate residues at the active site as well as two other residues, which can be 
glutamine or histidine depending on the organism, exert the acid-base catalyzed isomerization 
of the diastereomeric hemithioacetals to the single corresponding thioester (Deponte, 2013). 
Eukaryotic Glo1 enzymes commonly contain zinc whereas nickel is the co-factor in many 
prokaryotes, even though this is not a strict pattern (Deponte, 2013; Frickel et al., 2001). The 
glutathione-binding pocket is predominantly composed of basic/polar residues via the γ-
glutamyl and glycine moiety (Deponte, 2013). The functional dimeric Glo1 enzyme thus 
consist of four βαβββ-motif contained in two subunits with the N-terminal domain of one 
subunit interacting with the C-terminal domain of the other (Deponte, 2013). In contrast, Glo1 
enzymes of some other prokaryotes, P. falciparum and S. cerevisiae are monomers with two 
different structural and functional active sites (Inoue et al., 2011; Deponte, 2014, 2013). The 
monomeric enzyme is similar in overall structural architecture to the homodimer isoform and 
is thought to have arisen from a second gene duplication event which occurred sometime in 
the evolutionary process (Deponte, 2013; Iozef et al., 2003). The catalytic mechanism 
generally accepted for Glo1 reaction involves base-catalyzed shielded-deprotonation from C-1 
of the hemithioacetal that is bound to the active site to form an ene-diolate intermediate that is 
converted to the thioester product. The role of glutathione is to provide specific binding to the 
active site and to activate the C-1 residue of the 2-oxoaldehyde by the formation of the 
hemithioacetal. The role of the enzyme is to control and define substrate specificity, the 
stereoselectivity of the reaction and to provide the base for base catalysis (Thornalley, 1993). 
Even though Glo1 is often considered ubiquitous, the gene encoding Glo1 is absent in some 
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organisms including the protozoans Entamoeba hystolytica, Giardia lamblia and 
Trypanosoma brucei (Silva et al., 2013). In other trypanosmatids that express the enzyme, 
trypanothione-derived hemithioacetal is the preferred substrate for Glo1 instead of a 
glutathione-derived substrate (Deponte, 2013; Ariza et al., 2006).  
 
 
1.4.1.3  Glo2 
 
Glo2 (also known as GloII or GlxII) is a monomeric metalloenzyme and has been 
characterized in a number of organisms including humans, plants, yeast, bacteria and 
protozoan parasites (Deponte, 2013; Marasinghe et al., 2005 ). Similar to Glo1, this enzyme is 
ubiquitous even though some mammals and bacteria are reported to lack the encoding gene 
(Deponte, 2013). Glo2 enzymes are composed of an N-terminal β-lactamase domain, which 
contains a single active site and a C-terminal domain with five α-helices. The active site of the 
enzyme consists of a binuclear metal center and a substrate-binding site which extends over 
the domain interface. Two Zn2+ ions, a Zn2+-Fe3+ combination or a combination of other metal 
ions form the metal center depending on the organism. The ions are coordinated by a highly 
conserved THxHxDH active site motif and a water molecule (Deponte, 2013). Due to the β-
lactamase domain, Glo2 is classified among the diverse group of binuclear metallohydrolases 
(Deponte, 2013). Some organisms, including P. falciparum and S. cerevisiae, express two 
different Glo2 enzymes (Silva et al., 2013; Deponte, 2014). One of these two Glo2 enzymes 
is cytosolic while the other is localized to the mitochondrion or apicoplast as in S. cerevisiae 
(Glo4) and P. falciparum (tGlo2) respectively (Deponte, 2013; Urscher et al., 2010). If 
multiple isozymes of Glo2 occur in an organism, the different enzymes are mostly encoded by 
separate genes rather than by a single gene. In humans, however, the two Glo2 isozymes, one 
localized to the cytosol and the other to the mitochondrion, are both encoded by the same 
gene (Marasinghe et al., 2005). To date, the actual function of the additional Glo2 isoenzymes 
localized to mitochondrion or apicoplast is still to be determined even though the catalytic 
activity of mitochondrial Glo2 is suggested to direct one of several routes through which 
glutathione is made available to the mitochondrion (Urscher & Deponte, 2009; Cordell et al., 
2004). Similar to Glo1, Glo2 is generally specific to glutathione thioesters. As an exception, 
the Glo2 of trypanosomatids, as expected, specifically hydrolyses S-D-lactoyltrypanothione 
(Silva et al., 2013). In the proposed reaction mechanism, the substrate first binds to the 
enzyme at the domain interface, with its glycine and cysteine residues hydrogen-bonding with 
the conserved substrate binding-site of the enzyme (Deponte, 2013). The reaction then 
proceeds with a nucleophilic attack by a hydroxide ion (OH-) on the C1 atom (carbonyl 
carbon) of the substrate to form a negatively charged tetrahedral intermediate that may be 
stabilized by coordination to the nearest metal ion. The C-S bond of the substrate 
subsequently breaks while glutathione is protonated. The catalytic products of reduced 
glutathione and lactic acid then diffuse out of the active site of the free enzyme to be replaced 
by a water molecule (Urscher & Deponte, 2009; Cameron et al., 1999). Binding of the active 
site residues to the two metal ions is thought to generate the nucleophile (the depronation of 
water at physiological pH) at the metal center (Deponte, 2013; Thornalley, 1993; Cameron et 
al., 1999). Histidine residues as well as an aspartate residue are important in metal ion binding 
in the active site of the enzyme (Deponte, 2013).   
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1.4.1.4.  2-Oxoaldehydes 
 
The primary 2-oxoaldehyde substrate of the glyoxalase system appears to be methylglyoxal, 
the metabolism of which leads to the production of D-lactate through the formation of the 
thioester S-D-lactoylglutathione (Cameron et al., 1999; Urscher et al., 2011). Other 
physiological and artificial substrates of the glyoxalase systems include glyoxal, 
phenylglyoxal, hydroxy-pyruvaldehyde, 3-phosphohydroxy-methylglyoxal, kethoxal and 4,5-
dioxovalerate (Silva et al., 2013; Thornalley, 1998; Akoachere et al., 2005). The products and 
intermediate metabolites produced in the course of the metabolism of these other substrates 
are different from those produced during the metabolism of methylglyoxal. For instance, 
glyoxal is metabolized through a glycolylglutathione thioester to the 2-hydroxycarboxylic 
acid glycolate (Thornalley, 1998). In living cells, the 2-oxoaldehydes can be generated from 
multiple different sources (Urscher et al., 2011). Methylglyoxal is considered the most 
important 2-oxoaldehyde because it is mainly produced as a spontaneous intermediate of the 
glycolytic pathway in all cells and organisms (Silva et al., 2013; Urscher et al., 2011; 
Thornalley, 1998). The compound is produced by the non-enzymatic (and to some extent by 
the enzymatic) elimination of a phosphate group from phosphate-ene-diolate of 
dihydroxyacetone-phosphate (DHAP) and glyceraldehyde-3-phosphate (GAP), the three-
carbon intermediates of glycolysis (Silva et al., 2013; Urscher et al., 2011; Thornalley, 1998, 
1996; Cooper, 1984). Methylglyoxal is also formed by the oxidation of acetone by cytochrone 
P450, by the oxidation of aminoacetone formed in the catabolism of L-threonine, by the 
oxidation of ketone bodies by myeloperoxidase and by lipoperoxidation reactions (Silva et al., 
2013; Thornalley, 1996). Some bacteria such as E. coli can also use the enzyme 
methylglyoxal synthase to produce methylglyoxal from DHAP as an important bypass of 
glycolysis, usually under conditions of limited inorganic phosphate (Urscher et al., 2011; 
Thornalley, 1996; Cooper, 1984). Methylglyoxal synthase is also present in yeast, but 
concerning other eukaryotes, there has been till date only one reported isolation of the enzyme 
from goat liver (Silva et al., 2013; Vander Jagt et al., 1990).  
In general, most 2-oxaldehydes including glyoxal and hydroxypyruvaldehyde found in many 
organisms, seem to be unwanted by-products of the biochemical pathways mentioned above 
(Silva et al., 2013; Urscher et al., 2011; Akoachere et al., 2005). Nevertheless, the 2-
oxoaldehydes are also thought to have several functions in the living cell. For instance, 
methylglyoxal is reported to function in osmoregulation and transcription regulation in yeast 
(Maeta et al., 2004; Inoue et al., 2011). Some studies also suggest a direct involvement of 
some 2-oxoaldehydes in cellular regulatory processes and in signal transduction. 
Methylglyoxal for example, has been implicated in the regulation of the co-repressor mSin3A 
in kidneys of diabetic mice (Deponte, 2014, 2013). Methylglyoxal-derived glycation of α-
crystallin and hsp27 has also been demonstrated to enhance the function of these two 
chaperones. The same effect has been reported for glycation of hsp26 and hsp71/72 of yeast 
(Silva et al., 2013). Some level of glycation caused by the 2-oxoaldehyds therefore seems to 
be physiologically beneficial to the living cell.  
The major reason why the 2-oxoaldehydes have been a centre of recent studies is, however, 
because of their high spontaneous reactivity to important cellular molecules leading to their 
modification and damage (Urscher et al., 2011). Owing to their adjacent carbonyl groups, the 
2-oxoaldehydes are strong electrophiles, making them potentially cytostatic at low 
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concentrations, and cytotoxic and mutagenic at high concentrations (Urscher et al., 2011; 
Cameron et al., 1997; Urscher et al., 2012; Deponte, 2013). They can react irreversibly with 
nucleophiles in proteins, membrane lipids and nucleic acids leading to the formation of so-
called advanced glycation endproducts (AGE) both in vivo or in vitro (Urscher et al., 2011; 
Thornalley, 1996; Deponte, 2013). The accumulation of AGE in cells is thought to lead to 
many disease conditions such as cancer, diabetes, renal failure and neurological disorders 
(Thornalley, 1996; Deponte, 2013; Akoachere et al., 2005). The activation of the receptor to 
AGE (RAGE) by AGE, which initiates downstream activities in the AGE-RAGE system for 
example, is believed to be involved in the pathogenesis of diabetes (Inoue et al., 2011). 2-
Oxoaldehydes react reversibly and irreversibly with arginine, lysine and cysteine residues of 
proteins under physiological conditions and concentrations (Thornalley, 1996; Lo et al., 
1994). This reactivity can cause fatal cross-linking, conformational changes and inactivation 
of enzymes and other important proteins. It can also lead to the endocytosis and degradation 
of important proteins by monocytes and macrophages (Thornalley, 1996; Lo et al., 1994). The 
2-oxoaldehydes also react with cytosine, adenine and predominantly guanine residues of 
DNA and RNA leading to mutations and inter-strand cross-links in these macromolecules. 
These are mostly irreversible changes in nucleic acids that can cause apoptosis (Thornalley, 
1998; Akoachere et al., 2005; Thornalley, 1996; Marasinghe et al., 2005). The glyoxalase 
system is therefore thought to play the very important physiological role detoxifying the 2-
oxoaldehydes and keeping AGE concentrations at healthy levels in the living cell (Urscher et 
al., 2011; Deponte, 2014).  The system is particularly thought to act at the Amadori product 
level by preventing the glycation cascade in the early steps of the Maillard reaction (Silva et 
al., 2013). Glo1 and or Glo2  have thus gained attention as potential drug targets in several 
parasitic protozoans and cancer cells that are known to have elevated glycolytic fluxes leading 
to increased formation of methylglyoxal (Urscher & Deponte, 2009). In cancer cells in 
particular, higher levels of expression of the glyoxalases are observed (Silva et al., 2013). 
Inhibition of the detoxification pathway in these cells may therefore lead to cellular damage 
(Silva et al., 2013; Urscher & Deponte, 2009). In fact, experimental support for this 
observation in some cells and organisms has led to the development of glutathione-based and 
nonglutathione Glo1 and Glo2 inhibitors including S-p-bromobenzylglutathione diesters, 
curcumin and methyl-gerfelin (Urscher et al., 2011; Ariza et al., 2006). Some of these 
inhibitors have been identified to exhibit antimalarial and antitrypanosomal properties 
(Urscher et al., 2011; Ariza et al., 2006; Urscher et al., 2012; Thornalley, 1998).  
 
 
1.4.1.5. Other pathways of methylglyoxal metabolism 
 
In the trypanosomatids and S. cerevisiae, other pathways of 2-oxoaldehyde metabolism have 
been described over the years. Two of such additional pathways are known in the 
trypanosomatids; NADPH-dependent aldose reductase metabolizes methylglyoxal to 
hydroxyacetone and D-lactaladehyde, while the NADPH-dependent methylglyoxal reductase 
reduces methylglyoxal to L-lactaldehyde through a reduction/oxidation system (Silva et al., 
2013; Thornalley, 1996). A similar route of detoxification of methylglyoxal to L-lactic acid is 
found in S. cerevisiae involving the enzymes methylglyoxal reductase and lactaldehyde 
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dehydrogenase (Inoue et al., 2011). Again in the yeast Hansenula mrakii, the enzyme 
aldehyde reductase converts methylglyoxal to acetol (Inoue et al., 2011). 
 
 
1.4.2. Glyoxalase system of the human erythrocyte 
 
The glyoxalase system of human cells comprises two enzymes: glyoxalase 1 (hGlo1) and 
glyoxalase 2 (hGlo2) (Table 1.1) (Cordell et al., 2004; Thornalley, 1993). hGlo1 has been 
purified from many human tissues including pancreas, lung, liver, brain and blood 
(Thornalley, 1993). As stated above, hGlo1 is a homodimer with two structurally identical 
active sites (Ariza et al., 2006; Urscher et al., 2011). The enzyme ís encoded by a diallelic 
gene located on chromosome 6 with a translational product of 184 amino acids and is 
transmitted in an autosomal codominant manner. There are thus three different allozymes 
(Glo1a-a, Glo1a-b and Glo1b-b) of hGlo1, all of which are present in the erythrocytes of 
heterozygotes (Thornalley, 1993; Urscher et al., 2011; Aronsson et al., 1979; Thornalley, 
2003).  
 
 
Table 1.1. Summary of properties of the glyoxalases in the host/parasite unit. 
 
    Plasmodium falciparum glyoxalases Homo sapiens glyoxalases 
   
   Protein  
name(s) 
PfGlo1   
(GloI, GlxI)                
PfcGlo2  
(cGloII, GlxIIb) 
PftGlo2   
(tGloII, GlxII)       
PfGILP   hGloI 
 
hGloII  
(HAGH, GlxII) 
       
       
Accession  
number 
PF110145 a or              
AF486284 b 
PFD0311w a or 
AY494055 b 
PFL0285w a or                
AF486285 b 
PFF0230c a L07837 b NM001040427 & 
NM005326 c 
       Gene locus  Chr. 11 Chr. 4 Chr. 12 Chr. 6 Chr. 6p21.3-p21.1 Chr. 16p13.3  
       mRNA length 1071 bp 792 bp 969 bp 924 bp 623 bp 783 bp & 927 bp 
       Authentic  
Mw/pI 
42441/ 
5.75 
30528/  
7.64 
38414/ 
8.71 
35838/ 
8.59 
20720/ 
5.24 
28860/6.86               
33806/8.34 
       His-tagged   
Mw/pI d,e) 
43,708/ 
6.10 
31,795/ 
8.10 
32,940/ 
6.94 
34,782/ 
8.06 
- 30544/  
7.01   
       Subcellular locali-
zation/N-terminal 
signal sequence 
Cytoplasm/ 
none 
Cytoplasm/ 
none 
Apicoplast/ 
yes 
Apicoplast?/  
yes 
Cytoplasm/ 
none 
Cytoplasm & mito-
chondrial matrix/ 
none & yes 
       
Activity/  
Protein  
superfamily 
Isomerase/ 
Vicinal oxygen 
chelate metallo-
enzyme 
Hydrolase/ 
Binuclear 
metallo- 
hydrolase 
Hydrolase / 
Binuclear 
metallo- 
hydrolase 
Inactive?/ 
Vicinal oxygen 
chelate metallo-
enzyme? 
Isomerase/ 
Vicinal oxygen 
chelate metallo-
enzyme 
Hydrolase/ 
Binuclear 
metallo- 
hydrolase 
       Structural  
motives  
Four βαβββ 
motifs/domains 
N-term. metallo- 
β-lactamase fold 
and C-term. α-
helical domain 
N-term. metallo- 
β-lactamase fold 
and C-term. α-
helical domain 
Four putative 
βαβββ motifs/ 
domains 
Two βαβββ 
motifs/domains 
N-term. metallo- 
β-lactamase fold 
and C-term. α-
helical domain 
       Quaternary 
structure /  
Active sites 
Monomer/  
A + B  
Monomer-dimer 
equilibrium/A& 
A+A'  
?/? ?/A + B? Dimer/  
A + A'  
Monomer  
(dimer ?)/A (& A 
+ A' ?)  
       
Metal ion Zn2+  Zn2+  Zn2+   none?  Zn2+  Zn2+  
       
Catalytic 
mechanism 
Two conforma-
tions and alloste-
ric coupling  
Theorell-Chance  
acid-base mecha-
nism  
Regular Micha-
elis-Menten 
kinetics?  
No activity with     
MG and GSH  
Regular Micha-
elis-Menten 
kinetics?  
Regular Micha-
elis-Menten 
kinetics?  
       
aPlasmodium genome database annotation (http://plasmodb.org); bGenBank annotation; cNCBI Reference 
Sequence; dRecombinant protein sizes; eCalculated molecular weight (average) and isoelectric point 
(http://www.expasy.org/tools). Taken and modified from (Uscher et al., 2011). 
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The allozymes have a molecular weight of approximately 44 kDa (the molecular weight of 
each subunit measuring approximately 22 kDa) but have different charge densities and 
molecular shapes (Thornalley, 1993; Thornalley, 2003). The physiological substrate of hGlo1 
is thought to be the hemithioacetal formed spontaneously from the unhydrated form of 
methlyglyoxal and reduced glutathione (Thornalley, 1993; Cameron et al., 1999). The 
reaction of the enzyme generally follows the Michaelis-Menten kinetics that effects the metal 
ion-dependent isomerization of the substrate glutathione hemithioacetal to a glutathione 
thioester (Thornalley, 1993).  
Human Glo2 (hGlo2) activity has been detected in the cytosol and mitochondrion of human 
liver, brain and red blood cells (Thornalley, 1993; Uotila, 1973; Board, 1980). The gene 
(hydroxyacylglutathione hydrolase, HAGH, gene) that encodes the cytosolic hGlo2 is located 
on chromosome 16 and adopting an alternative exon usage, this gene is also able to encode 
the mitochondrial hGlo2-isoform which carries a mitochondrion targeting sequence. Only the 
cytosolic form of 260 amino acids is found in mature human erythrocytes (Cordell et al., 
2004; Urscher et al., 2011). Genetic polymorphism of HAGH is extremely rare but 
occasionally, expression of a second form of the gene is detected among Japanese and 
Micronesian people. Inheritance of the alleles of the HAGH gene also proceeds in an 
autosomal codominant manner (Urscher et al., 2011; Board, 1980; Thornalley, 1993).  hGlo2 
is a monomer consisting of two domains (Thornalley, 1993; Cameron et al., 1999 ) with a 
molecular mass in the range of 23-29 kDa (Thornalley, 1993; Uotila, 1973; Cameron et al., 
1999 ). Though the enzyme is known to have a broad substrate specificity for glutathione thiol 
esters, its physiological substrate in the cytosol is S-D-lactyoglutathione (Cordell et al., 2004; 
Thornalley, 1993; Cameron et al., 1999 ). The rate of reaction of hGlo2, as in hGlo1, follows 
the Michaelis-Menten kinetics leading to the hydrolysis of S-D-lactyoglutathione to D-lactate 
in the cytosol (Thornalley, 1993; Allen et al., 1993). About 95% of hGlo2 activity is found in 
the cytosol while the rest (5%) is detected in the mitochondrion (Cordell et al., 2004). Even 
though the specific role of the mitochondrial hGlo2 enzyme is not determined yet, it is 
possible this enzyme hydrolyses S-D-lactoylglutathione that has diffused or is transported into 
the mitochondrion from the cytosol (Scire` et al., 2000). hGlo2 is inhibited by reduced 
glutathione, the hemethioacetal formed from methylglyoxal and reduced glutathione, and 
several anions (Uotila, 1973). 
 
 
1.4.3. Glyoxalase system and methylglyoxal metabolism in P. falciparum 
 
The genome of P. falciparum encodes four glyoxalases: a cytosolic Glo1 (PfGlo1), two Glo2 
isozymes (a cytosolic protein, PfcGlo2, and an apicoplast-localized protein, PftGlo2), and a 
Glo1-like protein (PfGILP) that also carries an apicoplast targeting signal (Table 1.1) 
(Deponte, 2014; Urscher et al., 2010 ). PfGlo1, PfcGlo2 and PftGlo2 are functional enzymes 
but recombinant PfGILP till date is reported to be inactive in standard enzyme assays 
(Deponte, 2014; Urscher et al., 2011). Localization studies have revealed a cytosolic 
gyloxalase system of P. falciparum comprising the cytosolic enzymes PfGlo1 and PfcGlo2 
(Deponte, 2014; Urscher et al., 2010).  
PfGlo1 belongs to the subgroup of large monomeric Glo1 proteins which consist of highly 
homologous N- and C-terminal amino acid sequences with two different active sites (Deponte 
et al., 2007). This is in contrast to the smaller homodimer subgroup to which the human Glo1 
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enzyme belongs (Deponte, 2013; Urscher et al., 2011; Akoachere et al., 2005). The two 
halves of PfGlo1 are also homologous to each of the 2-domain subunits of hGlo1 (Iozef et al., 
2003; Akoachere et al., 2005). Both halves of recombinant PfGlo1 have been produced in E. 
coli, and the C-terminal half was shown to yield a stable protein that formed an enzymatically 
active dimer. This result supports the hypothesis that the enzyme was generated by an 
evolutionary subunit fusion (Iozef et al., 2003). Similar to Glo1 enzymes of most eukaryotes, 
PfGlo1 uses Zn2+ as a co-factor. The active site of PfGlo1 also consists of the binding sites for 
glutathione, Zn ions and a catalytic loop. With the exception of a few residues, almost all the 
amino acid residues representing these three parts of the active sites are also conserved in 
PfGlo1 as in hGlo1, resulting in a similar enzymatic action (Deponte et al., 2007). The two 
active sites of the monomeric PfGlo1 have similar turnover numbers but significantly 
different substrate affinities (Urscher et al., 2012; Deponte et al., 2007). Both active sites also 
adopt two distinct conformations and are allosterically coupled in a substrate concentration-
dependent manner. This means that PfGlo1 exists in a high affinity-conformation at low 
substrate concentrations and a high activity-conformation at high substrate concentrations 
(Urscher et al., 2012; Deponte et al., 2007). Allosteric coupling points to a possible 
adaptation of the parasite to growth in the environment of variant methylglyoxal fluxes as 
occurs during the vertebrate and mosquito stages of the parasite (Urscher et al., 2011; 
Deponte, 2014; Deponte et al., 2007). The two active sites of PfGlo1 may also reflect and 
adaptation to alternative substrates or even play regulatory functions by allowing signal 
molecules to bind to one site, leading to the control of the overall enzyme activity or 
stimulating interaction with other effector molecules (Urscher et al., 2011; Deponte, 2014). 
PfcGlo2 is a monomeric thioesterase and the first member of this class of binuclear 
metallohydrolases for which acid-base catalysis was described (Urscher et al., 2011; Urscher 
& Deponte, 2009). The Zn2+/metal binding motif THxHxDH as well as two additional 
histidine residues essential for Zn2+ and or Fe2+ binding are conserved to a large extent in 
PfcGlo2, pointing to a comparable catalytic pathway to that which occurs in hGlo2 
(Akoachere et al., 2005). The metal ions (Zn2+ and or Fe2+) of PfcGlo2 are thought to activate 
water and to generate the nucleophile (OH-) at the reaction centre (Urscher & Deponte, 2009). 
As in hGlo2, substrate binding is revealed to be through the highly conserved glutathione-
mioety (Urscher & Deponte, 2009; Urscher et al., 2011). Even though most Glo2 enzymes are 
functional monomers, cross-linking experiments with glutaraldehyde and disuccinimidyl 
substrate revealed that recombinant PfcGlo2 can also form dimers in solution and the enzyme 
usually exists in rapid monomer-dimer equilibrium. There is as yet no experimental evidence 
of dimer occurrence in vivo but dimer formation may play regulatory functions in the cytosol. 
In addition, a role of dimer formation in signal transduction was suggested (Urscher et al., 
2011). Dimerization has also been reported in hGo2 and is expected to occur in Glo2 enzymes 
of other organisms (Urscher et al., 2010).  
PfGILP is only present and highly conserved in Plasmodium species. An apicoplast targeting 
sequence located at the N-terminus of PfGILP suggests that the protein is localized to the 
apicoplast (Akoachere et al., 2005). As mentioned above, PfGILP is inactive and this is most 
likely due to the fact that the enzyme lacks the essential highly conserved active site residues 
found in all Glo1 enzymes (Urscher et al., 2011; Deponte, 2013). The physiological substrate 
of PfGILP, if any, is yet to be determined. 
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PftGlo2 is the first experimentally confirmed plastid glyoxalase (Urscher et al., 2010). As in 
PfGILP, PftGlo2 also carries an apicoplast targeting sequence located at the N-terminus 
(Urscher et al., 2010; Akoachere et al., 2005). The Zn2+/metal binding motif THxHxDH as 
well as other amino acid residues essential for metal binding are conserved in PftGlo2 as in 
PfcGlo2. The catalytic properties of the enzymes are therefore thought to be similar to those 
of hGlo2 and PfcGlo2 (Urscher & Deponte, 2009; Akoachere et al., 2005). Even though 
PftGlo2 has been found to be active in vitro, its actual physiological function as well as the 
source and structure of its substrate are still unknown (Urscher et al., 2011). Localization of 
triosephosphate isomerase (TIM) in the apicoplast was confirmed experimentally in 
apicomplexan parasites (Fleige et al., 2007) suggesting that the production of methylglyoxal 
in the apicoplast is possible (Urscher et al., 2011). There is, however, no confirmation of the 
existence of a functional apicoplast-targeted Glo1 (tGlo1). The most probable candidate in 
this regard is PfGILP which, however, does not exhibit a typical Glo1 activity (Urscher et al., 
2011; Silva et al., 2012). The extent to which GSH is imported into or utilized in the 
apicoplast is also unclear (Urscher et al., 2011). Thus, the existence of a functional apicoplast 
glyoxalase system is still to be discovered (Urscher et al., 2011; Akoachere et al., 2005). 
Concerning expression profiles of the glyoxalases of the malaria parasite, reports suggest a 
constitutive expression of the encoding genes during the erythrocytic cycle and 
gametogenesis. Only the levels of mRNA of PftGlo2 and PfGILP seem to slightly increase in 
the late trophozoite and early schizont blood stages of the parasite (Urscher et al., 2011). 
Protein mass spectrometric data has also confirmed that mRNAs encoding the four 
glyoxalases are translated in the blood-stage parasites (though only a few PfGILP mRNAs) 
(Urscher et al., 2011).   
 
 
1.4.4. Glyoxalase systems of the host-parasite unit as a potential drug target 
 
P. falciparum and all other Plasmodium species develop and proliferate in the anucleated, 
nutrient-rich and relatively safe intracellular environment of the erythrocyte, which is also 
devoid of all cellular organelles (Urscher et al., 2011; Acharya et al., 2017). In the 
erythrocyte, the parasite encapsulates itself within the parasitophorous vacuole but 
communicates to the external host cytosol using intricate membranous extensions that include 
the Maurer’s clefts and the tubulovasicular network (Acharya et al., 2017; More & Vince, 
2009). Two D-lactate producing glyoxalase systems are found in the host-parasite unit of the 
P. falciparum-infected erythrocyte: one in the cytosol of the erythrocyte and the other in the 
parasite cytosol (Fig 1.8) (Urscher et al., 2011). The apicoplast of the parasite also harbours a 
functional Glo2 isozyme and a highly mutated Glo1-protein (Urscher et al., 2011). The 
erythrocyte-parasite unit has been shown to consume more glucose than uninfected 
erythrocytes (Sherman, 1979; Vander Jagt et al., 1990; Deponte, 2014). The consequence of 
this high glucose demand is the increased level of methlygloxal and other intermediates of 
glucose breakdown in the host-parasite unit (Urscher et al., 2011; Vander Jagt et al., 1990). 
Results form two studies confirmed that the high influx of glucose in the (infected) 
erythrocyte indeed leads to elevated levels of methlyglyoxal in the cell (Vander Jagt et al., 
1990; Thornalley, 1988). Since neither the erythrocyte nor the parasite harbour methlyglyoxal 
synthase activity, the source of methylglyoxal in the host-parasite unit is suggested to be 
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solely from glucose breakdown (Vander Jagt et al., 1990; Thornalley et al., 1994). A key 
study by Vander Jagt and colleagues also revealed that infected erythrocytes produce about 30 
fold more D-lactate than uninfected erythrocytes (Vander Jagt et al., 1990). Apart from 
PfGlo2, P. falciparum is known to be devoid of D-lactate producing enzymes such as lactate 
racemase. Methlyglyoxal reductase activity was also found to be negligible in the parasite unit 
(Urscher et al., 2011; Vander Jagt et al., 1990). Thus, D-lactate production in the host-parasite 
unit is thought to be only by the highly active and efficient glyoxalase systems (Urscher et al., 
2011; Vander Jagt et al., 1990).  
 
 
 
 
Figure 1.8. Formation, reactivity and detoxification of methylglyoxal in parasitized erythrocytes. The 
erythrocyte (E) and the malaria parasite (P) both consume high levels of glucose via glycolysis. During the 
interconversion of dihydroxyacetone-phosphate and glyceraldehyde-3-phosphate, the three-carbon intermediates 
of glycolysis, methylglyoxal is spontanously produced by elimination of a phosphate group from their 
phosphate-ene-diolate intermediate. Methylglyoxal (MG) is a highly electrophilic compound and reacts with 
bases in nucleic acids and proteins resulting in the generation of advanced glycation endproducts (AGE, two 
examples are shown at the right side). Thus, the 2-oxoaldehydes can be cytotoxic and mutagenic especially when 
they accumulate in the cell. To circumvent such detrimental effects, the canonical glyoxalase system – consisting 
of the two enzymes Glo1 and Glo2, and reduced glutathione (GSH) as a co-factor – converts harmful 2-
oxoaldehydes to non-toxic 2-hydroxycarboxylic acids such as D-lactic acid. Owing to the exceptionally high 
glycolytic fluxes in the host-parasite unit, inhibition of the glyoxalase system (grey crosses) should result in the 
accumulation of AGE and could be lethal to the parasite. Taken and modified from (Urscher et al., 2011). 
 
 
There is therefore the plausible suggestion that, the glyoxalase system is essential to the 
survival of the parasite and so inhibition of the glyoxalases of the host-parasite unit could 
have toxic effects on the parasite and may lead to cell death. If this hypothesis is true, it would 
also mean that the glyoxalase enzymes of the host-parasite unit could serve as potential 
targets for the development of new antimalarial drugs (Urscher et al., 2011; Iozef et al., 2003; 
Vander Jagt et al., 1990; Thornalley et al., 1994). Inhibition of the glyoxalases of the host-
parasite unit could then be pursued in two ways: i) a general inhibition of both glyoxalase 
systems of the unit using nonspecific Glo1 or Glo2 inhibitors, or ii) selective inhibition of the 
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parasite glyoxalase system using parasite-specific Glo1 and Glo2 inhibitors. In the first 
approach, the exceptionally high glycolytic fluxes in parasitized erythrocytes, coupled with 
the fact that the parasite consumes more glucose than the host erythrocytes (Sherman, 1979; 
Vander Jagt et al., 1990), could make the host-parasite unit more sensitive to glyoxalase 
inhibition compared to unparasitized erythrocytes. Treatment with inhibitor concentrations 
that should normally be save for uninfected erythrocytes could therefore be disruptive to the 
unit leading to parasite death. Since the erythrocyte lacks de novo protein bio-synthesis, 
moderate inhibitor concentrations may inactivate key redox enzymes leading to the 
development of redox imbalaces in the cell and presenting a hostile environment for the 
parasite to survive. The second approach is based on the fact that the kinetic properties and 
quaternary structures of the parasite glyoxalases are different from those of the host (Urscher 
et al., 2011; Vander Jagt et al., 1990). Novel PfGlo1- or PfcGlo2-specific inhibitors can thus 
be used to induce selective toxicity to the parasite.  
One strategy that can be employed to investigate the essentiality of glyoxalases of the host-
parasite unit is to generate glyoxalase knockout of lines of the parasite. To date, there are no 
reports of knockout lines for any of the P. falciparum glyoxalases. The relevance of the host 
glyoxalase system for parasite development is also unknown. Concerning the latter, a couple 
of important questions need to be addressed. Firstly, does the parasite import host glyoxalase 
enzymes to cope with elevated 2-oxoaldehyde concentrations?  Enzyme import is plausible as 
P. falciparum, for example, imports human peroxiredoxin 2 for peroxide detoxification 
(Koncarevic et al., 2009). Secondly, does the parasite export methlyglyoxal to the host? The 
answers to the above questions will help address the relevance of the host glyoxalase system 
to parasite development.  
A number of compounds have already been investigated as potential inhibitors of the P. 
falciparum glyoxalases (Urscher et al., 2012; Thornalley et al., 1994; Kawatani et al., 2008; 
Thornalley et al., 1996 ). Curcumin, methyl-gerfelin and glutathione-derived compounds such 
as S-p-bromobenzyl glutathione have been tested against recombinant PfGlo1 or P. 
falciparum blood-stage parasites and are reported to exhibit promising but variant degrees of 
potency. Curcumin was reported to act on only one active side of recombinant PfGlo1 while 
methylgerfelin was shown to act on both sites and is also more potent in cell culture (Urscher 
et al., 2012). S-p-bromobenzylglutathione ethylester has also been shown to have antimalarial 
properties against P. falciparum culture with an IC50 value of approximately 5 µM after 6 h of 
exposure (Iozef et al., 2003; Thornalley et al., 1994). A few not-so impressive PfcGlo2 
glutathione-based inhibitors were also described (Akoachere et al., 2005). The common 
theme of these early P. falciparum glyoxalase inhibitor studies is the fact that, almost all have 
IC50 values in the lower micromolar concentration range (Urscher et al., 2011). Furthermore, 
two potent glutathione-based yeast Glo1 inhibitors were tested with PfGlo1. These inhibitors, 
compounds 1 and its gamma-glutamyltranspetidase (γ-GT)-resistant derivative, compound 2, 
were found to be specific and to inhibit both active sites of PfGlo1 regardless of the enzyme 
conformation. Both compounds were reported to be non-competitive tight-binding inhibitors 
with Ki
app values in the nanomolar range (Urscher et al., 2012). A major issue concerning 
some of the tested P. falciparum glyoxalase inhibitors is, however, the question of whether 
the compounds specifically target the parasite glyoxalase, the host enzymes or both (Silva et 
al., 2013). In summary, the glyoxalases of the host parasite-unit are hypothesized as potential 
drug targets for the development of new antimalarials. Even though a number of potential 
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inhibitors have already been identified, the suitability of the glyoxalases of P. falciparum as 
drug targets should be investigated by reverse genetics.  
 
 
1.5. Inhibitory effects of standard pro- and antioxidants on P. falciparum 
 
Malaria manifests when Plasmodium parasites infect and multiply in the red blood cells of the 
human host (Schofield & Grau, 2005). It is also known that, even upon blood invasion, most 
cases of infection in malaria-endemic regions are clinically silent, reflecting the ability of the 
host immune system to prevent disease (Schofield & Grau, 2005). In individuals with 
insufficient immunity, however, blood infection normally leads to overt disease with life 
threatening consequences if antimalarial treatment is not administered appropriately 
(Schofield & Grau, 2005; Gazzinelli et al., 2014). The redox metabolism of the host-parasite 
unit has been suggested to play a key role in the parasite survival and clearance (Becker et al., 
2004; Goyal et al., 2012). Sources of redox agents in the host-parasite unit may be 
endogenously produced or from exogenous sources such as antimalarial drugs (Goyal et al., 
2012; Jortzik & Becker, 2012). For instance, the metabolism of hemoglobin in the digestive 
vacuole has been proposed as a major endogenous source of reactive oxygen species that 
affects parasite survival. Endogenous oxidative stress is also suggested to be exerted on the 
parasite-host unit by the host immune system in reaction to immunogens from lysed 
erythrocytes (Goyal et al., 2012; Jortzik & Becker, 2012). Furthermore, genetic traits such as 
sickle-cell haemoglobin and glucose-6-phosphate dehydrogenase deficiency are suggested to 
affect parasite survival by generating oxidative stress in the erythrocytes (Jortzik & Becker, 
2012). Hemoglobin S trait in particular is suggested to be able to reduce cytoadhersion of 
infected erythrocytes by generating redox agents that affect the actin cytoskeleton of the cell 
(Cyrklaff et al., 2016). It is also known that chloroquine and quinacrine, among other 
quinolone drugs, work by inhibiting the heme detoxification system of the parasite (Petersen 
et al., 2011; Goyal et al., 2012). In principle, oxidative stress has been defined as a prolonged 
redox imbalance that results in the accumulation of oxidized and damaged molecules (Sies, 
1986). A major question that needs to be address is whether redox agents and oxidative stress 
really play a physiological role in parasite survival or clearance by the host system. While 
numerous studies point to the physiological relevance of the redox state of the host-parasite 
unit to parasite survival and host immune response, mechanistic insights in support of the 
diverse hypotheses on oxidative stress are surprisingly scarce. Data regarding specific effects 
of standard redox agents on the parasite survival are also limited. There is, in particular, a lack 
of IC50 values for these agents for parasite survival in culture. This lack is remarkable 
especially on the account that some redox agents have already been used as adjuvants in 
clinical trials (Isah & Ibrahim, 2014; Charunwatthana et al., 2009). A common approach to 
test the relevance of oxidative stress on the development of the malaria parasite is to challenge 
infected erythrocytes in vitro with bolus amounts of standard pro- and antioxidants. 
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1.6.  Hypothesis and aims of the study 
 
Deletion of the genes coding for the P. falciparum glyoxalases is expected to lead to the 
accumulation of methylglyoxal and the depletion of glutathione in the parasite-host unit and 
may cause growth impairment or death of the parasite (Vander Jagt et al., 1990; Urscher et 
al., 2011). Disruption of each of the four glyoxalase genes or their combination could 
generate transgenic parasites, 3D7glo1, 3D7cglo2, 3D7tglo2 and 3D7gilp, that should 
have no activity for P. falciparum enzymes PfGlo1, PfcGlo2, PftGlo2 and PfGILP 
respectively. This would lead to an abolished or impaired parasite glyoxalase sytem and the 
accumulation of toxic 2-oxoaldehydes in the parasite. If disruption of any of the genes is 
lethal to the parasite, it would point to their essentiality, thereby signifying their use as 
antimalarial drug targets. This hypothesis is plausible considering that chloroquine, one of the 
few potent antimalarials, works by targeting a detoxification system of the parasite (Urscher 
et al., 2011). The main objective of this project was to determine whether knockout of one or 
more of the glyoxalase genes of the malaria parasite P. falciparum impairs parasite growth or 
is even lethal. In this study, the CRISPR/Cas9 system gene knockout strategy (Ghorbal et al., 
2014) was employed to attempt the deletion of each of the four P. falciparum glyoxalase-
encoding genes and to investigate whether the enzymes are essential for the blood-stage 
development of the parasite. Viable transgenic parasites were characterized phenotypically 
using microscopy and biochemical methods.  
A second objective of the thesis was to investigate the relevance of the host glyoxalase system 
for the survival of the parasite in the host-parasite unit. To address this aspect, known Glo1-
specific tight-binding inhibitors were employed to inactivate the glyoxalase system of 
erythrocytes. The treated erythrocytes were subsequently used to culture purified P. 
falciparum parasites. Since there are no glyoxalase knockout erythrocytes available, this 
strategy allowed for an indirect assessment of the contribution the host Glo1 to parasite 
growth and survival in the host-parasite unit of the P. falciparum-infected erythrocyte.  
A third objective of the thesis was to investigate the effects of standard pro- and antioxidants 
on the survival of the chloroquine-sensitive 3D7 strain of P. falciparum as a way of 
addressing the relevance of oxidative stress on the development of the parasite. Specifically, 
IC50 values for hydrogen peroxide (H2O2), N-acetyl-L-cysteine (NAc), ascorbate and 
dithiothreitol (DTT) were determined for in vitro cultures of the malaria parasite using SYBR 
green-based growth assays. The growth analysis of P. falciparum 3D7 parasites which were 
treated with different concentrations of ascorbate was also performed. Results from these 
investigations might serve as a guideline to manipulate the redox state of the host-parasite unit 
and the use of redox agents in the management of malaria. 
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2. MATERIALS 
 
 
2.1. Technical equipments 
 
Equipment   Company, Design 
Agarose gel running system           Bio-Rad, Mini-sub cell GT®               
Agarose gel documentation system   Herolab, UVT-28 MV, Easy syst, Hama 390 UV 
filter 
Autoclave                                            Systec, VX-95 
Automated pipette controller            Brand GmbH + CO KG, accu-het®pro 
Automatic film processor                   LiCOR, JP-33  
Balances and scales                         Sartorius, Entris-124-1S, Kern & Sohn, 440 
Blotting system                                   Peqlab Sedec M, PerfectBlue apparatur 
Bunsen burner                                     Labogaz, 470 
Centrifuges                                          Beckmann, J2-21M centrifuge, Heraeus,  
 multifuge 1 S‐R   
Electroporation system                        Bio-Rad, Gene Pulser II 
Fridges -20°C, -80°C fridge                   Liebherr, labor freezers, Kleinfeld, Labortechnik 
Hemocytometer                                   Marienfeld, superior CE 
Glass cuvettes  Hellma Analytics, OS blue quartz 
Incubator (Bacterial)                                 Heraeus, B5050 E  
Incubator (CO2)                                    Mytron, BS250/S  
Incubator shaker   Infors HT, triple stack 
Light microscope                                 Carl-Zeiss, Axio scope.A1 Pol 
Microfuge                                             Eppendorf, 5417R 
Microplate reader                                  BMG Latech, stapel machine stacker 
Microwave                                          AEG, micromat FX 175 Z                            
Molten glass pipette                           Lenz Laborglasinstrumente,  
Multichannel pipette                            Abimed, discovery comfort  
NanoDrop                                              Thermo Scientific, ND-1000 spectrophotometer 
Orbital shaker                                        Ratek, RPM5 
Overhead shaker                                   Heidolph, duomax 1030 
pH meter                                             Sartorius, PY-P10 
Rotator mixer                                     Grant-Bio, PTR-30 
Red light                                               Petra electric, IR 10 
SDS-PAGE system                             Bio-Rad, mini-protean tetra electrophoresis cell 
Sterile bench-Bacterial culture                   Gelaire®, BSB 3A 
Sterile bench-Plasmodium culture              Thermo Fischer Scientific, HerasafeTM KS  
Thermoblocks                                  Eppendorf, thermomixer comfort   
Thermal cycler                                 Eppendorf, mastercycler gradient 
Ultrasonic laboratory homogenizer      Bandelin, electronic sonopuls HD 2070 
UV/vis-Photomer                                Jasco, V-550 UV–vis spectrophotometer 
Magnetc cell separator                     Miltenyi Biotec, SEVarioMACS™ Separator 
Vortex mixer                                        Heidolph instruments, reax2000 
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Water bath                                             Fischer Scientific, Isotemp 210                          
 
 
2.2. Chemicals, Consumables and kits 
 
Company                                                     Chemical, consumable, kit 
Abcam Anti-AGE antibody, anti-P. Berghei heat shock  
                                                              protein 70 
Amersham ECL Western blotting detection reagent 
Bio-Rad                                                Goat anti-rabbit IgG (H+L)-HRP conjugate, 
HRP-conjugated goat anti-mouse, coomassie 
brilliant blue R-250 
Carl Roth                                              Giemsa solution, Akasolv aqua care, 
phenol/chloro-form /isoamylalcohol solution, 
milk powder 
c.c.pro                                                   Gentamycin, hypoxanthine,  
Clontech                                                In-Fusion HD cloning kit, stellar competent cells 
Fischer Scientific                                  Culture tubes 
Fischer-Sehner                                    Super RX-N film, fujifilm 
Fermentas                                             dNTPs 
GE Healthcare Life Sciences                Whatman paper, Nitrocellulose blotting 
membrane Protran BA85 
Gibco/Life Technologies                      Kanamycin, RPMI 1640   
Greiner Bio-One, cellstar                     2 mL cryovial, 15 and 50 mL Falcon tubes, 
culture dishes and flasks, 96 well plates, black 
fluotrac microplates, 15 and 50 mL centrifuge 
buckets 
Infors HT  Incubator shaker                                     
Invitrogen                                             TOPO-TA cloning kit, SYBR green 1 solution 
Life technologies GmbH                       Albumax II 
Metabion                                               Primers 
Millex GV                                             0.22 µm filter  
New England Biolabs                           Taq DNA polymerase, ThermoPol Taq-buffer, 
6X purple gel loading dye, 1kb and 100 bp 
Quick-Load DNA ladder, restriction enzymes, T4 
ligase and ligase buffer 
Nippon Genetics                                   Midori green advance DNA stain   
Novagen                                                E. coli NovaBlue 
Pierce                                                    SulfoLink resin  
Pineda Antibody Service                      Peptide synthesis and antibody production 
Promega Corperation                           Wizard Gel and PCR clean-up system  
Qiagen                                                  Plasmid maxi kit 
Roche                                                   Protease inhibitor, proteinase K  
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Sarstedt                                                0.5, 1.5 and 2 mL micro tubes, 1, 5, 10 and 25 
mL, serological pipettes, disposable cuvettes, 
TEMED 
Serva                                                    Agar, LB agar, bovine serum albumin                  
                                                             Ampicillin, isopropanol, absolute ethanol 
Sigma-Aldrich                                     Parafilm, methanol, ethanol, isopropanol, D-
sorbitol, 5-fluorocytosine, saponin, SDS, DNAse-
free RNase, chloroform, 2-mercaptoethanol, 
Ponceau S‐stain, Tris 
                                                           Tween-20, GSH, S-D -lactyolglutathione,                                                  
 methylglyoxal, glyoxal, phenylglyoxal,   
 ascorbate, dithiothreitol, hydrogen peroxide,  
 N-acetyl-L-cysteine   
Simax                                                   2L, 3L culture flasks 
Steinbrenner                                         Pipette tips 
Ted Pella, Inc                                       Glass chamber with a lid 
Thermo Sci./Menzel-Glaezer               Frosted-end microscope glass slides 
 
All other chemicals and reagents not listed above were obtained in analytical grade from 
certified distributors including Carl Roth, Merck, Sigma-Aldrich, Serva, Bio-Rad and 
AppliChem, or prepared using tested standard protocols in the laboratory. 
 
 
2.3. Plasmids, Primer and Strains 
 
Table 2.1. Table of plasmids used. 
Plasmid Properties/application Reference 
pQE30GLO1 AmpR, Expression of wild-type PfGlo1, N-term. His-tag (Iozef et 
al., 2003) 
TOPO-TA KanR, AmpR, Single 3’-thymidine overhang for TA Cloning, 
Topoisomerase I 
Invitrogen 
pUF1-Cas9 Expression of Cas9 protein in P. falciparum, 5’hsp : 3’Pb dhfr 
regulatory elements. NLS, ydhodh - positive selection. 
(Ghorbal et 
al., 2014)* 
pL6  Expression of sgRNA in P. falciparum, 5’ U6 : 3’ U6 regulory 
elements hdhfr- positive selection, ycfu- negative selection. 
(Ghorbal et 
al., 2014)* 
pL7-PFGLO1 pL6 containing guide sequence and HR for generation of 
PfGlo1 knockout strains 
This thesis 
pL7-PFcGLO2 pL6 containing guide sequence and HR for generation of 
PfcGlo2 knockout strains 
This thesis 
pL7-PFtGLO2 pL6 containing guide sequence and HR for generation of 
PftGlo2 knockout strains 
This thesis 
pL7-PFGILP pL6 containing guide sequence and HR for generation of 
PftGILP knockout strains 
This thesis 
* Kindly provided by Dr Jose-Juan Lopez-Rubio, Montpellier, France. 
 
 
Table 2.2. Oligonucleotides used. 
Primer No. Primer Name Sequence 5’   3’ 
P1 PfGlo1/5'fragKO/s:(SacII) GATCCCGCGGATTGCACAAGAAATATCAAATTTAG 
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P2 PfGlo1/5'fragKO/as:(XbaI) GATCTCTAGACCAATAATTATTAGGATCTAAAGC 
P3 PfGlo1/3'fragKO/s:(EcoRI) GATCGAATTCCAATGATTAGGGTTAAGAACCC 
P4 PfGlo1/3'fragKO/as:(NcoI) GATCCCATGGTTTGCAATAAATGAAGTGTCCC 
P5 PfcGlo2/5'fragKO/s:(SacII) GATCCCGCGGGTAGCCATGCGCACAAGTAC 
P6 PfcGlo2/5'fragKO/as:(XbaI) GATCTCTAGATTGGTTCATATGCTGATCCGAC 
P7 PfcGlo2/3'fragKO/s:(EcoRI) GATCGAATTCCGACGGTCAAATTATACGTTTAG 
P8 PfcGlo2/3'fragKO/as:(NcoI) GATCCCATGGTTAAGGGTATACTCATGTCCGC 
P9 PftGlo2/5’fragKO/s:(SacII) GATCCCGCGGGAGGAAGGTATTGTTGTTGATC 
P10 PftGlo2/5’fragKO/as:(XbaI) GATCTCTAGATCGAGTGTATATTCATGACCAC 
P11 PftGlo2/3’fragKO/s:(EcoRI) GATCGAATTCCCATTCCTAAGATGTGATCAG 
P12 PftGlo2/3'fragKO/as:(NcoI) GATCCCATGGTGTCACACTATAATCTATTAACTC 
P13 PfGILP/5’fragKO/s:(SacII) GATCCCGCGGGATGGTATAGAATATAAGGTCC 
P14 PfGILP/5'fragKO/as:(XbaI) GATCTCTAGACGACTTCAATTCCATAACCATC 
P15 PfGILP/3’fragKO/s:(EcoRI) GATCGAATTCCTACGTCAACAAAAGATGCTC 
P16 PfGILP/3'fragKO/as:(NcoI) GATCCCATGGTAAACATTATATCCGTCTAGGTC 
P17 PfGlo1/guideRNA/s TAAGTATATAATATTAAAGATCCAATCAAGTTAAA 
GTTTTAGAGCTAGAA 
P18 PfGlo1/guideRNA/as TTCTAGCTCTAAAACTTTAACTTGATTGGATCTTT 
AATATTATATACTTA 
P19 PfcGlo2/guideRNA/s TAAGTATATAATATTTACTTTCTCGTTTACACCTG 
GTTTTAGAGCTAGAA 
P20 PfcGlo2/guideRNA/as TTCTAGCTCTAAAACCAGGTGTAAACGAGAAAGTA 
AATATTATATACTTA 
P21 PftGlo2/guideRNA/s  TAAGTATATAATATTTCAAGTAATGTAGGAACAGT 
GTTTTAGAGCTAGAA 
P22 PftGlo2/guideRNA/as TTCTAGCTCTAAAACACTGTTCCTACATTACTTGA 
AATATTATATACTTA 
P23 PfGILP/guideRNA/s TAAGTATATAATATTTGAGAGCGACAAATTAGATA 
GTTTTAGAGCTAGAA 
P24 PfGILP/guideRNA/as TTCTAGCTCTAAAACTATCTAATTTGTCGCTCTC 
AAATATTATATACTTA 
P25 3D7/Cas9/s CTCTTGGAGAACTCGCTGATCTG 
P26 hDHFR s CATGGTTCGCTAAACTGCATC 
P27 hDHFR as CCTTTCTCCTCCTGGACATC 
P28 PfGlo1_5'UTR s GTGAGTATAGATCCTCATAACAACTTA CG 
P29 PfGlo1_3'UTR as CATTGAATAATTGTGCATATATGATATACACAC 
P30 PfcGlo2_5'UTR s     CGAGGATATGATTTCTTTATTTTTATAACC 
P31 PfcGlo2_3'UTR as     AATCCTTATAAACAGTGACACATTACAC 
P32 3D7/Cas9/as ACCGAGATTACCCTGGCCAACG 
P33 MCS1 primer pL6 CAAAATGCTTAAGTCCTCCAC 
P34 MCS2 primer pL6 AACATTTGCTTTCTTGAAACGG 
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P35 SP6 primer ATTTAGGTGACACTATAGAA 
P36 guideRNA Rev TTATGGTAGCCTTAAAAACTTC 
P37 PftGlo2 5’UTR s ATTATAAAGGCTTGTTACAATTGTGGAATG 
P38 PftGlo2 3’UTR as TTACAAGAATATATGGAAATAGGGTTACAG 
P39 Pf GILP 5’UTR s  TTAAGCCACTTTAATATCAATCC 
P40 Pf GILP 3’UTR as  GCTAGCTATTCATAATTTCATAAC 
Introduced restriction sites are underlined; guide sequence and its complementary sequence are 
captilized and italized respectively. 
 
 
Table 2.3. Table of bacterial and P. falciparum strains used. 
Strain Genotype/Description Reference 
E. coli XL 1-Blue recA1 endA1 hsdR17 supE44 thi-1 recA1 gyrA96 
relA1 lac[F’proAB lacIqZ∆M15Tn10] (TetR) 
Qiagen 
NovaBlue endA1 hsdR17(rK12
-mK12
+)supE44 thi-1 recA1 
gyrA96 relA1 lacF’ [proA+B+ lacIq Z∆M15::Tn10] 
(TetR) 
Novagen 
Stellar  F–, endA1, supE44, thi-1, recA1, relA1, gyrA96, 
phoA, Φ80d lacZΔ M15, Δ (lacZYA - argF) U169, Δ 
(mrr - hsdRMS - mcrBC), ΔmcrA, λ– 
Clontech 
P. falciaprum 3D7 Clonal line derived from NF54 (isolated from a 
person in Amsterdam, The Netherlands) 
(Rosario, 
1981; 
Walliker et 
al., 1987)* 
P. falciaprum 3D7glo1 PfGlo1 knockout clone This thesis 
P. falciaprum 3D7cglo2 PfcGlo2 knockout clone This thesis 
*kindly provided by Prof. Dr. M. Lanzer, Heidelberg 
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3. METHODS 
 
 
3.1. Design of strategy for P. falciparum glyoxalase gene disruption 
 
The gene maps and complete open reading frames of the four P. falciparum glyoxalases, 
PfGlo1, PfcGlo2, PftGlo2 and PfGILP, were obtained from the Plasmodium genomic 
resource PlasmoDB (PlasmoDB.org) with the gene identification numbers PF3D7_1113700, 
PF3D7_0406400, PF3D7_1205700 and PF3D7_0604700 respectively. PFGLO1, PFcGLO2, 
PFtGLO2 and PFGILP are located on chromosomes 11 (529493 - 530563), 4 (332,043 - 
333,856), 12 (253155 - 254123) and 6 (204,640 - 206,207) respectively. The length of the full 
coding sequence of PFGLO1, PFcGLO2, PFtGLO2 and PFGILP are 1071 bp, 1814 bp, 969 
bp and 1568 bp respectively. Regions within the coding sequences of the genes or areas just 
extending outside the 3’ or 5’ untranslated regions were selected as areas to be amplified by 
PCR for the cloning of the HRs (Table 3.1). The selected regions were areas that had the 
lowest A-T content in order to avoid non-specific homologous recombination. JustBio 
(JustBio.com), an online bioinformatics tool, was used to ‘clean’ gene sequences and to 
identify restriction sites for fragment selection and cloning. 
 
 
Table 3.1. 5’ and 3’ HRs and primers used for PCR amplifications. 
Gene locus Fragment Primer set Size of amplicon 
PFGLO1 5’ P1 & P2 ~ 477 bp  
 3’ P3 & P4 ~ 521 bp 
PFcGLO2 5’ P5 & P6 ~ 642 bp  
 3’ P7 & P8 ~ 442 bp 
PFtGLO2 5’ P9 & P10 ~ 467 bp  
 3’ P11 & P12 ~ 640 bp 
PFGILP 5’ P13 & P14 ~ 612 bp  
 3’ P15 & P16 ~ 625 bp 
 
 
3.2. Design and purification of pepetide antibodies 
 
For the production of antibodies against PfGlo1 and PfcGlo2, the synthetic peptides NH2-
CLKYQTDEDYENFKQSWEPV-CONH2 and NH2-CSAYEPTPGVNEKVYDGQ-CONH2 
were respectively generated and used to immunize rabbits by Pineda Antibody Service, 
Berlin, Germany. The two antibodies were subsequently purified from sera of the immunized 
animals by affinity chromatography according to previously described protocols. Antibody 
purification and testing were performed by Linda Liedgens. Briefly, the peptides were 
reduced by 25 mM borohydride in 50 mM Tris/HCl, 5 mM EDTA, pH 8.5 overnight at 4°C. 
The reduced peptides were coupled for 45 min to 1 ml SulfoLink resin (Pierce, Bonn, 
Germany). Unspecific binding sites were blocked by 50 mM cysteine solution in 50 mM Tris, 
5 mM EDTA, pH 8.5. Chromatography and elution were performed according to the 
manufacturer´s protocol. Antibody-containing eluate fractions were identified on a 
coomassie-stained 15% sodium dodecyl sulphate (SDS)-gel. Approximately 2*107 purified 
malaria parasites were analyzed per lane on a SDS-gel followed by western blotting using 
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preimmune serum (PS), serum (S) and purified antibody (Ab) for decoration of the 
membrane. 
 
 
3.3. Plasmid constructs  
 
3.3.1. Cloning strategy of knockout plasmids 
  
The Cas9-encoding plasmid (pUF1-Cas9) and the pL6 plasmid containing the single guide 
RNA (sgRNA) that carries only the Cas9 binding sequence were generously supplied by Jose-
Juan Lopez-Rubio (Ghorbal et al., 2014). pL7 transfection plasmids containing the full 
complement of the sgRNA expression-cassette (including the 20 bp guide sequence) and the 
5’ and 3’ homologous regions of PFGLO1, PFcGLO2, PFtGLO2 and PFGILP were 
generated by multiple cloning steps into the pL6 plasmid. The 3’ and 5’ homologous regions 
of each gene were first cloned one-after-the-other into the empty pL6 plasmid to generate 
plasmids pL6-PFGLO1, pL6-PFcGLO2, pL6-PFtGLO2 and pL6-PFGILP respectively. The 
specific guide sequence for each gene was then cloned into the pL6-PFGLO1, pL6-
PFcGLO2, pL6-PFtGLO2 and pL6-PFGILP plasmids to generate the respective pL7 
plasmids.  
 
 
3.3.2. PCR amplification of homologous regions 
 
The 5’ and 3’ homologous regions of PFGLO1 were amplified by PCR from the 
pQE30/PFGLO1 plasmid (Urscher et al., 2012). The homologous regions of PFcGLO2, 
PFtGLO2 and PFGILP were amplified from genomic DNA (gDNA) of P. falciparum 3D7 
wild-type strain. All PCR-generated homologous regions were initially sub-cloned into the 
pCRII-TOPO vector as single entry fragments before they were excised and recloned into the 
pL6 vector. A summary of the sizes of the 5’ and 3’ fragments together with the primers used 
for the amplifications PCR is shown in table 3.1. Primers used in this project were ordered 
from Metabion International AG, Germany, in 100 µM concentrations as listed in table 2.2. 
Taq DNA polymerase was used for all fragment PCR amplifications in order to generate the 
3’ deoxyadenosine (A) overlap required for TOPO cloning. All PCRs contained 100 ng (0.5 
µL) of genomic DNA in a reaction mixture with 2 µL of dNTPs (0.4 mM), 5 µL ThermoPol 
Taq-buffer, 1 µL Taq DNA polymerase  and 0.5 µL of each primer (1 µM) in 40.5 µL of 
Millipore water. The cycler program used was: 94°C for 3 min, followed by 30 cycles of 94°C 
45 s, 58°C 45 s and 68°C 60 s, and then a final extension at 68°C for 2 min and hold at 4°C. 
PCR reactions were performed in an Eppendorf mastercycler gradient thermal cycler. To 
analyze the PCR products, 8 µL of the product was added and mixed with 2 µL of gel loading 
dye that was supplemented with Midori green advance DNA stain. Two (2) µL of Midori 
green solution was added to the original 1 mL volume of the loading dye , purple 6X (NEB). 
The samples were then loaded on a 2% agarose gel along with 5 µL of 100 bp DNA ladder to 
estimate the length of the PCR products. To enhance ladder-band clarity, the original Quick-
Load 100 bp DNA ladder vial (NEB) of 1.25 mL was also supplemented with 2 µL Midori 
green advance DNA stain. The gel was ran at 100 V for 30 min in 1x Tris-acetate-EDTA 
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(TAE) buffer in a Bio-Rad agarose gel running system. To produce the 2% agarose gel, 8 g of 
agarose powder was heated to melt in an AEG Micromat at 100% for 3 min. The gel was 
viewed on a gel documentation system transilluminator/ UV and a picture was taken with a 
camera fitted with a Hama 390 UV filter.  
 
1x TAE buffer           40 mM Tris (pH 7.6) 
                                  20 mM acetic acid 
                                  1 mM EDTA 
 
 
3.3.3. TOPO cloning of homologous regions 
 
Positive HR PCR products were cloned into TOPO-TA vectors using the TOPO-TA cloning 
kit from Invitrogen according to the manufacturer’s protocol. Briefly, 4 µL of positive PCR 
product was mixed with 1 µL each of salt solution and linearized TOPO vector to give a final 
reaction volume of 6 µL. The reaction was incubated at room temperature (22-23°C) for 5 
min and then after stored on ice or at -20°C pending transformation. The TOPO reaction was 
used to transform commercial Novablue chemical competent cells following the 
manufacturer’s protocol. Briefly, 1 µL of the reaction was gently mixed with 20 µL of thawed 
Novablue chemical competent cells and the mixture was stored on ice for 5 min. The mixture 
was heat-shocked at 42°C for 30 s on a heating block and immediately returned to ice for 2 
min. Eighty (80) µL of room-temperature super optimal broth with catabolite repression 
(SOC) was added and gently mixed. To regenerate the cells, the mixture was incubated whilst 
shaking at 37°C (250 rpm, orbital shaking) for 30 min. Fifty (50) and 150 µL of the 
transformed cell suspension were plated and selected on kanamycin agar overnight at 37°C in 
a laboratory incubator after sealing the plates with parafilm. Plates with grown colonies were 
removed and stored at 4°C pending plasmid expansion, extraction and purification.  
 
 
3.3.4. Plasmid minipreparation from E. coli cells 
 
TOPO-TA plasmid DNA was extracted and purified by minipreparation of plasmid DNA 
based on alkaline lysis of transformed E. coli cells (Birnboim & Doly, 1979 ). Briefly, several 
single colonies from each plate were picked and used to inoculate sterile glass test tubes 
containing 3 mL of autoclaved lysogeny broth (LB) medium that was supplemented with 
ampicillin to a final concentration of 100 µg/mL. The cultures were transferred to an Infors 
triple stack shaker and incubated overnight at 37°C whilst shaking (130 rpm, orbital shaker). 
Bacterial cells were harvested by the step-wise transfer of each of the overnight cultures into a 
2 mL microtube and centrifugation at 16 000 g in a microfuge for 30 s at 4°C. After 
discarding the supernatant, the cell pellets were thoroughly dried and completely resuspended 
in 100 µL of ice cold buffer 1. To lyse the cells, 200 µL of room-temperature buffer 2 was 
added to the cell suspensions and gently mixed by inverting the tube five times. The mixtures 
were incubated at room temperature for 5 min to ensure complete cell lysis. One hundred and 
fifty (150) µL of ice cold buffer 3 was added to each mixture to neutralize the pH and 
precipitate the genomic DNA and proteins. After mixing by gently inverting the tube 3 times, 
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the suspensions were centrifuged at 16 000 g in a microfuge for 10 min at 4°C. The clear 
supernatants were decanted into a 1.5 mL micro tubes and the plasmid DNA precipitated by 
adding 600 µL of room-temperature isopropanol. The tubes were inverted 3 times and the 
suspensions were centrifuged at 16 000 g for 5 min at 4°C to pellet the plasmid DNA. Note 
was taken of the position of the formed DNA pellets for each preparation and the supernatants 
was gently removed by aspiration using a molten glass pipette. Six hundred (600) µL of 70% 
ethanol (-20°C) was added and the tubes inverted 3 times to wash the pellets. The suspensions 
were again centrifuged at 16 000 g for 5 min at 4°C and the supernatants completely removed 
by aspiration. The plasmid DNA pellets was finally dried under red light for 10 min, 
dissolved in 30 µL of autoclaved Millipore water and stored at -20°C. To analyze the 
extracted TOPO-TA plasmids for integration of the 5’ and 3’ fragments of each gene, 4 µL of 
each plasmid suspension was digested with the restriction enzyme EcoRI (NEB) according to 
NEB recommendations and ran on a 1% agarose gel. Positive plasmids were checked for the 
fidelity of the integrated 5’ and 3’ fragments by Sanger sequencing (GATC Biotech, Cologne 
Germany) using the GATC Biotech SP6 TOPOTA plasmid negative sense primer, P23. A 1:4 
dilution of plasmid in a total volume of 20 µL was sent for sequencing. Positive plasmids of 
high sequence fidelity were stored at -20°C pending pL6 cloning. 
 
Buffer 1             10 mM EDTA, pH 8.0 
50 M Tris  
 0.1 mg/ml RNAse A (store Buffer 1 at 4°C) 
 
Buffer 2             1% (w/v) SDS 
                           200 mM NaOH (store Buffer 2 at room temperature) 
 
Buffer 3             60 ml 3 M potassium acetate 
                          11.5 ml glacial acetic acid 
                          28.5 ml millipore water (store Buffer 3 at 4°C) 
 
 
3.3.5. Cloning of homologous regions into the pL6 plasmid 
 
To generate the pL6-PFGLO1, pL6-PFcGLO2, pL6-PFtGLO2 and pL6-PFGILP plasmids, 
the pL6 plasmid was first amplified. This was achieved by transforming home-made XL1-
Blue chemical competent cells with the plasmid following the protocol described above but 
with slight changes. Briefly, 3 µL of plasmid was mixed with 50 µL of competent cells and 
stored on ice for 30 min. The suspension was then heat-shocked at 42°C for 90 s in a heating 
block and transferred to ice for 5 min. Five hundred (500) µL of room-temperature LB 
medium was added to the suspension and incubated at 37°C while shaking at 500 rpm on a 
heating block for 1 hr. Fifty (50) and 150 µL aliquots were plated on ampicillin selection agar 
and grown overnight at 37°C in a laboratory incubator. Plasmid expansion, extraction and 
purification were achieved through minipreparation as described above for TOPO-TA 
plasmid. For the cloning steps, the 3’ and 5’ fragments were excised from the TOPO-TA 
vector using double restriction digestion according to NEB protocol. Restriction enzyme-pairs 
used to excise the 5’ and 3’ fragments from the TOPO-TA plasmids were SacII/XbaI (NEB) 
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and EcoRI/NcoI (NEB) respectively. pL6 plasmids were also step-wise double digested with 
the enzymes EcoRI/NcoI for cloning-in the 3’ fragment and SacII/SpeI for cloning-in the 5’ 
fragments. Digested TOPO-TA and pL6 plasmids were run on 2% and 0.8% agarose gels 
respectively. Gel portions containing the fragments and linearized pL6 plasmid were cut out 
and collected in 2.0 mL microtubes. The gel pieces were purified using the Wizard SV gel 
and PCR clean-up system (Promega Corperation) according to the manufacturer’s instructions 
and stored at -20°C. Ligation of the fragments and the linearized plasmid was performed 
according to NEB protocol. Briefly, 1 µL of purified plasmid, 4 µL of purified fragment, 2 µL 
of T4 ligase buffer (NEB) and 1 µL T4 ligase (NEB) were adjusted to a total reaction volume 
of 20 µL with autoclaved Millipore water in a 0.5 mL micro tube. The reaction was incubated 
overnight at 16°C and then heated to 65°C for 10 min in a heating block to inactivate the 
ligase. Eight (8) to 15 µL of the ligation mixture was used to transform 50 µL of home-made 
XL1-Blue competent cells as described above. Transformed cells were plated and selected on 
ampicillin agar that was subsequently incubated overnight at 37°C in a laboratory incubator. 
Plasmid expansion, extraction and purification were achieved as described above. The 
integration of the 3’ and 5’ fragments into the plasmid was controlled by PCR and Sanger 
sequencing. For the PCR control, the primer sets P1/P33, P5/P33, P9/P33 and P13/P33 were 
used to check for 5’ fragment integration on the pL6-PFGLO1, pL6-PFcGLO2, pL6-
PFtGLO2 and pL6-PFGILP plasmids respectively (Table 2.2). To check for the 3’ fragment 
integration, the primer sets P3/P34, P7/P34, P11/P34 and P15/P34 were used for the pL6-
PFGLO1, pL6-PFcGLO2, pL6-PFtGLO2 and pL6-PFGILP plasmids respectively (Table 
2.2). The PCR conditions and cycler program followed the same parameters used to amplify 
fragments as described above. Primers P33 and P34 were also used to respectively sequence 
the integrated 5’ and 3’ fragments of all four plasmids (Table 2.2). 
 
 
3.3.6. Cloning of guide sequence into the pL6 plasmid 
 
To generate plasmids pL7-PFGLO1, pL7-PFcGLO2, pL7-PFtGLO2 and pL7-PFGILP, the 
BtgZI-adaptor on the sgRNA of the pL6-PFGLO1, pL6-PFcGLO2, pL6-PFtGLO2 and pL6-
PFGILP plamids was replaced by the guide RNA (gRNA) using the In-Fusion HD cloning kit 
from Clontech following the manufacture’s protocol. In-Fusion HD cloning procedure 
employs a special In-Fusion enzyme to join complementary 15 bp overlaps on the pL6 
plasmid and on specially designed 50 bp primers that also carry the specific guide sequence 
(gRNA) of each target gene. Twenty- (20)-base gRNAs for each target were designed flanked 
with the 15 bases (necessary for In-Fusion cloning) using the Protospacer software and 
ordered as two complementary oligonucleotides (guide sequence primers). The guide 
sequence primer pairs for cloning of the pL7-PFGLO1, pL7-PFcGLO2, pL7-PFtGLO2 and 
pL7-PFGILP were P17/P18, P19/P20, P21/P22 and P23/P24 respectively (Table 2.2). The 
modified pL6 vectors were first amplified, extracted and purified, as described above, to 
obtain enough plasmid DNA for the reaction. Ten (10) µL of purified plasmid was digested 
stepwise with AvrII and BtgZI. The plasmid was first digested with AvrII for 2 hr at 37°C and 
then BtgZI for 2 hr at 60°C. For the cloning procedure, the excised plasmid was separated on 
a 1% agarose gel and purified using the Wizard SV Gel and PCR clean-up system. The 
plasmid concentration was subsequently determined on a gel by band intensity analysis. Fifty 
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(50) µL of each guide sequence primer pair were mixed in a 0.5 mL micro tube, heated at 
94°C for 2 min and slowly cooled down to anneal. In the ligation step, approximately 100 ng 
of purified linearized plasmid and 50 ng of duplex oligonucleotide were mixed with 2 µL of 
In-Fusion HD enzyme. The mixture was topped up with distilled water to a final reaction 
volume of 10 µL, incubated for 15 min at 50°C and then placed on ice or stored for longer 
periods at -20°C pending transformation. In-Fusion reaction products were used to transform 
Stellar chemical competent cells from Clontech following the producer’s directions. Briefly, 5 
ng (2.5 µL) of reaction product was mixed with 50 µL of Stellar chemical competent cells. 
The cell suspension was placed on ice for 30 min and heat shocked for exactly 60 s at 42°C. 
The suspension was transferred back to ice for 2 min, 450 µL of 37°C pre-warmed SOC was 
added and then after incubated at 37°C while shaking (225 rpm) for 1 hr on a heating block. 
Twenty (20) µL, 50 µL and 100 µL of the transformed cell suspension as well as 50 µL of a 1 
in 100 dilution in SOC medium were plated and selected on ampicillin plates. The rest of the 
suspension (about 330 µL) was centrifuged for 5 min at 6000 rpm and plated after 200 µL of 
the supernatant was discarded. The plates were incubated overnight at 37°C. Plasmid 
expansion, extraction and purification were achieved by minipreparation as described above 
for pL6 plasmid. The integration and sequence fidelity of the cloned-in guide sequence of 
each pL7 plasmid was confirmed by PCR and Sanger sequencing. PCR analyses were 
performed using the primer pairs P17/P24, P19/P36, P21/P36 and P23/P36 to control the 
guide sequence integration on the pL7-PFGLO1, pL7-PFcGLO2, pL7-PFtGLO2 and pL7-
PFGILP plasmids respectively (Table 2.2). PCR conditions and cycler program followed the 
same parameters used to amplify the fragments from genomic DNA as described above. 
Sequencing was done using primer P36 (Table 2.2). 
 
 
3.3.7. Maxipreparation of pL7 plasmid for transfection 
 
To produce appropriate quantities of pL7 plasmid DNA for the transfection of P. falciparum 
3D7 wild-type strains, a maxipreparation of controlled plasmids was performed using a 
Qiagen plasmid maxi kit according to the manufacturer’s instructions. Briefly, 2 µL of 
minipreparation of each plasmid was used to transform 50 µL of home-made XL1-Blue 
competent cells as described above for the transformation with pL6 plasmids. A single colony 
from each plasmid plate was picked and used to inoculate a sterile glass test tube of 3 mL 
starter culture made up of autoclaved LB medium supplemented with ampicillin to a final 
concentration of 100 µg/mL. The cultures were transferred to an Infors triple stack shaker and 
incubated at 37°C for 8 hr whilst shaking (130 rpm, orbital shaker). After the incubation, 500 
µL of each culture was used to inoculate 500 mL of autoclaved LB medium supplemented 
with ampicillin to a final concentration of 100 µg/mL in a 2 liter flask. The cultures were 
grown while shaking at 300 rpm in a triple stack shaker set at 37°C. Bacterial cells from each 
culture were harvested after 16 hr of growth and transferred into two 500 mL J10 rotor 
centrifuge buckets. The cells were pelleted by centrifugation at 6 000 g for 15 min at 4°C in a 
Beckmann centrifuge using a J10 rotor. Each cell pellet (about 1.7 g) was resuspended in 10 
mL of resuspension buffer (P1) and then transferred to a 30 mL J17 rotor centrifuge tube. Cell 
lysis was performed by the addition of lysis buffer (P2). Suspensions was thoroughly mixed 
and incubated at room temperature for 5 min to ensure complete cell lysis. Ten (10) mL of ice 
cold neutralizing buffer (P3) was added and the mixtures were incubated on ice for 20 min to 
3 METHODS 
 
46 
 
neutralize the pH and precipitate the genomic DNA and proteins. The mixtures were 
subsequently centrifuged at 20 000 g for 30 min at 4°C in a Beckmann centrifuge using a J17 
rotor. Each plasmid supernatant was promptly transferred into a fresh sterile J17 rotor 
centrifuge tube and centrifuged again at the same speed and temperature for 15 more min to 
further clear the supernatant. The clear supernatants were loaded onto different Qiagen-tip 
500 column that was already equilibrated with 10 ml of equilibration buffer. After DNA 
binding to the column resin and after discarding the follow-through, the columns were washed 
with 60 mL of wash buffer (QC) to remove carbohydrates and other plasmid contaminants. 
Purified plasmid DNA was then eluted with 15 mL of elution buffer (QF) into fresh sterile 
J17 rotor centrifuge tubes. Ten and half (10.5) mL of isopropanol at room-temperature was 
added to each DNA elution and mixed to precipitate the DNA. The mixtures were centrifuged 
at 15 000 g for 30 min at 4°C in a Beckmann centrifuge using a J17 rotor to pellet the plasmid 
DNA. Note was taken of the sites of DNA pellet formation on the tubes during centrifugation. 
After decanting the supernatants, each DNA pellet was washed once with 70% ethanol that 
was at room-temperature and then centrifuged again for 15 min at the same speed and 
temperature. The pellets were air-dried for 10 min after carefully decanting the supernatants. 
The air-dried DNA was finally redissolved in 250 µL of Tris-EDTA (TE) buffer and a 2 µL 
aliquot of each DNA suspension was taken for determination of the concentration using a 
Nanodrop spectrophotometer. Pending transfection, the purified plasmid DNA samples were 
stored at -20°C. 
 
TE buffer            10 mM Tris, pH 8.0 with HCl 
                            1 mM EDTA 
 
 
3.4.  P. falciparum cell culture 
 
3.4.1. P. falciparum parasite culture 
 
Culture of P. falciparum parasites was performed aseptically on a cell culture sterile bench. 
Culture media, solutions, flasks, plates, tubes, equipment, pipettes and drugs were sterilized or 
autoclaved before use to avoid contamination. Parasite cultures were performed using fresh 
and steril human A+ red blood cells which were kindly provided by the laboratory of Prof. 
Michael Lanzer, Heidelberg. Sterile gloves were worn at all times when working on the sterile 
bench and handling cell culture materials. After every work day, the sterile bench was 
sterilized with U-V light for one hour. The sterile bench was then started 15 min before work 
commences again. The working area and gloves were disinfected with 70% ethanol before 
beginning every cell culture session. The Isotemp 210 water bath for prewarming media and 
solutions was cleaned regularly, and the water was replaced with fresh Millipore water that 
was supplemented with Akasolv aqua care. The parasite incubator and cell culture centrifuge 
were also kept clean and disinfected at all times. 
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3.4.2. Thawing and cultivation of parasite strains 
 
Thawing of glycerol frozen stocks of P. falciparum strains followed the method of Stanisic et 
al. (Stanisic et al., 2015) with slight changes. Suspension of cells in cryo-protectants such as 
glycerol and then freezing in liquid N2 is effective and increases parasite survival in and after 
long storage (Miyake et al., 2004). To ensure parasite recovery, survival and viability, the 
thawing process also involves a method of stepwise suspension cells in three sterile solutions 
of reducing concentrations of sodium chloride (NaCl). The general effect of the serial 
application of these solutions is to gradually reconstitute isotonicity of the parasite after the 
thawing  process (Diggs et al., 1975).  
A culture of erythrocyte-stage P. falciparum 3D7 wild-type strains or transgenic parasite 
strains was started from a frozen glycerol stock that was previously stored in liquid nitrogen 
(N2) in a 2 mL cryovial. The cryovial was removed from the nitrogen tank with a pair of 
tweezers and quickly thawed for 1 min in a 37°C water bath. The vial was then disinfected 
and taken to the sterile bench where the content was transferred into a 15 mL Falcon tube 
using a 1 mL serological pipette. A small volume of solution A (0.2 volumes) that was sterile-
filtered with a 0.22 µm filter and prewarmed at 37°C was added drop-wise to the infected 
erythrocytes while swirling to allow osmosis to occur. The cell suspension was incubated for 
2 min to allow the removal of glycerol from the cells. Ten (10) volumes of prewarmed and 
sterile-filtered solution B was next added drop-wise to the suspension using a 10 mL 
serological pipette while swirling. The erythrocytes were pelleted by centrifugation at 1198 
rpm (300 g) in the Heraeus multifuge for 5 min at room temperature and the supernatant was 
discarded. The cell pellet was then resuspended in 10 volumes of sterile-filtered solution C 
and centrifuged again at 300 g for 5 min at room temperature. Most of the supernatant was 
again discarded and the cell pellet was washed once with 10 ml of complete RPMI medium. 
After a final centrifugation step to pellet the washed infected-erythrocytes, the supernatant 
was discarded and the cell pellet was resuspended in 8 mL of complete medium. Finally, the 
cell suspension was transferred to a new 100 x 20 mm culture petri dish or a 250 mL culture 
flask that already contained 500 µL of fresh, washed human A+ red blood cells (RBCs) in 6 
mL of complete RPMI medium. The starting culture volume was thus set at 14.5 mL with a 
hematocrit of 3.5%. The new culture was resuspended, transferred to a CO2 incubator and 
cultured according to the method of Trager and Jensen (Trager & Jensen, 1976). All pipetting 
steps were performed with sterile 1 mL or 10 mL pipettes to avoid contamination. The 
incubation conditions were set at 36.5°C, 5% O2, 5% CO2 and 80% humidity. Culture 
medium was replaced every 24 hr with fresh complete RPMI medium. Giemsa-stained blood 
smears were performed after 48 hr to determine the culture parasitemia by counting and 
averaging three microscopic fields using a light microscope (Carl-Zeiss). At ≤ 7% ring 
parasitemia, the culture was split to a desired parasitemia to maintain the parasites well-
nourished and healthy. 
 
Solution A           12% NaCl 
Solution B           1.6% NaCl 
Solution C           0.9% NaCl 
                            0.2% (v/v) glucose (energy source) 
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Complete RPMI medium            incomplete RPMI 1640 medium (500 mL) 
                                                     0.45% (w/v) albuMAX II 
                                                     2.7 µg/mL gentamicin 
                                                     0.2 mM hypoxanthine 
 
 
3.4.3. Splitting the culture 
 
To split a culture to a desired parasitemia, a new culture petri dish or culture flask was set up 
containing 14 mL of complete culture medium (minus the volume of the original culture to be 
added to it to make the culture dilution). Four (4) mL of supernatant was removed from the 
original 14 mL culture to be split and the remaining culture (10 mL) was resuspended. The 
estimated volume of original culture to make the new parasitemia was pipetted and added to 
the new petri dish or flask. Five hundred (500) µL of fresh erythrocytes (minus the volume of 
erythrocytes added from the old culture), was added to the new culture to give a new starting 
hematocrit of 3.5% in a final culture volume of 14.5 mL. The new culture suspension was 
mixed, transferred to the incubator and cultured under standard conditions.  
 
 
3.4.4. Determination of parasitemia and culture viability  
 
The estimation of culture parasitemia and determination of parasite viability were carried out 
using Giemsa-stained thin blood smears. A portable laboratory Bunsen burner and a lighter 
were disinfected with 70% ethanol and moved onto the sterile bench along with two 
microscope glass slides with frosted ends. The culture to be analyzed was also gently moved 
onto the sterile bench. Using the tip of a 1 mL pipette that was briefly flamed in Bunsen 
burner fire to create a wider slanting opening, infected erythrocytes were removed from the 
bottom of the slightly tilted flask and transferred to the upper part of one of the glass slide that 
was also labeled. With the second slide, the erythrocyte drop was smoothly and gently spread 
along the labelled slide. The culture was returned to the incubator. The smeared slide was 
allowed to air-dry and the infected-erythrocytes fixed for 10 seconds in 100% methanol in a 
glass chamber with a lid. After fixation, the slide was allowed to dry in air before the smear 
was stained for 30 min in 40 mL of 4% (v/v) Giemsa solution that was freshly prepared in 
deionised water. Excess stain was washed off both sides of the slide using a strong jet of 
deionised water. The slide was subsequently dried using a paper towel and analyzed under a 
light microscope (using the 100 x objective with oil immersion). Employing the incorporated 
objective grid, the parasitemia was estimated from five (5) to seven (7) random microscope 
fields (750-1500 erythrocytes). The morphology of the parasites in the erythrocytes was also 
assessed as one of the signs of parasite viability. 
 
 
3.4.5. Synchronization of parasite growth 
 
The method of synchronization proceeded as described by Lambros and Landerberg  
(Lambros & Vanderberg, 1979) but with slight modification. To obtain synchronized cultures, 
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parasites were treated with 5% (v/v) D-sorbital. Sorbitol treatment causes selective destruction 
of trophozoites and schizonts in a mixed-stage P. falciparum culture (Lambros & Vanderberg, 
1979). A Giemsa-stained thin blood smear was thus first performed to confirm that the culture 
to be synchronized contained mostly parasites at the young ring-stage of development. To 
proceed with synchronization, the culture was resuspended in the old medium with a 10 mL 
pipette on the sterile bench and transferred to a 15 mL Falcon tube. Infected erythrocytes were 
pelleted by centrifugation of the suspension at 300 g in a Heraeus multifuge for 5 min at room 
temperature. After discarding the supernatant back on the sterile bench, the pellet was 
thoroughly resuspended in 10 volumes of sterile-filtered 5% D-sorbitol that was pre-warmed 
to 37°C. The suspension was incubated for 5 min at room temperature and then after 
centrifuged at 300 g for 5 min at room temperature to pellet the treated infected-erythrocytes. 
To remove residual D-sorbital, the pellet, after discarding the supernatant, was washed in 10 
mL of pre-warmed complete RPMI medium and centrifuged at 300 g for 5 min. The 
supernatant was again discarded. The washed cell pellet was finally resuspended in 14 mL of 
prewarmed complete medium, transferred into a new culture petri dish and maintained under 
standard culture conditions as above. 
 
 
3.4.6.  Cryopreservation of P. falciparum parasites 
 
Long-term storage of wild-type and mutant strains of P. falciparum was achieved by 
suspending parasites in a freezing solution that contains 28% (v/v) glycerol following the 
method described by Stanissic and colleagues (Stanisic et al., 2015). A Giemsa-stained blood 
smear was first performed to confirm that the cultured parasites to be frozen were in the ring-
stage of development and have a parasitemia of more than 3%. The sterile-filtered freezing 
solution was prewarmed to 37°C and transferred to the sterile bench. A 2 mL sterile cryovial 
was also transferred to the sterile bench and labeled. The ring-stage culture (14.5 mL) was 
first resuspended in the old medium, transferred to a 15 mL Falcon tube and centrifuged at 
300 g in the Heraeus multifuge for 5 min at 23°C. After discarding the supernatant back on 
the sterile bench, the cell pellet was resuspended in 500 µL of freezing solution. The freezing 
solution was added drop-wise while swirling after each drop. The cell suspension (about 1 
mL) was then transferred into the labeled cryovial. The vial was tightly closed, snap-frozen in 
a Dewar vessel for 1 minute and then transferred with a pair of tweezers to a liquid nitrogen 
tank for long-term storage. 
 
Freezing solution           28% (w/v) glycerol 
                                       0.65% (w/v) NaCl 
                                       3% (w/v) sorbitol 
 
 
3.5. Transfection and selection of transgenic parasites 
 
Transfection of P. falciparum parasites was performed using the erythrocyte pre-load method 
of electroporation and involved an indirect and consecutive introduction of the pUF1-Cas9 
and pL7 plasmids into the parasite (Deitsch et al., 2001; Hasenkamp et al., 2012). 
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Transfection of parasites with the pUF1-Cas9 plasmid was performed first. Trangenic 
parasites expressing the Cas9 gene were then transfected with the different pL7 plasmids. 
 
 
3.5.1. Transfection of the pUF1-Cas9 plasmid 
 
Transfection of P. falciparum 3D7 wild-type strain with the pUF1-Cas9 plasmid proceeded as 
described below. Hundred (100) µg of plasmid DNA (≈ 900 ng/ µL) in a 2 mL micro tube 
was prepared for transfection by adding a volume of 3 M (pH 5) sodium acetate to make a 
final concentration of 0.3 M. Total volume of the plasmid DNA suspension was adjusted with 
autoclaved Millipore water to 200 µL. Five hundred (500) µL of absolute ethanol that was 
stored at -20°C was added to precipitate the DNA and the suspension was vortexed for 3 min. 
To enhance the precipitation of the plasmid DNA, the suspension was incubated at -20°C for 
30 min. The plasmid DNA was subsequently pelleted by centrifugation at 20 800 g for 30 min 
at 4°C. After discarding the supernatant, the DNA pellet was washed in 500 µL of 70% 
ethanol that was stored at -20°C and centrifuged at 20 800 g for 15 min at 4°C. The 
supernatant was discarded and the washed plasmid DNA pellet was air-dried on the sterile 
bench for 10 min after which it was resuspended in 30 µL of TE (Tris-EDTA) buffer, pending 
transfection. In addition, fresh and sterile erythrocytes were washed in preparation for 
electroporation. Two (2) mL of the red blood cells were suspended in 6 mL of cold sterile-
filtered incomplete cytomix (transfection medium) in a 15 mL Falcon tube. The suspension 
was centrifuged at 800 g for 2 min. After discarding the supernatant, the wash step was 
repeated and the supernatant was discarded. 
For the transfection process, the parasitemia of a 14 mL schizont-stage synchronized culture 
of  P. falciparum 3D7 wild-type parasites was estimated by Giemsa-stained thin blood 
smears. The culture was then resuspended in old medium and diluted to 1% parasitemia in a 
new petri dish with appropriate volumes of sterile, fresh erythrocytes and complete medium. 
The diluted culture was resuspended, transferred to a sterile 15 mL Falcon tube and 
centrifuged at 300 g for 5 min at 23°C. After discarding the supernatant, 100 µL of the 
infected erythrocytes were aliquoted into a new flask and resuspended in 8 mL of complete 
culture medium.  
The prepared plasmid DNA (30 µL) was next resuspended in the 2 mL micro tube together 
with 400 µL each of cold transfection medium and fresh, sterile and washed erythrocytes. 
Approximately 400 µL of the mixture was transferred to each of two pre-cooled transfection 
cuvettes and incubated on ice for 5 min. Electroporation was executed for each cuvette at a 
voltage of 0.3 KV and a capacitance of 950 µF using a Bio-rad electroporation system. The 
cuvettes were incubated on ice for 5 min after electroporation, and aseptically moved back to 
the sterile bench. The electroporated erythrocytes were resuspended in 2 x 4 mL of 
transfection medium and transferred into a 15 mL Falcon tube. After centrifugation at 800 g 
for 2 min at 23°C, the supernatant was discarded and the cell pellet was resuspended in 6 mL 
of prewarmed complete RPMI medium. The cell suspension was transferred into the culture 
flask containing 8 mL of infected red blood cell (RBC) suspension that was prepared earlier. 
The new 14.5 mL culture of 3.5% hematocrit and a starting parasitemia of approximately 
0.2% was returned to the incubator and maintained under standard conditions.  
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For the selection of parasites expressing yDHODH and Cas9, atovaquone (Sigma-Aldrich) 
was administered at a final culture concentration of 100 nM 20 hr post-transfection. From the 
second to the sixth day post transfection, drug and medium were renewed every 24 hr. After 
the first week, drug and medium were renewed every other day. Seventy (70) µL of fresh 
erythrocytes were also added to the culture once every week until resistant parasites were 
detected by Giemsa-stained thin blood smears. Transgenic parasites were immediately split 
and cultured in several plates to be used later to prepare parasite glycerol freeze-downs and to 
extract gDNA for PCR control of plasmid uptake. Transgenic confirmed by PCR to be Cas9-
expressing parasites were cultured and transfected with the pL7 plasmids.  
 
Incomplete cytomix            120 mM KCl, 0.15 mM CaCl2, 2 mM EGTA, 5 mM MgCl2,  
                                          10 mM K2HPO4, 10 mM KH2PO4, 25 mM Hepes, pH 7.6 at RT 
 
 
3.5.2.  Transfection of the pL7 plasmid 
 
For the second step of transfection, 100 µg of the pL7-PFGLO1, pL7-PFcGLO2, pL7-
PFtGLO2 or pL7-PFGILP plasmids was used to transfect Cas9-expressing transgenic strains 
following the preload method described above. Briefly, fresh and washed human A+ cells 
were preloaded with each of the four different pL7 constructs. Four hundred (400) µL of 
preloaded erythrocytes were subsequently washed and mixed with 100 µL of erythrocytes 
infected with Cas9-expressing transgenic parasites. The new 14.5 mL transfection culture of 
about 3.5% hematocrit and a starting parasitemia of approximately 0.2% was subsequently 
maintained under standard culture conditions. Positive selection for hdhfr integration and 
expression with WR99210 (WR) (Courtesy of David Jacobus, Jacobus Pharmaceuticals, 
Priston, NJ) commenced 20 hr post-transfection at a final concentration of 2.7 nM. The drug 
treatment regime proceeded as described above for atovaquone until transgenic parasites that 
were resistant to WR were detected in Giemsa-stained blood smears. As soon as transgenic 
parasites were detected, cultures were split into several plates to generate enough parasites for 
freeze-storage and to proceed with negative selection. Negative selection against unintegrated 
pL7 plasmid or single-crossover events was achieved with 40 µM 5-flourocytosine (5-FC) 
(Sigma-Aldrich) for 9 days while maintaining WR pressure. Transgenic mixed-culture 
parasites detected by Giemsa-stained thin blood smears after negative selection were split into 
several plates and amplified for further freeze-storage and genomic DNA analysis. Parasites 
from plates that were confirmed by preliminary PCR analysis to contain knockout strains 
were cultured further and used to perform a limiting dilution for the generation of single clone 
knockout parasites.   
 
 
3.5.3. Limiting dilution and generation of single knockout clones 
 
Generation of single clone knockout parasites from a mixed-population of transfectants 
followed the method described by Butterworth and colleagues (Butterworth et al., 2011) with 
slight modifications. The dilution was performed from a 14.5 mL transgenic P. falciparum 
parasite culture that was sorbitol-synchronized at the trophozoite-stage. The parasitemia of the 
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culture was first estimated by Giemsa-stained thin blood smears. The culture was 
subsequently resuspended in old culture medium on the sterile bench, mixed well and a 200 
µL aliquot was removed into a 1.5 mL micro tube. Fifteen (15) µL of the well-mixed aliquot 
was used to estimate the RBC concentration per mL of culture using a hemocytometer. Using 
the estimated parasitemia and erythrocyte concentration, the original trophozoite culture was 
diluted in a 15 mL Falcon tube with prewarmed complete culture medium and washed fresh 
erythrocytes. The dilution was to obtain a cell suspension that contained approximately one 
parasite or less per 200 µL of culture and a hematocrit of 2%. 200 µL of the diluted culture 
was dispensed after resuspension into each of the 24 wells of rows A & B of a 96 well culture 
plate. 1/10 and 1/100 dilutions of the original dilution were also made in separate 15 mL 
Falcon tubes. 200 µL of these further diluted cultures were also dispensed into each of the 24 
wells of rows C & D and rows E & F for 1/10 and 1/100 dilutions respectively. 200 µL of an 
erythrocyte culture of 2% hematocrit but with no parasites was dispensed into the 24 wells of 
rows G & H to serve as negative control wells. The plate was incubated at standard culture 
conditions. On days 4, 7, 11, 14, 17 and 21, 140 µL of the culture medium was replaced using 
a 20-200 µL multichannel pipette. Giemsa-stained blood smears were performed to check for 
growth on days 14 and 21. As soon as parasites appeared in any of the wells, the culture of 
those wells was amplified into 14.5 mL cultures. Preference was given to the clones from the 
wells that contained a lower dilution of parasites. Amplified clone cultures were subsequently 
split and recultured to extract gDNA for control PCRs and for parasite freeze-downs when 
confirmed positive for glyoxalase gene disruption. 
 
 
3.6. Genome and western blot analyses of clonal knockout lines 
 
3.6.1.  Saponin lysis of infected erythrocytes and purification of parasites 
 
Saponin lyses the membranes of infected and uninfected red blood cells. It also damages the 
Maurer’s cleft and the membrane of the parasitophorous vacuole without affecting the 
parasite or its membrane (Heiber & Spielmann, 2014). Saponin is therefore a convenient 
reagent for the isolation of intact parasites for protein and genomic analyses. Depending on 
the analysis to be performed with the purified parasites, different procedures of saponin lysis 
were followed. For the extraction of parasite genomic DNA, erythrocytes were lysed with 
0.05% (w/v) saponin in modified Ringer solution (lysis buffer) following the method by 
Elandalloussi and Smith, and others (Elandalloussi & Smith, 2002 ; Doolan, 2002) with slight 
modification. Briefly, a 14 mL culture of late schizont or early ring-stage at ≥ 5% parasitemia 
was resuspended in old medium and transferred into a 15 mL Falcon tube. The suspension 
was centrifuged at 755 g in a Heraeus multifuge for 5 min at 23°C. After completely 
discarding the supernatant, the cell pellet was resuspended in 10 mL of ice-cold lysis buffer 
and incubated on ice for 10 min. The erythrocyte cell lysate was centrifuged at 1800 g for 10 
min at 23°C to pellet the parasites. After discarding the lysed erythrocyte supernatant, the 
parasite pellet was resuspended in 1.5 mL of modified Ringer solution, transferred into a 2 
mL micro tube and centrifuged again at the same speed and temperature for 10 min. The 
supernatant was again discarded and the wash step repeated. The parasite pellet was 
subsequently resuspended in 190 μL of room temperature TE‐buffer pending gDNA isolation.  
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For the extraction of parasite proteins for western blot analysis, erythrocytes were lysed with 
0.1% (w/v) saponin in phosphate buffered saline (PBS) following the method of Hsiao and 
colleagues (Hsiao et al., 1991 ) with slight modification. Briefly, a 35 mL trophozoite-stage 
culture of ≥ 5% parasitemia was resuspended in old medium and transferred to a 50 mL 
Falcon tube. The suspension was centrifuged at 1000 g in a Heraeus multifuge for 5 min at 
23°C. After completely discarding the supernatant, the erythrocyte pellet was resuspended in 
9 mL of ice-cold PBS. 1 mL of 1% saponin solution in PBS was added to the cell suspension 
and mixed well. Erythrocyte lysis was allowed to progress for 60 s on ice after which the 
lysate was centrifuged at 2000 g for 10 min at 4°C. The supernatant was removed and the 
parasite pellet was washed two times with 10 mL of ice-cold PBS. The pellet was 
resuspended in 1 mL of ice-cold PBS/Protease inhibitor (Roche) (PBS/PI) solution and 
transferred to a 1.5 mL micro tube for a last wash at 20800 g for 1 min at 4°C. The protease 
inhibitor neutralized the effect of released proteases. After discarding the supernatant, the 
parasite pellet was immediately processed to extract parasite proteins or snap-frozen and 
stored in liquid N2 pending future parasite protein analysis.  
 
Modified ringer solution          115 mM NaCl, 10 mM KCl, 1.2 mM CaCl2, 0.8 mM MgCl2,  
                                               5.5 mM glucose, 1.0 mM NaH2PO4, 10 mM HEPES  
                                              pH 7.1 at 37 °C 
 
PBS                          1.84 mM KH2PO4, 10 mM Na2HPO4, 137 mM NaCl,  
                                 2.7 mM KCl, pH 7.4 at 24°C 
 
PBS/PI                                 1 tablet of protease inhibitor cocktail/50 ml PBS 
 
 
3.6.2. Isolation and purification of genomic DNA of knockout strains  
 
The method of isolation and purification of parasite genomic DNA was adopted from a 
technique used by Denise L. Doolan (Doolan, 2002). Proteinase K solution was added to the 
parasite cell suspension from saponin lysis (above) to a final concentration of 20 μg/mL. To 
remove parasite membrane, 20% SDS solution was also added to make a final concentration 
of 0.5%. The cell suspension was gently inverted several times in the tube and incubated 
overnight at 55°C in a heating block to liberate the gDNA from the lysed cells and neutralize 
all liberated parasite proteins. After incubation, the lysate was allowed to cool down to room 
temperature. DNAse-free RNase (Sigma-Aldrich) solution was added to the cooled lysate to a 
final concentration of 60 μg/mL and the lysate was again incubated for 1 hr at 37°C to destroy 
all RNA contamination. After the lysate was allowed to cool down to room temperature, 400 
μL of phenol/chloroform/isoamylalcohol solution (Carl-Roth) was added to trap debris of cell 
lysis including proteins. The suspension was mixed by slowly rotating the micro tube on 
programmable rotator mixer (Grant-Bio) for 10 min. gDNA was isolated from the trapped cell 
debris by centrifugation at 14000 g at room temperature in a microfuge. The upper aqueous 
layer containing the gDNA was transferred to a new micro tube using a cut pipette tip to 
avoid damage to the DNA. The isolation step was repeated one more time and subsequently 
200 μL of absolute chloroform was added to the removed upper aqueous layer. The 
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suspension was slowly mixed on a programmable rotator mixer for 5 min and then 
centrifuged at 14000 g for 5 min at room temperature. The upper aqueous layer was carefully 
transferred without contamination into a new 1.5 mL mirco tube. DNA-bound proteins were 
further removed by adding 1/10 volume of ice-cold sodium acetate buffer to the suspension. 
gDNA was precipitated by adding 2.5 volumes of absolute ethanol stored at -20°C. The 
suspension was mixed by inverting the micro tube several times and then centrifuged at 14000 
g for 10 min at 4°C in a microfuge to pellet the gDNA. After discarding the supernatant, the 
gDNA pellet was washed with 1 mL of 70% ethanol that was stored at -20°C and the 
centrifugation step repeated. The gDNA pellet was dried for 10 min in red light after 
discarding the supernatant. The dried pellet was then resuspended in 50 μl of 10 mM Tris 
buffer and incubated over night at 65°C. gDNA concentration was determined by a NanoDrop 
spectrophotometer and the purity checked by 0.5% agarose gel analysis. Extracted gDNA was 
stored at 4°C pending use for PCR analysis. 
 
 
3.6.3.  Genotyping of wild-type parasites and clonal knockout lines 
 
pUF1-Cas9 uptake or targeted-gene disruption and hdhfr integration in case of the pL7 
transfection, was verified in gDNA of transgenic parasites by PCR using Taq DNA 
polymersase. The primer set P25/P32 (Table 2.2) was used at a final concentration of 1 µM to 
detect pUF1-Cas9 uptake in gDNA of transgenic parasites that were resistant to atovaquone. 
The expected amplicon size for the pUF1-Cas9 uptake PCR was 695 bp. A summary of the 
primers used for the analytic PCRs of gDNA of pL7-PFGLO1, pL7-PFcGLO2, pL7-
PFtGLO2 and pL7-PFGILP transfectants as well as the expected amplicon sizes is shown in 
table 3.2. For each of these transfectant-gDNA sample, three different sets of primers were 
used to target i) the whole locus, ii) the 5’ untranslated region (UTR), and iii) the 3’ 
untranslated region (UTR) of each gene. Genomic DNA from the P. falciparum 3D7 wild-
type strain served as a negative control to all the PCR cycles. All PCR reactions contained 
100 ng (0.5 µL) of genomic DNA in a reaction mixture with 2 µL of dNTPs (0.4 mM), 5 µL 
ThermoPol Taq-buffer (NEB) and 1µL Taq DNA polymerase in 40.5 µL of Millipore water. 
The cycler program used for the pUF1-Cas9 control PCR was: 94°C for 2 min, followed by 
30 cycles of 94°C 45 s, 65°C 45 s and 72°C 1.5 min, then a final extension at 72°C for 3 min 
and hold at 4°C. The cycler program used for the gene disruption control PCR was: 94°C for 
2 min, followed by 30 cycles of 94°C 30 s, 57°C 45 s and 60°C 5 min, then a final extension 
at 60°C for 10 min and hold at 10°C. Due to the high A-T content of the target loci, a reduced 
extension temperature ensure a more realiable DNA replication (Su et al., 1996). The reaction 
was performed in an Eppendorf mastercycler gradient thermal cycler. All PCR products were 
analyzed on agarose gels as described above (Section 3.3.2). Products of the pUF1-Cas9 
control PCR were analyzed on a 0.8% agarose gel using a 100 bp DNA ladder. The products 
of the gene disruption control PCR were analyzed on 1% or 2% agarose gel using a 1kb DNA 
ladder.  
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Table 3.2. Summary of primers used and expected amplicon sizes: PCR analysis of    
                knockout and wild-type gDNA. 
gDNA template Region of amplicon PCR # Primer set Amplicon 
3D7 wild-type PFGLO1/5’UTR - PFGLO1/3’UTR 1 P28 & P29 2203 bp 
 PFGLO1/5’UTR – HDHFR insert 2 P27 & P28 -  
 HDHFR insert - PFGLO1/3’UTR 3 P26 & P29 -  
3D7glo1 PFGLO1/5’UTR - PFGLO1/3’UTR 1 P28 & P29  4295 bp 
 PFGLO1/5’UTR - HDHFR insert 2 P27 & P28  2525 bp 
 HDHFR insert - PFGLO1/3’UTR 3 P26 & P29  2290 bp 
3D7 wild-type PFcGLO2/5’UTR – PFcGLO2/3’UTR 1 P30 & P31  1991 bp 
 PFcGLO2/5’UTR - HDHFR insert 2 P27 & P30 -  
 HDHFR insert – PFcGLO2/3’UTR 3 P26 & P31 -  
3D7cglo2 PFcGLO2/5’UTR – PFcGLO2/3’UTR 1 P30 & P31  4127 bp 
 PFcGLO2/5’UTR - HDHFR insert 2 P27 & P30  2588 bp 
 HDHFR insert – PFcGLO2/3’UTR 3 P26 & P31  2061 bp 
3D7 wild-type PFtGLO2/5’UTR – PFtGLO2/3’UTR 1 P37 & P38  2556 bp 
 PFtGLO2/5’UTR - HDHFR insert 2 P27 & P37 -  
 HDHFR insert – PFtGLO2/3’UTR 3 P26 & P38 -  
3D7tglo2 PFtGLO2/5’UTR – PFtGLO2/3’UTR 1 P37 & P38 4588 bp 
 PFtGLO2/5’UTR - HDHFR insert 2 P27 & P37 3072 bp 
 HDHFR insert – PFtGLO2/3’UTR 3 P26 & P38 2037 bp 
3D7 wild-type PFGILP/5’UTR - PFGILP /3’UTR 1 P39 & P40 1752 bp 
 PFGILP/5’UTR - HDHFR insert 2 P27 & P39 -  
 HDHFR insert - PFGILP/3’UTR 3 P26 & P40 -  
3D7gilp PFGILP/5’UTR - PFGILP/3’UTR 1 P39 & P40 3764 bp 
 PFGILP/5’UTR - HDHFR insert 2 P27 & P39 2463 bp 
 HDHFR insert - PFGILP/3’UTR 3 P26 & P40 1818 bp 
 
 
3.6.4. SDS-PAGE and western blot analyses of wild-type parasites and knockout lines 
 
The protocol for preparation of parasite samples for western blot analysis followed the 
methods of Southworth and colleagues, and of Heiber and Spielmann (Heiber & Spielmann, 
2014; Southworth et al., 2011). SDS-PAGE and western blot analysis of knockout parasites 
was performed by Linda Liedgens. Purified parasites from saponin lysis (see above) were 
resuspended in an appropriate volume (≈150 µL) of PBS/PI solution and disrupted by the 4x 
freeze-thaw cycles comprising 5 min freezing in liquid nitrogen, 1 min in a water bath set at 
37°C and 30 s of vortexing. An equal volume of 2x laemmli buffer supplemented with 30% 2-
mercaptoethanol was added to the lysate and boiled at 95°C for 5 min to denature and reduce 
the release proteins. Twenty (20) µL of lysate (≈2.0 x 107 parasites) was loaded into each well 
of a small SDS-PAGE gel and electrophoresis was performed according to the method of 
Laemmli (Laemmli, 1970). The gel was run for 1.5 hr in a Bio-rad electrophoresis chamber at 
an electric current of 35 mA. For the detection of cytosolic PfGlo1 and PfcGlo2 proteins, a 
15% gel was used. For the analysis of AGE, a 10% gel was used. All gels were precast with 
two parts: a shorter stacking gel part where samples were loaded and brought to the same 
front, and a longer resolving part in which sample proteins were separated according to their 
molecular weight. Gels were set using protein electrophoresis equipment from Bio-rad. 
Separated proteins were transferred from the gel onto a nitrocellulose blotting membrane 
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using the semi-dry blotting method according to standard protocol (Towbin et al., 1979). 
Blotting was performed using an Apparatur PerfectBlue blotting device. Appropriately sized 
Whatman paper pieces served as a clean support for the delicate gel and membrane. The 
pieces of Whatman paper, gel and membrane were incubated in 100 mL of transfer buffer to 
enhance homogeneity in pH and conductivity, and to enable effective elution and transfer of 
proteins from the gel to the membrane. The set up of the blotting step was as follows: Anode 
(+), five soaked Whatman paper pieces, soaked membrane, incubated gel, five soaked 
Whatman paper pieces and cathode (-). Air bubbles were gently removed from the Whatman 
papers, membrane and gel by gently rolling a cut 25 mL serological pipette over the set up. 
Excess buffer from the blotting set up was dried up using a paper towel. Removal of air 
bubbles and excess water before blotting helps to produce a more efficient transfer. The blot 
was run at a constant electric current of 100 mA for 1.5 hr. Efficiency of the blotting was 
checked by staining the membrane in 20 mL Ponceau staining solution for 5 min on an 
overhead shaker. Excess stain was gently washed away with small volumes of deionised 
water until the protein bands were clearly visible. Complete destaining of the membrane was 
later done by 40 mL of tris buffered saline (TBS) for 15 min while shaking on an overhead 
shaker. The parts of the membrane carrying no transferred protein were blocked with 40 mL 
of 5% milk powder in TBS buffer for 1 hr at room temperature, after which the membrane 
was rinsed once with TBS. The blocked membrane was incubated with appropriate primary 
antibodies diluted in 40 mL of 5% milk/TBS at 4°C overnight on a shaker. For the detection 
of PfGlo1, PfcGlo2, and AGE, the antibodies αPfGlo1, αPfcGlo2 and Anti-AGE (Ab23722, 
Abcam) were used in the dilutions 1:500, 1:1000 and 1:500 respectively. As loading controls, 
cut sections of the membranes for the analyses of PfGlo1 and PfcGlo2, corresponding to 
protein band size of ≈ 70 kDa, were decorated with 20 mL 1:800-dilution of anti-P. berghei 
heat shock protein 70 (PbHsp70) primary antibody. For AGE analysis, a blotted membrane of 
a gel ran parallel with the test gel was decorated with 40 mL 1:800-dilution of anti-PbHsp70 
primary antibody to serve as a loading control. After overnight incubation, the primary 
antibody was removed and stored at -20°C for future use, while the membrane was washed 
five times for 10 min each with 40 mL of TBS-T (0.1% Tween) and once with 40 mL of TBS 
for 10 min. The membrane was incubated with 40 mL of secondary antibody for 45 min on a 
shaker at room temperature. The secondary antibody used for PfGlo1, PfcGlo2 and AGE 
detection was a 40 mL dilution (1:10000) of goat anti-Rabbit IgG (H+L)-HRP conjugate 
antibody (Bio-rad) in 5% milk/TBS Buffer. The anti-PbHsp70 antibody was detected with a 
30 mL dilution (1:10000) of HRP-conjugated goat anti-mouse secondary antibody in 5% 
milk/TBS. The secondary antibody solution was discarded after incubation and the membrane 
washed five times with 40 mL TBST-T (0.1% Tween, 0.2% Triton) for 10 min each and once 
with 40 mL of TBS for 10 min. Secondary antibodies bound to target proteins were detected 
on Super RX-N film (Fujifilm) using a LiCOR scanner after activation with detection 
reagents. Five hundred (500) µL each of reagents 1 and 2 were mixed and used per 
membrane. The AGE western blot was repeated five more times.  
 
2x Laemmli buffer                    50 mM   Tris/HCl pH 6.8 
                                                  10% (w/v) SDS 
                                                  25% (v/v) glycerol   
                                                  0.1% (w/v) bromophenol blue  
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                                                  30% (v/v) -mercaptoethanol 
 
10x Transfer buffer                    200 mM tris 
                                                   1.5M glycin 
                                                   0.2% SDS 
 
1x Transfer buffer                      700 mL Millipore water 
                                                   100 mL 10x transfer buffer 
                                                   200 mL methanol 
 
 TBS                                          10 mM tris 
                                                   0.9% NaCl, pH 7.4 at room temperature 
 
 
3.7.  Growth and morphological analyses of knockout strains 
 
3.7.1. Growth analysis 
 
The growth phenotype of confirmed PFGLO1 and PFcGLO2 knockout clones (3D7Δglo1 and 
3D7Δcglo2) was analyzed in comparison with the control 3D7 wild-type strain by generating 
growth curves of asynchronous cultures (Djuika et al., 2017). Growth curves were generated 
for three PFGLO1 and two PFcGLO2 clonal knockout lines. Briefly, a 14.5 mL asynchronous 
culture was set up for each clone at a starting parasitemia of 0.1% and a hematocrit of 3.5% at 
standard culture conditions as above. Cultures were maintained for six days, changing the 
medium once every 24 hr for the first three days and thenafter twice every 24 hr. The 
parasitemia of each culture was assessed every day until the sixth day by counting 7 
microscope fields (750-1500 erythrocytes) of Giemsa-stained thin blood smears. The average 
parasitemia of each clone for each time point was calculated from three independent 
experiments. Statistical analysis of growth was done by one way ANOVA on SigmaPlot 12.5. 
 
 
3.7.2. Gametocyte formation assay 
 
Gametocyte formation assays were performed in collaboration with Prof. Gabriele Pradel’s 
laboratory by Alexandra Golzmann. The protocol used is as described in (Wezena et al., 
2018). “Wild-type as well as 3D7Δglo1 and 3D7Δcglo2 knockout parasites were cultured as 
described above except for the replacement of albumax with 10% inactivated A+ serum as 
described previously (Wirth et al., 2014). Two days after synchronization with 5% sorbitol, 
gametocyte commitment was induced by setting up the culture at 2% parasitemia and a 
hematocrit of 10% in 5 ml of the human A+ medium. The medium was replaced daily and 
Giemsa-stained blood smears were analyzed 14 days post-induction of gametocyte 
commitment. The gametocytemia was determined per 1000 red blood cells and the 
gametocyte stages II-V were counted in triplicate. Data analysis was performed using MS 
Excel 2010 and GraphPad Prism 5’’. 
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3.7.3. Determination of IC50 values for external 2-oxoaldehydes for knockout strains 
 
IC50 values were determined using a SYBR green 1 assay according to established protocols 
(Smilkstein et al., 2004; Wezena et al., 2017). The parasitemia of a standard culture of each 
clonal knockout line or the control strain was evaluated by light microscopy of Giemsa-
stained thin blood smears. The culture was subsequently transferred to a 15 mL Falcon tube 
and centrifuged at 300 g for 5 min at room temperature. The supernatant was discarded and 
cells were adjusted with fresh erythrocytes in complete RPMI medium containing 2x albumax 
II (0.9% w/v) to a hematocrit of 3% and a parasitemia of 0.5%. Likewise, a suspension 
containing only uninfected erythrocytes with a hematocrit of 3% was prepared in complete 
RPMI medium containing 2x albumax II. Albumax-free medium (50 μL) was dispensed in 
each of the wells of sterile, black 96 well fluotrac microplates (Greiner). The outer wells 
(including the first column) of each plate were supplemented with 50 μL of the suspension 
that contained only uninfected erythrocytes. These wells served as parasite- and drug-free 
controls to determine the background fluorescence at a final culture volume of 100 μL and a 
hematocrit of 1.5%. Stock solutions of glyoxal, methylglyoxal and phenylglyoxal were 
freshly prepared in albumax-free RPMI medium and filter-sterilized for the 2-oxoaldehyde 
susceptibility assays. Aliquots (25 μL) of these stock solutions were pipette into the second 
column of the microplates. After mixing, 25 μL of the now 75 μL solution in column 2 were 
transferred to column 3, yielding a 1:3 dilution. This step was repeated for columns 3 to 10 
(the 25 μL aliquot from column 10 was discarded). Column 11 served as a drug-free control 
cultures. Columns 2 to 11 of each plate were supplemented with 50 μL of parasitized 
erythrocytes yielding a final culture volume of 100 μL, a hematocrit of 1.5% and a 
parasitemia of 0.5%. Final concentrations of glyoxal, methylglyoxal and phenylglyoxal in the 
treated wells (columns 2-11) were from 5 mM - 0.38μM, 15 mM - 2.3 μM and 45 mM - 6.9 
μM respectively in 1:3 serial dilutions. All microplates were incubated under standard culture 
conditions for 72 hr. The plates were later removed from the incubator and sealed with 
parafilm before storage at −80°C. Prior to analysis, the microplates were thawed at room 
temperature for 1 hr. For each plate, complete lysis buffer was freshly prepared by diluting 
1.2 μL of 10,000x SYBR green 1 solution in 10 mL incomplete lysis buffer. The microplates 
were supplemented with 100 μL of complete lysis buffer per well and immediately covered 
with aluminium foil. The set up was mixed thoroughly on a horizontal shaker for 2 min and 
incubated in the dark for 1 hr at room temperature. Fluorescence intensity on each plate was 
determined using a microplate reader with a gain of 60, an excitation wavelength of 485 nm 
and an emission wavelength of 535 nm. All data were corrected for the background 
fluorescence of uninfected erythrocytes, normalized to the growth of control parasites in 
column 11, and fitted to a sigmoidal dose-response curve using the four parameter Hill 
function in SigmaPlot 12.5. Each experiment was done in triplicates and was repeated three to 
seven independent times. 
 
Incomplete lysis buffer        20 mM Tris-HCl, pH 7.5, 5 mM EDTA, 0.08% Triton X-100                               
                                              0.008% saponin 
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3.8. Relevance of host cell Glo1 activity for P. falciparum growth 
 
Since there are no human glyoxalase knockout erythrocytes, an indirect approach was 
employed to investigate the contribution of the host glyoxalase system to the parasite’s blood-
stage development. Tight-binding Glo1 inhibitors were used to inhibit the human Glo1 
activity of fresh erythrocytes before using the pretreated erythrocytes to cultivate purified 
parasites (Figure 4.1 A). To identify the most potent and effective Glo1 inhibitors for this 
purpose, four glutathione-derived compounds, 1 and 2, and their respective carboxylic tert-
butyl ester derivatives, compounds 3 and 7 (Figure 3.1) (Wezena et al., 2016), were first 
tested on fresh erythrocyte cultures. Briefly, five (5) culture plates were set up, each 
containing 500 µL of washed fresh erythrocytes resuspended in 14 mL of complete RPMI 
medium. Four of the plates were each treated with 10 µM of compound 1, 2, 3 or 7. The fifth 
plate served as a drug-free control plate. Glo1 and Glo2 activities of the erythrocyte stock 
used to set up the cultures were determined (see section 3.9), and the erythrocyte cultures 
were maintained under standard conditions for 96 hr. Every 24 hr, the cultures were 
resuspended in a 15 mL Falcon tube and centrifuged at 300 g for 5 min at room temperature. 
A 40 µL aliquot of erythrocyte pellet was removed form each culture into different 1.5 mL 
micro tubes for Glo1 and Glo2 enzyme assays (section 3.9.1). The remaining erythrocytes 
were resuspended in the original medium and recultured. The experiment was repeated with 
five different blood donors. Analyses of Glo1 and Glo2 activities of the treated erythrocytes 
revealed compounds 1, 3 and 7 to be the most potent and effective of the four Glo1 inhibitors 
(Figure 4.1 C). The three compounds were therefore employed to investigate the contribution 
of the erythrocyte Glo1 to P. falciparum blood-stage development.  
To perform this investigation, the erythrocyte glyoxalase activity was first inhibited by 
treating fresh erythrocytes separately with 10 µM each of compounds 1, 3 and 7 for 96 hr. 
The erythrocytes were subsequently washed three times with complete RPMI medium to 
removed residual inhibitor. The washed erythrocytes were used to culture synchronized 
schizont-stage parasites that were enriched to approximately 98% purity by magnetic cell 
separation using a VarioMACS™ Separator (Staalsoe et al., 1999). Parasites were cultured 
under normal conditions for 6 days. The growth rate of parasites in each of the differently 
treated erythrocytes was averaged every day from 7 microscope fields (750-1500 
erythrocytes) by counting Giemsa-stained thin blood smears. Results were calculated from 
three independent experiments and analyzed statistically in SigmaPlot 12.5 using the one way 
ANOVA on ranks method. 
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1 X = CH2
2 X = NH 
3 R = But , X = CH2
7 R = Bu,t X = NH
 
 
Figure 3.1. Structures of Glo1 inhibitors and their esterified analogues used in inhibition studies. The 
hydroxamic acid moiety mimics the transition state and interacts with the metal center of Glo1. tBu is the tert-
butyl ester group. Taken and modified from (Wezena et al., 2016). 
 
 
3.9. Glyoxalase activity assays of erythrocytes and knockout strains 
 
3.9.1. Preparation of erythrocyte lysate for enzyme assays 
 
Erythrocyte lysate for enzyme assays was prepared by resuspending 40 µL of treated or 
untreated (control) erythrocyte pellets in 500 µl of PBS and centrifuging at 2000 g in a 
microfuge at 4°C for 5 min. The supernatant was discarded and the wash step was repeated 
two more times to remove all residual inhibitors and serum contaminants. The washed 
erythrocytes were subsequently lysed by resuspension in 200 µL of ice-cold Millipore water 
for 1 min on an overhead shaker in the cold room to prevent deactivation of enzymes. The 
lysis step was delayed until all erythrocytes were lysed. The lysate was subsequently 
transferred on ice and centrifuged at 20000 g in a microfuge for 10 min at 4°C. The 
supernatant containing erythrocyte enzymes were quickly decanted into a fresh precooled 1.5 
mL micro tube and stored on ice for immediate enzyme assays. 
                                                                    
 
3.9.2. Preparation of parasite lysate for enzyme assays 
 
Parasite lysate for enzyme assays was prepared from a 35 mL trophozoite-stage synchronous 
culture at ≥ 5% parasitemia using a slightly modified saponin lysis and freeze-thaw method 
(Harwaldt et al., 2002; Akoachere et al., 2005). Briefly, infected erythrocytes were first 
resuspended in the old culture medium and transferred into a 50 mL Falcon tube. The 
suspension was centrifuged at 1000 g for 5 min at 23°C after which the supernatant was 
discarded. The erythrocyte pellet was resuspended for 10 min in 20 volumes of saponin lysis 
buffer that was prewarmed at 37°C. Following centrifugation of the cell lysate at 2000 g for 3 
min at 25°C, the supernatant was discarded and the parasite pellet was washed three times 
with lysis buffer. The parasites (~5 x 107 cells) were subsequently resuspended in 150 μL of 
the lysis buffer and disrupted by four cycles of freezing and thawing. The freeze-thaw cycles 
were composed of 5 min freezing in liquid nitrogen, 1 min in a 37°C water bath and 30 s of 
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vortexing. The parasite lysate was then cleaned with a spin at 20800 g for 60 min at 4°C. The 
supernatant was decanted into a fresh precooled 1.5 mL micro tube and stored on ice. The 
protein content as well as the activities of PfGlo1 and PfcGlo2 of the parasite extract were 
immediately determined.  
 
Lysis buffer                      7 mM K2HPO4, 1 mM NaH2PO4, 11 mM NaHCO3, 58mM KCl, 
                                         56 mM NaCl, 1 mM MgCl2, 14mM glucose, and 0.02% saponin  
                                         (pH 7.5 at RT). 
 
 
3.9.3. Measurement of erythrocyte hemoglobin concentration 
 
The concentration of hemoglobin in the erythrocyte lysate was estimated using a 
thermostatted Jasco V-550 UV–vis spectrophotometer. Freshly prepared 50 Mm Tris/HCl 
(pH7.4 at 37°C) was used as a buffer in the hemoglobin absorbance measurements. 
Measurements of change in absorbance were performed at a fixed-wavelength of 523 nm, 
which is also the isosbetic point of of Hb (O2), Hb and Hb (met) (Olsen & Elvevoll, 2011 ). 
Briefly, 980 µL of the 50 mMTris/HCl (pH 7.4), pre-warmed to 37°C, was added to a 1 mL 
disposable plastic cuvette in the spectrophotometer. The assay was set to ‘autozero’ and the 
baseline absorbance was measured for 30 s. Twenty (20) µL of lysate supernatant was added 
and the change in absorbance measured for 1.5 min. The measurement was repeated for two 
more lysate samples. The concentration of Hb (mM or g/L) in the lysate was calculated using 
the extinction coefficient of ε240nm=7.12 mM
−1 cm−1 with the formula [Hb]=Abs523nm x50x7.12 
[mM] or [Hb]=Abs523nm x16.1x50x7.12 [g/L]. All hemoglobin absorbance measurements were 
performed in triplicates. 
 
 
3.9.4. Bradford assay 
 
The total protein content of parasite cell lysate was determined by the Bradford assay using 
bovine serum albumin (BSA) as a standard protein (Bradford, 1976). The assay is based on 
the shift in absorbance of Coomassie brilliant blue R-250 stain (Bio Rad) with proteins. 
Coomassie stain is converted from a red form to a blue form as it binds protein and shifts in 
absorbance wavelength from 465 nm to 595 nm. The increase in absorbance at 595 nm is a 
measure of protein concentration in the mixture. The assay was performed using a 
thermostatted Jasco spectrophotometer set at the fixed absorbance wavelength of 595 nm at 
25°C. A calibration curve was generated by measuring the absorption of eight disposable 
plastic cuvettes of serially diluted concentrations of BSA that were thoroughly mixed with 
Bradford reagent. Briefly, BSA was diluted to a final volume of 800 µL in deionised water 
and 200 µL Bradford reagent was added. The total volume of reaction in each vial was 1 mL 
while the known BSA concentrations ranged from 0 – 14 µg/mL. Triplicates of two dilution 
of the parasite lysate were also made in disposable plastic cuvettes to a final volume of 800 
µL in deionised water and mixed well with 200 µL of Bradford reagent. Care was taken that 
the measured absorbance of lysate (the total protein concentration) fell within the range of the 
calibration curve. Measurements of absorbance of both the BSA dilutions and lysate dilutions 
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were done in a manner corresponding to the time interval within which the Bradford reagent 
was added to each dilution. This helped to eliminate variations in absorbance due to 
differences in incubation time. A calibration curve was generated by plotting the 
concentration of BSA (μg) against the measured absorption in Sigmaplot 12.5 using the 
hyperbolic parameters (y=a*x/(b+x)). The mean of the triplicate absorptions of lysate 
dilutions were projected on the calibration curve to determine the concentration of total 
protein in the lysate. 
 
 
3.9.5. Glyoxalase 1 activity assay 
 
PfGlo1 activity in parasite lysate was measured by determining the rate of formation of the S-
D-lactoylglutathione (SLG) from the hemithioacetal of methylglyoxal (MG) and glutathione 
(GSH). Measurements were performed in a thermostatted Jasco spectrophotometer at 
wavelength of 240 nm and temperature of 25°C following standard protocols (Akoachere et 
al., 2005; Iozef et al., 2003). The extinction coefficient of ε240nm= 2.86 mM
−1 cm−1 was used 
in the calculation of the enzyme activity. The assay buffers comprising potassium phosphate 
buffer, buffer 1, (pH 7.0) and 1M potassium chloride, buffer 2, (pH 7.0) were freshly prepared 
and stored at 4°C. 100 mM GSH and 100 mM MG stock solutions were also freshly prepared 
in distilled water and stored on ice. The hemithioacetal substrate was formed by mixing 100 
µL each of prewarmed buffer 1 and 2, 10 µL of GSH and 20 µL of MG in 740 µL of 
prewarmed double distilled water in a 1 mL quartz cuvette. The final concentrations of GSH 
and MG in the assay mixture were 1 mM and 2 mM respectively. The mixture was incubated 
for 15 min at 25°C. After 14.5 min of incubation, the measurement was set to ‘auto zero’ and 
the baseline was recorded for 30 seconds. Thirty (30) µL of parasite lysate supernatant (~1 x 
107 parasites) was added to the mixture and thoroughly mixed. The change in absorbance at 
A240 was immediately monitored for 1.5 min. 
For the determination of human Glo1 activity, measurements were performed at 37°C in 50 
mM NaxHyPO4 (pH 6.6 at 37 °C) assay buffer. GSH and MG stock solutions were both made 
in the sodium phosphate buffer. The final concentration of GSH and MG in the hGlo1 assays 
was 2 mM. In the hGlo1 assay, the incubation period for hemithioacetal formation was 10 
min (Thornalley, 1988; Arai et al., 2014) while 5 µL of cell lysate was used for the hGlo1 
assay. The change in absorbance at A240 was also immediately monitored for 1.5 min. The 
initial rate of change (increase) at A240 (dA240/dt)0 was deduced and the activity of PfGlo1, 
aPfGlo1, and hGlo1, ahGlo1, were calculated as follows:  
                                                    
                                             aGlo1= (dA240/dt)0/2.86 [mM/min].  
 
Glo1 activity in parasite and erythrocyte lysates was determined from two-four triplicate 
measurements. PfGlo1 activities were normalized to corresponding concentration of total 
parasite lysate protein (µg/µL) determine by a Bradford calibration curve and reported in 
units/mg protein. hGlo1 activities were normalized to hemoglobin concentration of the 
corresponding erythrocyte lysate. Further statistical analysis of enzyme activities was 
performed in SigmaPlot 12.5 using the one way ANOVA method. 
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3.9.6. Glyoxalase 2 activity assay 
 
PfcGlo2 activity in parasite lysate was measured by determining the decrease in absorbance 
resulting from SLG hydrolysis at 240 nm. The assay was performed at 25°C in a 
thermostatted Jasco spectrophotometer following to standard protocols. An extinction 
coefficient of ε240nm= 3.1 mM
−1 cm−1 was used in the calculation of the enzyme activity (Iozef 
et al., 2003; Akoachere et al., 2005). Briefly, 100 mM Tris/HCl (pH 7.4 at 25°C) and 3 mM 
SLG (in tris buffer) were freshly prepared and stored on ice. The assay set up comprised 
mixing 500 µL of Tris buffer, 100 µL of SLG (final concentration of 0.3 mM) stock solution 
and 350 µL of water in a 1 mL quartz cuvette. The measurement was set to ‘auto zero’ and the 
baseline measured for 30 seconds.  Fifty (50) µL of cell lysate supernatant (~1.7 x 107 
parasites) was added and mixed thoroughly. The change in absorbance at A240 was 
immediately monitored for 1.5 min. 
For the determination of human Glo2 activity, measurements were performed at 37°C in 50 
mM Tris/HCl (pH 7.4 at 37 °C) assay buffer. The SLG stock was diluted in the Tris/HCl 
assay buffer. The final concentration of SLG in the assay buffer was 0.3 mM for the human 
Glo2 assay (Arai et al., 2014; Thornalley, 1988). Ten (10) µL of cell lysate was used for the 
human Glo2 assay. The change in absorbance at A240 for was immediately monitored for 1.5 
min. The initial rate of change (decreases) in A240 (dA240/dt)0 was deduced and the activities of 
PfcGlo2, aPfcGlo2, and hGlo2, ahGlo2, were calculated as follows: 
           
                                         aGlo2 = -(dA240/dt)0/3.10 [mM/min]. 
 
Glo2 activity in parasite and erythrocyte lysates was determined from two-four triplicate 
measurements. PfcGlo2 activities were normalized to corresponding concentration of total 
parasite lysate protein (µg/µL) determine by a Bradford calibration curve and reported in 
units/mg protein. hGlo2 activities were normalized to hemoglobin concentration of the 
corresponding erythrocyte lysate. Further statistical analysis of enzyme activities was 
performed in SigmaPlot 12.5 using the one way ANOVA method. 
 
 
3.10. Determination of IC50 values for standard pro- and antioxidants for P. falciparum 
3D7 parasites 
 
IC50 values for H2O2, NAc, ascorbate and DTT were determined using a SYBR green 1 assay 
as described above (Section 3.7.3). Stock solutions of the prooxidant H2O2 and antioxidants, 
NAc, ascorbate and DTT were freshly prepared in albumax-free RPMI medium and filter-
sterilized for the assessment of their effects on the growth of P. falciparum 3D7 wild-type 
strain. The final concentrations of H2O2, NAc, ascorbate and DTT in the drug wells were set 
from 1.63 mM - 0.25 mM, 300 mM - 0.05 mM, 300 mM - 0.05 mM and 33.33 mM - 0.01 
mM respectively in 1:3 serial dilutions. As the antioxidants ascorbate, N-acetylcysteine and 
DTT were found to produce a background fluorescence that varied from compound to 
compound, microplates with unparasitized erythrocytes but with the same compound dilutions 
were set up in parallel as controls. As above, all data were also corrected for the background 
fluorescence of uninfected erythrocytes, normalized to the growth of untreated control 
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parasites and fitted to a sigmoidal dose-response curve using the four parameter Hill function 
in SigmaPlot 12.5. Each experiment was done in triplicates and was repeated three to seven 
independent times. 
 
 
3.11. Growth analysis of ascorbate treated P. falciparum 3D7 parasites 
 
To assess the time-dependent growth inhibition of P. falciparum 3D7 wild-type strain by 
ascorbate, a growth curve was generated following the protocol above (see section 3.7.1). 
Briefly, six 14.5 mL synchronous cultures of P. falciparum 3D7 wild-type strain were set up 
at an initial parasitemia of 0.1% and a hematocrit of 3.5%. Five of the six parasite cultures 
were treated to final concentrations of 0.05 mM, 0.1 mM, 1 mM, 2.5 mM or 5 mM with 
aliquots from a sterile-filtered 200 mM ascorbate stock solution that was freshly prepared in 
complete medium. The sixth plate served as an untreated control parasite culture. The plates 
were incubated under normal culture conditions. Parasitemia of each culture was monitored 
for six days by counting 7 microscope fields (750-1500 erythrocytes) of Giemsa-stained thin 
blood smears. The medium of each flask was replaced every 24 hr. Each culture was retreated 
after medium replacement with the same concentrations of freshly prepared ascorbate solution 
as previously. Parasitemia for each data point was averaged from six independent experiments 
and analyzed as in section 3.7.1 above.  
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4. RESULTS 
 
 
4.1. Effect of the host cell Glo1 activity on P. falciparum blood-stage cultures 
 
Before the effect of the deletion of a P. falciparum glyoxalase can be effectively analyzed in a 
knockout line, the contribution of the host glyoxalase system to the parasite blood-stage 
development should be quantified. To date, there are no reports of erythrocyte glyoxalase 
knockout cells. The use of efficient glyoxalase inhibitors to eliminate the activities of human 
enzymes in parasite cultures therefore offers an alternative and effective molecular tool to 
investigate the relevance of the human glyoxalase system to the parasite’s development in the 
host-parasite unit of the infected-erythrocyte.   
 
 
 
 
Figure 4.1. Effect of the host cell Glo1 activity on P. falciparum blood-stage cultures. (A) 
Strategy to investigate the contribution of hGlo1 to the blood-stage parasite development. Uninfected 
erythrocytes were incubated with 10 µM of compounds 1–3, 7 or DMSO for 96 hr in complete RPMI medium to 
inhibit the hGlo1 activity. The erythrocytes were washed and subsequently infected with purified schizont-stage 
parasites in the absence of the tight-binding inhibitors. (B) Representative time course measurement of human 
Glo1 activity upon treatment of uninfected erythrocytes with 10 µM of compound 1. (C) Time-dependent effect 
of 10 µM of compounds 1–3 and 7 on hGlo1 and hGlo2 activities in uninfected erythrocytes. Stars indicate a p-
value of <0.05; n.s., not significant. (D) Growth curve analysis of P.falciparum parasites according to the 
scheme outlined in panel A. Erythrocytes were pre-treated for 96 h with 10 µM of compounds 1, 3 and 7, 
washed, and infected with purified parasites (day 0). All data points in panels B-D were averaged from 3–5 
independent experiments with different blood donors. Taken from (Wezena et al., 2016). 
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Compounds 1-3 and 7 were identified earlier as strong tight-binding Glo1-specific inhibitors 
(More & Vince, 2009). At concentrations of 30 μM and above, the compounds are slightly 
toxic to the uninfected erythrocyte host cell through hemolysis and the formation of 
methemoglobin (Wezena et al., 2016). To eliminate the toxic effects, 10 μM of each drug was 
used to treat uninfected erythrocytes for 96 hr to inhibit host cell Glo1 activity (Figure 4.1 C). 
Results averaged from five different blood donors revealed the activities of human Glo1 and 
Glo2 in the DMSO controls to be about 0.154 ± 0.038 and 0.056 ± 0.016 U/mg hemoglobin 
respectively. These results fitted well with previously reported erythrocyte glyoxalase 
activities (Mclellan et al., 1994). Compound 1 particularly acted quite strongly, though 
slowly, on uninfected erythrocytes resulting in a three-fold reduction of the Glo1 activity after 
96 hr of drug treatment (Figure 4.1 B & C). Treatment of erythrocytes with compounds 3, 7 
and 2 also reduced the activity of Glo1 to 60%, 55% and 54% respectively (Figure 4.1 C). 
Esteriﬁcation of the carboxylate groups in compounds 3 and 7 did not confer improved 
pharmacokinetics nor increased the potency of the inhibitors after 96 hr of treatment as 
compared to the mother compounds, 1 and 2. Surprisingly, the activity of human Glo2 also 
increased significantly by about 25% after treatment of erythrocytes with compounds 2 and 7 
for 96 hr. There was no significant increase in the erythrocyte Glo2 activity after treatment 
with compounds 1 and 3. Parasite growth was not significantly affected after 6 days of culture 
in erythrocytes that were pretreated for 96 hr with 10 μM of compounds 1, 3 and 7 (Figure 4.1 
D). Inhibition of the erythrocyte Glo1 enzyme with slow acting tight-binding inhibitors did 
not affect parasite development in the host-parasite unit. The conclusion that can be drawn 
from these results is that, the human Glo1 appears to be dispensable for the development of P. 
falciparum 3D7 wild-type strain in cell culture. 
  
                                                                     
4.2. pL7-knockout constructs to disrupt the glyoxalase genes in P. falciparum 
 
In order to generate clonal knockout lines for the glyoxalase genes of P. falciparum 3D7 
strain, the recently developed CRISPR-Cas9 gene knockout strategy was employed. This 
project specifically adopted the P. falciparum genome editing method (Figure 4.2 A & B, 
Figure 4.3 A & B) previously described (Ghorbal et al., 2014). The two plasmids employed 
for gene disruption by double crossover homologous recombination in this method include the 
Cas9-encoding construct (pUF1-Cas9) and the pL6 plasmid. As the pUF1-Cas9 was acquired 
ready-to use, only the pL6 plasmid was adapted for specific gene disruption by cloning-in the 
guide sequence, which directs the Cas9 protein to the target gene, and the flanking HR for 
homologous recombination. The pL7 plasmids generated from the cloning steps above 
included pL7-PFGLO1, pL7-PFcGLO2, pL7-PFtGLO2 and pL7-PFGILP which target 
PFGLO1, PFcGLO2, PFtGLO2 and PFGILP loci respectively. Plasmid pL7-PFGLO1 carried 
a 477 bp 5’ HR and a 521 bp 3’ HR. Plasmid pL7-PFcGLO2 carried a 642 bp 5’ HR and a 
442 bp 3’ HR. Plasmid pL7-PFtGLO2 carried a 467 bp 5’ HR and a 640 bp 3’ HR. And 
plasmid pL7-PFGILP carried a 612 bp 5’ HR and a 625 bp 3’ HR. All pL7 plasmids also 
carried their respective 20 bp guide sequences to direct double strand cleavage of the target 
genes by the Cas9 protein. Depending on the A-T content and length of the target gene, the 5’ 
and 3’ HR both occurred within the coding sequence as in the cases of PFGLO1, PFcGLO2 
and PFGILP genes or one HR extended into the untranslated region (UTR) as in the case of 
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the PFtGLO2 gene (3’ region). The cloned-in 5’ and 3’ HR of the pL7 plasmids flanked the 
expression cassette for the human dihydrofolate reductase (hDHFR) gene that confers 
resistance to the P. falciparum antifolate drug WR9210 (WR) (Fidock & Wellems, 1997), 
 
 
 
 
Figure 4.2. Generation and validation of P. falciparum Glo1 and cGlo2 knockout clonal lines. (A) and (B) 
Knockout scheme for PfGlo1 and PfcGlo2 respectively, adopting the CRISPR-Cas9 strategy (Ghorbal et al., 
2014). (C) PCR analysis of isolated genomic DNA from 3D7glo1 and 3D7cglo2 clonal lines generated after 
transfection, selection and limited dilution. The results are compared with the 3D7 wild-type strain as control. 
Analyses are shown for two clonal lines (#1 and #2) each of the 3D7glo1 and 3D7cglo2 strain. (D) Analysis 
of purified rabbit peptide antibodies against PfGlo1 and PfcGlo2 in P. falciparum 3D7 wild-type parasites. 
Lysate from 2 x 107 cells was loaded per lane on a 15% gel, separated by reducing SDS-PAGE and analyzed by 
western blotting. The expected sizes of PfGlo1 and PfcGlo2 are indicated by arrowheads. PS, S, Ab: Decoration 
with pre-immune serum, serum and affinity-purified antibody, respectively. (E) Western blot analyses of PfGlo1 
and PfcGlo2 in extracts from two clonal lines of 3D7glo1 and 3D7cglo2 knockout strains from panel C using 
the purified antibodies from panel D. Analyses of PfGlo1 and PfcGlo2 in the same amount of lysate from the 
3D7 wild-type strain served as contol. As a loading control, membranes were decorated with an antibody against 
P. berghei Hsp70. The primer pairs used and the expected sizes of PCR products for the 3D7 wild-type strain as 
well as knockout clones are shown. Antibody purification and western blot analysis of the knockout clones was 
performed by Linda Liedgens. Taken and modified from (Wezena et al., 2018). 
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and thus served as a positive drug selectable-marker. The guide sequence of each pL7 plasmid 
completed the requirements for a functional sgRNA. The sgRNA on each of the plasmids was 
therefore capable of binding Cas9 protein expressed by the pUF1-Cas9 plasmid and guiding it 
via the specific guide sequence to target and cause double stand breaks at specific gene loci. 
The double strand breaks could then be repaired by the 5’ and 3’ homologous regions (donor 
or template DNA) on the pL7 plasmids.  
 
 
PFGLO1 
  969bp
Chr 12
Chr 12
  3269bp
10329 bp
hDHFR  5' HR   3' HR
  PCR 1: 3709bp
  PCR 1: 4623bp
  PCR 2: 3072bp
  PCR 3: 2037bp
  p37   p38
  p38
  p38
  p37
  p37   p27
  p26
hDHFRhDHFR
  bla
  pL7-tglo2
vTK
  5' HR   3' HR
 Cas9 binding   Guide5' U6 3' U6
y
F
C
U
tGLO2 
y
F
C
U
A
hDHFR
PFcGLO2 
  bla
  pL7-gilp
vTK
  5' HR
  1568 bp
Chr 6
Chr 6
  3400 bp
  3' HR
10460 bp
  5' HR   3' HR
  PCR 1: 1753 bp
  PCR 1: 3760 bp
  PCR 2: 2463 bp
  PCR 3: 1818 bp
 Cas9 binding   Guide5' U6 3' U6
  p39   p40
  p40
  p40
  p39
  p39   p27
  p26
y
F
C
U
hDHFR
hDHFR
PFGILP 
y
F
C
U
B
 
Figure 4.3. Strategy for the generation of P. falciparum 3D7tglo2 and 3D7gilp knockout clones. (A) and 
(B) Knockout scheme for PFtGLO2 and PFGILP respectively, adopting the CRISPR-Cas9 strategy (Ghorbal et 
al., 2014). The primer pairs used and the expected sizes of PCR products for the 3D7 wild-type strain as well as 
knockout strains are shown. 
 
 
P. falciparum 3D7 wild-type strains were first transfected with the pUF1-Cas9 plasmid which 
also carries the drug selectable marker yeast dihydroorotate dehydrogenase (yDHODH) gene. 
yDHODH confers resistance to atovaquone, an anti-protozoal mitochondrial electron 
transport inhibitor, by presenting a ubiquinone-independent DHODH for the essential 
pyrimidine bio-synthetic pathway (Ganesan et al., 2011). Parasites were detected by Giemsa-
stained blood smears 23 days post-transfection after selection with atovaquone. These 
transgenic parasites, 3D7Cas9, were amplified and transfected with each of the pL7 plasmids. 
pL7 transfectants were detected within four weeks after positive selection and also survived 9 
days of selection with the negative selectable maker 5-FC. 5-FC was used because the pL7 
plasmid also carries the fusion suicide-gene yeast cytosine deaminase and uridyl 
phosphoribosyl transferase (yfcu), the product of which deaminates 5-FC to cytotoxic 5-
fluorouracil leading to cell death (Braks et al., 2006). 5-FC selection therefore eliminated 
parasites carrying unintegrated pL7 plasmid or parasites in which only a single crossover 
event occurred after transfection. Transfectants were controlled by PCR and western blot 
analyses for the disruption of the respective PFGLO1, PFcGLO2, PFtGLO2 and PFGILP 
target loci. Disruption of PFGLO1 and PFcGLO2, the genes encoding the cytosolic 
glyoxalases was confirmed in a mixed population of transfectants.  
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4.3. Generation of single knockout clones by limiting dilution 
 
Clonal parasite lines are essential for cellular, molecular and biochemical analyses of parasite 
strains because of the need for accurate, unambiguous and reproducible results (Hasenkamp et 
al., 2012). Limiting dilution of culture to one or less parasites per culture well in a 96 well 
plate and cultivating the diluted cultures for 2-4 weeks is a common method of generating 
clonal parasite lines. Several versions of this method have been reported. The variations 
include the detection mode of parasites in 96 well plates. The cheapest, though quite tedious, 
variation is the detection of parasite growth in each well by light microscopy of Giemsa-
stained blood smears. This thesis adopted the above method to select single knockout clones 
of transgenic PFGLO1 and PFcGLO2 knockout strains, now referred to as 3D7glo1 and 
3D7cglo2, respectively. Parasites were detected by microscopy on day 21 of cell culture. Of 
24 wells that were cultured with approximately one parasite, growth was detected in 13 wells. 
Five (5) out of 24 culture wells of the 1/10 dilution of the approximately one-parasite culture 
were also positive for parasite growth by Giemsa-stained thin blood smears, while 1 well out 
of 24 culture wells of the 1/100 dilution of the approximately one-parasite culture was 
positive for parasite growth. No growth was detected in any of the 24 control wells.  
 
 
4.4. PCR and western blot analyses of 3D7glo1 and 3D7cglo2 clonal lines 
 
PCR analysis was repeated with gDNA of two clonal knockout lines each of the 3D7glo1 
and 3D7cglo2 strains; glo11 & glo12 and cglo21 & cglo22 respectively. The 
results confirmed the disruption of PFGLO1 and PFcGLO2 gene loci and the integration of 
the hDHFR gene sequence in these loci (Figure 4.2 C). Single bands were visible on the 
analytic agarose gel of PCR products that were generated using primers that targeted the 
whole PFGLO1 and PFcGLO2 gene loci on the 3D7glo1 and 3D7cglo2 strains 
respectively (4.3 kb and 4.1 kb bands were respectively visible compared to 2.2 kb and 2.0 kb 
bands of the respective wild-type PFGLO1 and PFcGLO2 genes). This clearly showed the 
integration of the 2.1 kb expression cassette of hDHFR. PCR analysis using specific primers 
that targeted the integrated hDHFR and the 5’ and 3’ UTRs of the PFGLO1 and PFcGLO2 
gene loci also confirmed the disruption of the native genes and the integration of the hDHFR 
gene sequence into the genome of the 3D7glo1 and 3D7cglo2 strains (2.5 kb and 2.3 kb 
bands were detected by PCR and agarose gel analyses of the 3D7glo1 strain corresponding 
to the respective 5’ and 3’ UTR segments of the disrupted PFGLO1 locus. 2.6 kb and 2.1 kb 
bands were also detected by PCR and agarose gel analyses of the 3D7cglo2 strains, 
corresponding to the 5’ and 3’ UTR segments of the disrupted PFcGLO2 locus). No bands 
were produced when P. falciparum 3D7 wild-type gDNA was analyzed for hDHFR 
integration. Western blot analysis confirmed the disruption of the two gene loci, and 
eliminated the possibility of gene multiplications and other genetic recombinations that may 
still have led to the expression of functional PfGlo1 and PfcGlo2 enzymes in the respective 
knockout strains (Figure 4.2 E). In the western blot analysis, PfGlo1 and PfcGlo2 proteins 
were detected at approximately 42 and 31 kDa respectively only in cell lysate of the P. 
falciparum 3D7 wild-type control strain. The PCR and western blot results together confirm 
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that the cytosolic glyoxalase enzymes, PfGlo1 and PfcGlo2, are not essential for the blood-
stage development of the P. falciparum 3D7 strain since single knockout clones were viable.  
 
 
4.5. Attempts to disrupt the PFtGLO2 and PFGILP loci were not successful 
 
Four attempts to disrupt the PFtGLO2 and PFGILP loci were unsuccessful. The four 
independent transfection attempts were performed using the same and slightly varied 
protocols as was used in the transfection of 3D7cas9 parasites with pL7-PFGLO1 and pL7-
PFcGLO2 plasmids. In the first attempt, transfections were maintained and selected with WR 
for 63 days but no parasites were detected in Giemsa-stained blood smears at various times 
during the culture. In the second attempt, parasites were detected in Giemsa-stained smears 
within 4 weeks post-transfection under WR selection. Transfectants also survived 9 days 
negative selection with 5-FC whilst maintaining WR pressure. Mixed population transfectants 
were ultimately analyzed by PCR for native gene disruption and the integration of the hDHFR 
expression cassette into the PFtGLO2 or PFGILP locus. Analytical PCR using primers that 
targeted the whole gene locus of PFtGLO2 and PFGILP generated DNA bands at 2.6 kb and 
1.8 kb respectively on agarose gels. These band sizes corresponded to the lengths of the intact 
wild-type whole gene sequences, and showed that the native PFtGLO2 and PFGILP genes 
were not disrupted. The expected band sizes of the disrupted PFtGLO2 and PFGILP loci 
should be 4.7 kb and 3.9 kb on the 3D7tglo2 and 3D7gilp strains respectively. Analytical 
PCR results using specific primers that targeted the probably integrated hDHFR expression 
cassette and the 5’ and 3’ UTRs of the native PFtGLO2 and PFGILP loci produced no bands 
on agarose gels. The expected band sizes for the 5’ and 3’ segments of the PFtGLO2 locus of 
the 3D7tglo2 strain should be 3.1 kb and 2.0 kb respectively. The expected bands for the 5’ 
and 3’ segments of the PFGILP locus of the 3D7gilp strains should be 2.5 kb and 1.8 kb 
respectively. Different PCR programs were also tried to increase the chances of amplifying 
any integrated hDHFR expression cassette. These included increasing and decreasing the 
annealing and extension temperatures and times. However, all the results suggested that the 
reporter hDHFR gene was not integrated in the PFtGLO2 and PFGILP native gene loci and 
so the target genes were not disrupted. In the third and fourth attempts, changes were made 
regarding the transfection protocol in order to increase the chance of disrupting the PFtGLO2 
and PFGILP genes. New transgenic 3D7cas9 parasites were generated for these attempts in 
order to eliminate the possibility that a mutated and inefficient Cas9 protein could result from 
the old population after many rounds of cell culture. A new dilution of WR was also used to 
increase the potency of the drug for positive selection. However, similar to the second 
transfection attempt, false-positive transfectants of the pL7 plasmids were detected by 
Giemsa-stained thin blood smears within four weeks of the third and fourth transfection 
attempts. In the fourth attempt, a repeat transfection of the pL7-PFGLO1 plasmid was also 
performed as a control of the protocol, along with the pL7-PFtGLO2 and pL7-PFGILP 
plasmids transfections. Transfectants were detected in the culture of pL7-PFGLO1 control 
transfection about the same time as were detected in the pL7-PFtGLO2 and pL7-PFGILP 
transfection cultures. PCR analysis of gDNA of the pL7-PFGLO1 control transfectants once 
again confirmed the disruption of the native gene and the integration of the hDHFR 
expression cassette into the PFGLO1 locus. This result showed that the transfection protocol 
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worked efficiently. The issues relating to the inability to disrupt the PFtGLO2 and PFGILP 
gene loci therefore seem to be directly related to the architecture of the pL7-PFtGLO2 and 
pL7-PFGILP knockout constructs, for example with the specificity of the guide sequence. 
 
 
4.6. Growth curve and morphological analyses of knockout strains 
 
Light microscopy examination of Giemsa-stained thin blood smears of the asexual stages of 
the 3D7glo1 and 3D7cglo2 strains helped analyze the phenotypic characteristics of these 
parasites (Figure 4.4 A, B & C). Analyses of different growth stages of over 20 parasites each 
of the two clonal knockout lines, glo11 & glo12 (of 3D7glo1 strain) and cglo21 & 
cglo22 (of 3D7cglo2 strain) detected no unusual morphological features of the knockout 
parasites in comparison with the 3D7 wild-type strain. Assessment of the viability and growth 
rate of three 3D7glo1 clonal lines and two 3D7cglo2 clonal lines showed a slight reduction 
in growth rate compared to the wild-type strain. From an averaged starting parasitemia of 
0.1%, an asynchronous 3D7 wild-type culture reached a parasitemia of approximately 12% 
after 6 days of culture compared to 9% and 10% for 3D7glo1 and 3D7cglo2 clonal lines 
respectively under the same culture conditions. This reduction in growth rate was, however, 
found not to be significant according to statistical analyses. In summary, 3D7glo1 and 
3D7cglo2 asexual blood-stage parasites have an inconspicuous morphology and show no 
obvious growth defect. 
 
 
          C 
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Figure 4.4. Growth curve analysis and general morphology of P. falciparum knockout strains 3D7glo1 
and 3D7cglo2.  (A) Growth analysis of three clonal lines of 3D7glo1 knockout strains in comparison to the 
3D7 wild-type strain. (B) Growth analysis of two 3D7cglo2 clonal lines in comparison with the 3D7 wild-type 
strain. The starting parasitemia of an asynchronous culture for all experiments was 0.1% and cultures were 
monitored for six days by counting Giemsa-stained blood smears. All data points represent the mean ± S.D. from 
three independent experiments. Statistical analysis using the one way ANOVA method in SigmaPlot 12.5 did not 
reveal a significant growth difference between the knockout strains and the 3D7 wild-type strain (p > 0.05). (C) 
Morphology of the asexual blood and gametocyte stages of 3D7glo1 and 3D7cglo2 strains by Giemsa-stained 
blood smears. Microscopical examination of smears of ring stages (RS), trophozoites (TZ), immature schizonts 
(imSZ), mature (mSZ) schizonts as well as gametocytes (GC) stages II-V of the knockout strains revealed no 
observable differences in morphology compared to the same stages in the 3D7 wild-type blood-stage parasites. 
Bar, 5 μm. Microscopy was performed by Alexandra Golzmann of the laboratory of Prof. Gabriele Pradel. Taken 
and modified from (Wezena et al., 2018). 
 
 
4.7. Glo1 and Glo2 activities of glyoxalase knockout strains 
 
The contribution of PfGlo1 and PfcGlo2 to the overall Glo1 and Glo2 activities in purified P. 
falciparum parasite extracts was determined for the 3D7 wild-type strain in comparison with 
the clonal 3D7glo1 and 3D7cglo2 knockout lines (Figure 4.5). The average Glo1 activities 
of 3D7 wild-type, 3D7glo1 and 3D7cglo2 clones were 184, 19 and 281 µU/mg protein 
respectively. Gene knockout clearly affected the activity levels of the enzymes in both 
knockout clones but in contrasting patterns. As expected, Glo1 activity in the 3D7glo1 
parasites significantly dropped by approximately 90% as compared to the activity in the 3D7 
wild-type strain. The 10% residual Glo1 activity recorded in the 3D7glo1 clones might 
either originate from a non-canonical parasite enzyme or from human Glo1 that is taken up 
into the parasite. In contrast, the Glo1 activity of the 3D7cglo2 parasites unexpectedly 
increased by approximately 50% in comparison with that of the wild-type strain. This increase 
could be due to an up-regulation of the Glo1 gene in the 3D7cglo2 parasites even though the 
averaged differences in Glo1 activity between wild-type strain and the 3D7cglo2 clonal 
knockout lines varied and were not significant according to statistical analyses. With regards 
to Glo2 activities, the averaged values 295, 308 and 101 µU/mg protein were recorded for 
3D7 wild-type, 3D7glo1 and 3D7cglo2 clones respectively. The 3D7cglo2 clones 
maintained about one third of the Glo2 activity recorded in the wild-type strain. This 
relatively high Glo2 activity recorded in the knockout lines might be explained by the PftGlo2 
activity in parasite extracts. As stated above, PftGlo2 is an active enzyme in standard Glo2 
assays. The residual Glo1 and Glo2 activities recorded in the respective knockout clones may 
explain the absence of a variant phenotype in these strains. While the residual Glo2 activity of 
around 30-40% is plausible in the 3D7cglo2 clonal lines in the presence of a functional 
PftGlo2 enzyme, a residual Glo1 activity of around 10% is quite surprising for 3D7glo1 
knockout parasites considering the absence of another functional canonical Glo1-isoform in 
P. falciparum.  
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Figure 4.5. Glo1 and Glo2 activity measurements of P. falciparum 3D7glo1 and 3D7cglo2 knockout 
strains after erythrocyte removal by saponin lysis. (A) Normalized Glo1 activity measurements of knockout 
strains in comparison with the 3D7 wild-type strain at 240 nm. Parasite extracts from approximately 107 
trophozoites were used. (B) Normalized Glo2 activity measurements of knockout strains in comparison with the 
3D7 wild-type strain at 240 nm. Parasite extracts from approximately 1.7x107 trophozoites were used. All data 
points represent the mean ± S.D. from two to four independent triplicate measurements. Statistical analyses were 
performed in SigmaPlot 12.5 using the one way ANOVA method (ns, not significant; ** p < 0.01; *** p < 
0.001). Taken and modified from (Wezena et al., 2018). 
 
 
4.8. Susceptibility of glyoxalase knockout strains to 2-oxoaldehydes  
 
IC50 assays of the susceptibility of the clonal 3D7glo1 and 3D7cglo2 knockout lines to the 
external physiological substrates glyoxal, methylglyoxal and phenylglyoxal (Figure 4.7) are 
summarized in Figure 4.6. The IC50 curves shown in Figure 4.7 are results from SYBR green 
1 assays of bolus treatments of ring-stage knockout and 3D7 wild-type parasites clones with 
the 2-oxoaldehydes. The results, which were averaged from three to seven independent 
triplicate measurements, showed that the IC50 values for glyoxal were approximately 75µM, 
40µM and 76 µM for the 3D7 wild-type, 3D7glo1 and 3D7cglo2 parasite lines 
respectively. The average IC50 values for methylglyoxal were 271µM, 255µM and 232µM for 
3D7 wild-type, 3D7glo1 and 3D7cglo2 parasite lines respectively. For phenylglyoxal, the 
average IC50 values were in the millimolar range for all parasite lines. IC50 values of 1.2 mM, 
1.3 and 1.2 mM were recorded for this compound for the 3D7 wild-type, 3D7glo1 and 
3D7cglo2 parasite lines respectively. The results revealed that the toxicity of the 2-
oxoaldehydes depended on the size and/or polarity of the compounds with lowest IC50 values 
for the lower molecular weight glyoxal and highest IC50 values for higher molecular weight 
phenylglyoxal. The results also showed a significant decrease by up to 60% in IC50 value for 
glyoxal for the 3D7glo1 knockout parasites in comparison to the wild-type strain, whereas 
no significant differences between wild-type and 3D7glo1 knockout parasites were observed 
after treatment with methylglyoxal and phenylglyoxal. No significant differences were 
observed between the susceptibility of the 3D7cglo2 knockout parasites and wild-type 
parasites towards the three external 2-oxoaldehydes. In summary, 3D7glo1 knockout 
parasites are more susceptibility to external glyoxal, which is more toxic to the P. falciparum 
3D7 strain than methylglyoxal and phenylglyoxal.     
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Figure 4.6. Summary of growth inhibitory effects of exogenous 2-oxoaldehydes on 3D7glo1 and 
3D7cglo2 knockout strains. Ring-stage synchronous cultures with 1.5% starting parasitemia were treated with 
bolus amounts of (A) glyoxal, (B) methylglyoxal and (C) phenylglyoxal and maintained in 96-well plates. IC50 
values were determined after 72 hr of incubation using a SYBR green 1 assay. All data points represent the mean 
± S.D. from triplicate measurements of three to seven independent experiments. Statistical analyses were 
performed in SigmaPlot 12.5 using the one way ANOVA method (ns, not significant; * p < 0.05; ** p < 0.01; 
*** p < 0.001). Taken and modified from (Wezena et al., 2018). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. 7. Growth inhibitory effects of exogenous 2-oxoaldehydes on synchronous ring-stage cell cultures 
of P. falciparum 3D7glo1 and 3D7cglo2 knockout strains. Cultures were maintained in 96-well plates with 
a starting hematocrit and parasitemia of 1.5% and 0.5% respectively. Cultures were treated with bolus amounts 
of (A) glyoxal, (B) methylglyoxal and (C) phenylglyoxal and the IC50 values were determined using a SYBR 
green I assay after 72 hr of incubation. All data points represent the mean ± S.D. from triplicate measurements of 
three to seven independent experiments. Data points at phenylglyoxal concentrations ≥10 mM were omitted 
because of a strong autofluorescence. The IC50 values are summarized in Figure 4.6. Taken and modified from 
(Wezena et al., 2018). 
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4.9. AGE accumulation in glyoxalase knockout strains  
 
To assess the potential accumulation of AGE in the 3D7glo1 and 3D7cglo2 knockout 
strains, western blot analysis of purified trophozoite-stage parasite extracts was performed 
using the commercial polyclonal anti-AGE antibody, Ab23722 (Figure 4.7). This antibody 
has specificity for general AGE and is suitably for the detection of the products in parasite 
cell extracts. The staining pattern by the antibody revealed a few AGE bands and smears 
around 40, 70 and 180 kDa. When cell lysates from steady state parasites and cell lysates 
from parasites that were treated with 50 µM glyoxal for 6 hr were analyzed, the AGE bands at 
70 and 180 kDa were visibly more intense for the 3D7glo1 and 3D7cglo2 parasite extracts 
than for wild-type parasite extracts. Band patterns and comparative intensities in relation to 
the wild-type samples were, however, similar under both conditions. Analysis of band 
intensities from three independent experiments of treated and untreated parasite extracts was 
performed using the ImageJ software. The results showed an increase of about 80% in 
accumulated AGE in the 3D7glo1 and 3D7cglo2 parasite lines compared to the 3D7 wild-
type parasites in extracts from both treated and untreated parasites. Results from the western 
blot analyses therefore support the accumulation of selected modified proteins in the 
glyoxalase knockout strains. However, parasite growth at the erythrocytic-stage appears to be 
normal and unaffected by the accumulation of the glycated products. 
 
 
 
Figure 4.8. Western blot detection 
of AGE in parasite extracts from 
P. falciparum 3D7Δglo1 and 3D7-
Δcglo2 knockout strains after er-
ythrocyte removal by saponin ly-
sis. 3D7 wild-type parasite extracts 
served as a control. (A) Dectection 
of AGE under steady-state conditi-
ons without treatment with external 
2-oxoaldehyde. (B) Dectection of 
AGE after a 6 hr bolus treatment 
with 50 μM glyoxal (50 μM glyoxal 
is used because this concentration 
corresponds approximately to the 
glyoxal IC50 value determined in 
Figure 4.6). Extracts from 2 x 107 
trophozoites were loaded per lane 
on a 15% gel, separated by reducing 
SDS-PAGE and decorated with a 
commercial polyclonal anti-AGE 
antibody. Detection of P. berghei 
Hsp70 on a parrelely ran blot using 
the same parasite extracts served as 
a loading control. Signal intensities 
were analyzed form three indepe-
ndent experiments using ImageJ 
and statistical analyses were perf-
ormed in SigmaPlot 12.5 using the 
one way ANOVA method (* p < 
0.05; *** p < 0.001). Taken and 
modified from (Wezena et al., 
2017). 
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4.10. Gametocytogenesis of glyoxalase knockout strains 
 
Experiments aimed to investigate how the loss of PfGlo1 or PfcGlo2 activity as well as the 
accumulation of AGE would affect gametocyte commitment were performed by Alexandra 
Golzmann in the laboratory of Gabriele Pradel at the RWTH University of Aachen. The 
results revealed that the 3D7Δglo1 and 3D7Δcglo2 glyoxalase knockout strains were both able 
to undergo gametocyte commitment and to develop mature gametocytes as the 3D7 wild-type 
strain. The gametocyte stages formed in the three lines exhibited morphologies comparable to 
the wild-type strain during maturation (Figure 4.4 C). Surprisingly, however, the 3D7Δcglo2 
parasites had an increased gametocytemia compared to the parental line and the 3D7Δglo1 
parasites in more than three independent experiments (Figure 4.8). This result indicated that 
the lack of PfcGlo2 results in increased gametocyte induction and gametocytogenesis. The 
3D7Δglo1 parasites were also shown to form a reduced number of gametocytes in all 
experiments compared with the two other strains. 
 
 
 
 
4.11. Antiproliferative effects of H2O2, ascorbate, NAc and DTT 
 
The effect of standard pro- and antioxidants on the erythrocytic development of P. falciparum 
3D7 wild-type strain was investigated using the SYBR green 1 assay. IC50 values for H2O2, 
ascorbate, NAc and DTT were determined for synchronous ring-stage parasite cultures. 
Results averaged from three to six independent experiments showed IC50 values for H2O2, 
ascorbate, NAc and DTT to be around 78 mM, 4.3 mM, 17 mM and 245 uM respectively 
(Figure 4.9). The IC50 value for H2O2 (Figure 4.9 D) is unexpectedly high considering the 
widely suggested susceptibility of Plasmodium species to reactive oxygen species (Dockrell 
et al., 1986; Clark & Hunt, 1983), and the relevance of oxidative stress for parasite survival 
(Becker et al., 2004; Jortzik & Becker, 2012). To completely kill parasites, even higher 
concentrations of H2O2 were required, that also caused intense catalase-dependent oxygen 
production and foaming of the culture (Wezena et al., 2017).  
During pre-trials to determine the order of magnitude of the IC50 values, it was observed that 
the reducing agents ascorbate, NAc and DTT promoted gelling of the medium, formation of 
methemoglobin and hemolysis at high concentrations. The same effects were observed when 
Figure 4.9. Analysis of gametocyte development of the 
P. falciparum 3D7Δglo1 and 3D7Δcglo2 knockout 
strains. Gametocyte commitment and induction were 
analyzed in the 3D7Δglo1 and 3D7Δcglo2 knockout 
strains in comparison with the 3D7 wild-type strain. 
Gametocytemia was determined by microscopy per 1000 
red blood cells in Giemsa-stained blood smears 14 days 
post-induction. All data points are the mean ± S.D. from 
triplicate measurements. Results shown are representative 
of three independent experiments. Taken from (Wezena et 
al., 2017). 
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cultures were incubated for prolonged periods with the compounds. The same observation 
was made by Johannes Krafczyk while determining the IC50 values for the reducing agents for 
the P. falciparum Dd2 strain. While the gelation was also detected at DTT concentrations 
lower than 1 mM, methemoglobin formation and hemolysis appeared to require higher DTT 
concentrations. All the reducing agents were found to exhibit a significant gelation-dependent 
increase in background fluorescence in the SYBR green 1 assay. To correct the experimental 
results for this background effect, reference values from uninfected erythrocytes that were 
cultured in parallel with the same amount of the reducing agents were used. The final results 
showed that all three reducing agents have antiproliferative rather than growth-promoting 
effects (Figure 4.9 A, B & C). The parasites, however, appear to be more sensitive to DTT 
than to NAc and ascorbate.  
The effects of ascorbate on the 3D7 strain were further analyzed by treating parasites in 
normal cultures with different concentrations of ascorbate (Figure 4.9 E). Cultures were 
grown for six days and the parasitemia was monitored daily by Giemsa-stained blood smears. 
The results showed that daily culture treatment with 2.5 mM and 5.0 mM ascorbate caused 
methemoglobin formation and hemolysis over time. These effects coincided with growth 
inhibition as the parasitemia after six days of culture was also reduced by around 46% and 
90% in the plates treated with 2.5 mM and 5.0 mM ascorbate respectively. As observed in the 
IC50 assay results above, millimolar ascorbate concentrations as well as prolonged incubation 
periods were required for these effects to be detectable. Ascorbate thus exhibited slow growth 
inhibition kinetics for standard cultures of P. falciparum 3D7 strain with an IC50 value of > 
1mM.  
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Figure 4.10. Growth inhibitory effects of hydrogen peroxide and the three reducing agents, NAc, 
ascorbate and DTT on P. falciparum 3D7 wild-type strain cultures. Panels (A-D) Ring-stage synchronized 
cultures were started in 96-well plates at a hematocrit of 1.5% and parasitemia of 0.5% for IC50 determination. 
IC50 values were determined using SYBR green I assay 72 hr after bolus treatment of cultures with NAc (A), 
ascorbate (B), DTT (C) and H2O2 (D). The number of replicates for each data point is indicated in each panel 
(e.g., n = 6 x 3 for six independent triplicate measurements). (E) Time-dependent growth inhibition of P. 
falciparum 3D7 wild-type strain by daily ascorbate treatment. Standard 14 mL 3D7 wild-type strain cultures 
synchronized at the ring-stage were started at a parasitemia of 0.1% and a hematocrit of 3%. Cultures were 
treated daily with the same concentration of ascorbate (0.05 mM, 0.10 mM, 1.00 mM, 2.50 mM and 5.00 mM) in 
fresh growth medium and the parasitemia was monitored over six days using Giemsa-stained blood smears. Data 
points represent the average of results from six independent 6-day experiments. Taken and modified from 
(Wezena et al., 2017).  
 
 
Table 4.1.  Summary of the IC50 values determined in this study compared with 
previously determined values from the Dd2 strain. 
 
Strain 
Oxidants Reductants 
H2O2 
(mM) 
tBOOH 
(μM) 
Ascorbate 
(mM) 
NAc 
(mM) 
DTT 
(μM) 
3D7a 77.8 ± 9.6 81.1 ± 6.4 4.3 ± 0.3 16.6 ± 2.1 245 ± 18 
Dd2b 46.1 ± 7.8 121 ± 9 3.0 ± 0.3 12.4 ± 3.0 389 ± 26 
IC50 value for tBOOH for the 3D7 strain was determined by Verena Staudacher. H2O2, tBOOH, ascorbate, NAc 
and DTT values for the Dd2 strain were determined by Johannes Krafczyk. 
a Bolus treatment of asynchronous parasite cultures. 
b Bolus treatment of synchronous ring-stage parasite cultures. 
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5. DISCUSSION 
 
 
5.1. A revolutionary CRISPR-Cas9 system for P. falciparum genome editing 
 
Malaria remains a major cause of global morbidity and mortality especially among children 
under five (5) years and pregnant women in the tropical regions of Africa (Bousema & 
Drakeley, 2011). Nearly half of the world’s population is at risk of the disease that caused 
about 731 000 deaths in 2015 alone and around 350 to 500 million infections every year 
(Bousema & Drakeley, 2011; Rosenberg, 2008; WHO, 2017a). Of the five Plasmodium 
species that cause human malaria, P. falciparum is the most virulent and accounts for up to 
85% of all global malaria cases (Dronamraju & Arese, 2006; Lee & Vythilingam, 2013). The 
combined effects of resistance to front-line malaria drugs, climate change and a rise in 
international travel have made control of the parasitic infection daunting and major gains 
made in the control of the disease are at risk of being eroded (Mirski et al., 2011; Bai et al., 
2013). To sustain these gains and improve on the fight against malaria, new potent 
antimalarial drugs as well as effective vaccines are urgently required. An improved molecular 
understanding of the complex life cycle of the malaria parasite will not only help in the 
identification of new drug targets and the evaluation of vaccine candidates, but will also help 
characterize the molecular basis of current drug resistance. Information revealed by the 
sequencing of the P. falciparum genome is an added advantage that should immensely benefit 
molecular research into the malaria parasite in many fronts (Carvalho & Ménard, 2005). 
Genetic manipulation of the P. falciparum genome is, however, a daunting task hampered by 
peculiar difficulties, and mostly limited to the blood stages of the parasites life cycle 
(Cowman & Crabb, 2005). The reasons for this situation are numerous and are mainly based 
on the complex life cycle of the species and on the specific genome architecture of P. 
falciparum (Carvalho & Ménard, 2005). For instance, the parasite spends most of its life 
located intracellularly within the parasitophorous vacuole in the infected erythrocyte, with its 
nucleus separated from the environment by four membranes. This causes a marked reduction 
in transfection efficiency (~10-6 frequency in P. falciparum) of the Plasmodium parasite 
(Carvalho & Ménard, 2005; Crabb, 2002).  Secondly, the genome of P. falciparum has a very 
high A-T content (81%) (Cowman & Crabb, 2005; Tuteja, 2007). This does not only make the 
preparation of transfection plasmids in E. coli difficult but also presents the very possible 
challenge of nonspecific DNA integration into the parasite genome during genetic 
manipulation (Cowman & Crabb, 2005; Tuteja, 2007). Thirdly, except for a few recent 
reports, only circular plasmid vectors have been used to successfully transfect P. falciparum 
parasites (Crabb, 2002). The use of linear DNA template shortens the time for the selection of 
integrants and circumvents the episomal maintenance of template DNA. It is the preferred 
template for homologous recombination in P. berghei, but, until recently, has not been 
workable in P. falciparum. This is presumably because linear DNA templates get degraded as 
they cross into the nucleus, making them unstable for ring-stage transfection (Cowman & 
Crabb, 2005). A longer period (~3-4 months) is required to select for integrants after 
transfection with circular plasmids because these plasmids preferentially replicate episomally 
rather than integrate into the parasite genome (Carvalho & Ménard, 2005). Another issue is 
that double crossover is a rare random process in P. falciparum as circular plasmids would 
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preferentially undergo only a single crossover event especially without drug pressure and 
negative selection (Carvalho & Ménard, 2005). Finally, the limited number of robust 
selectable markers for successful gene editing in P. falciparum has restricted the performance 
of consecutive genetic manipulations on the same parasite (Koning-Ward et al., 2015). The 
genome of blood-stage Plasmodium is haploid meaning that genetic manipulation involves 
targeting a single gene (Koning-Ward et al., 2015 ). This has the advantage that, for most 
genes, a single recombination event is sufficient for generating a modified parasite clone 
(Carvalho & Ménard, 2005). It is, however, difficult to study essential genes under standard 
blood-stage culture conditions because disruption of such genes is lethal (Koning-Ward et al., 
2015 ). 
Recently, an engineered CRISPR-Cas9 genome-editing system based on the type II CRISPR-
Cas system of S. pyogenes was effectively used to achieve results for both gene disruption and 
single-nucleotide gene editing in P. falciparum (Lee & Fidock, 2014; Ghorbal et al., 2014). 
Even though the earliest design of P. falciparum CRISPR-Cas9 system (Ghorbal et al., 2014) 
involves a two-plasmid approach, the strategy was shown to be highly efficient. As long as 
the requirement for a unique guide sequence of the sgRNA was met, virtually every locus of 
the malaria parasite that carries a PAM sequence could be targeted for modification (Ghorbal 
et al., 2014). Similar to other genome-editing tools, the CRISPR-Cas9 system can target and 
directly edit specific sites in the parasite genome. Having the choice of design of the guide 
sequence and the homologous regions for recombination helps avoid high A-T portions of 
target genes that will otherwise expose the strategy to non-specific recombination events. As 
the CRISPR-Cas9 system is not based on random induction of DNA double strand breaks 
(hallmark of conventional genome modification systems) selection of integrants can be 
achieved in a shorter period (within 3 weeks) (Ghorbal et al., 2014). Compared with other 
genome-editing tools, the CRISPR-Cas9 system was demonstrated to be more workable with 
P. falciparum (Koning-Ward et al., 2015; Ghorbal et al., 2014 ). For these reasons, the 
CRISPR-Cas9 system, initially used by Ghorbal and colleagues was employed to disrupt the 
glyoxalase genes, PFGLO1 and PFcGLO2, of P. falciparum. An attempt was also made to 
disrupt the genes, PFtGLO2 and PFGILP that encode the apicoplast targeted glyoxalase 
enzymes. Furthermore, the Glo1 inhibitors, compounds 1, 3 and 7, were employed to 
investigate the relevance of the hGlo1 enzyme for the Plasmodium parasite’s blood-stage 
development. 
 
 
5.2. Human Glo1 appears to be dispensable for asexual blood-stage development 
 
Tight-binding Glo1-specific inhibitors (compounds 1, 3 and 7) inhibited host (erythrocyte) 
Glo1 activity and were therefore used as a chemical tool to address the relevance of the 
functional hGlo1 for parasite survival in the host-parasite unit. Contribution of the host 
glyoxalase system to parasite development can be envisioned in two possible ways: import of 
hGlo1 to help cope with elevated levels of 2-oxoaldehydes or the export of excess 2-
oxoaldehydes into the host to be detoxified by the more abundant human glyoxalase system. 
The outcome of the study supports neither of the two possibilities but rather suggests that the 
activity of hGlo1 does not play a major role for the intraerythrocyte development of the 
parasite in cell culture. Inhibition experiments with the most potent of the inhibitors, 
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compound 1, however, still allowed for the assay of as much as one-third residual hGlo1 
activity in the erythrocyte. This hGlo1 activity residue, though unlikely (please see below), 
may be sufficient to compensate for the loss of hGlo1 activity and thus aid the parasite to 
survive in the inhibited erythrocytes. One other significant observation from the inhibition 
study is that esterification of the tight-binding inhibitors can impact the growth inhibition of 
malaria parasites and the inhibition of the host cell Glo1 activity in different ways. Previously, 
direct growth inhibition of P. falciparum blood-stage cultures by the esterified analogues of 
compounds 1 and 2 (compounds 3 and 7) yielded a three-fold reduction in IC50 values 
compared with the respective mother compounds (Wezena et al., 2016). This result conforms 
to earlier findings that esterification of glutathione-derived inhibitors reduce the polarity of 
the compounds and improve their uptake (Wezena et al., 2016). Surprisingly, however, under 
the same culture conditions, esterification did not result in a faster or more potent inhibition of 
hGlo1 in uninfected erythrocytes. Assuming that esterification improves uptake, compounds 3 
and 7 appear to bind or inhibit hGlo1 less, leading to a reduction in inhibition potency of the 
compounds. The slightly higher inhibitory potency of compound 7 to hGlo1 compared to 
compound 3 can be explained by the stability of compound 7 to γ-glutamyltranspeptidase 
cleavage (More & Vince, 2009). In agreement with this possibility is the slightly lower IC50 
for compound 7 for direct growth inhibition of P. falciparum in comparison with compound 3 
(Wezena et al., 2016).  
 
 
5.3. Cytosolic glyoxalases of P. falciparum are dispensable for blood-stage 
development 
 
The cytosolic glyoxalases, PfGlo1 and PfcGlo2, of P. falciparum are dispensable during 
asexual blood-stage development and, PFGLO1 and PFcGLO2 knockout parasites are viable 
with no significant growth defects in standard culture conditions. This result is in contrast to 
results from the only previous preliminary knockout analysis of P. falciparum glyoxalases 
using pHTK vectors, which suggested that the cytosolic glyoxalases might not be deletable 
(Deponte, 2014). Western blot analysis, however, supports the accumulation of selected 
modified proteins in the 3D7Δglo1 and 3D7Δcglo2 knockout strains both under steady-state 
conditions and under bolus treatment with external glyoxal. This is in agreement with results 
from studies of the glyoxalase system in yeast, bovine endothelial cells and in Caenorhabditis 
elegans. In the yeast study, GLO1-null mutants were reported to have an increased protein 
glycation even though the mutants were viable and did not exhibit any particular growth 
defects when compared to the wild-type cells (Gomes et al., 2005; Bito et al., 1997). The 
glyoxalase system was therefore strongly suggested to play a key role in controlling the levels 
of methylglyoxal in yeasts cells (Silva et al., 2013; Inoue et al., 2011). In bovine endothelial 
cells, in vitro overexpression of hGlo1 was also reported to prevent the accumulation of AGE 
(Shinohara et al., 1998) while in C. elegans the overexpression of Glo1 decreased the 
methylglyoxal-derived modification of proteins resulting in an increase in the life span of the 
roundworm (Moros et al., 2008). It is therefore plausible to suggest that, though PFGLO1 
knockout is not immediately lethal, it could lead to downstream defects in the life cycle of the 
parasite. The fact that 3D7Δglo1 and 3D7Δcglo2 knockout strains were observed to have a 
slightly reduced (though statistically insignificant) growth rate when compared with 3D7 
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wild-type strains gives a subtle support to the above suggestion. In addition, the lack of a 
severe phenotype for the knockout clones could be due to the fact that their metabolism is 
robust. This robustness allows for enzymes in different but related metabolic pathways to 
compensate for variations in an individual enzyme’s activity without significant changes in 
flux (Silva et al., 2013). In a final conformation with the above results, a recent study in the 
rodent parasite P. berghei, also revealed that PBGLO1 (PBANKA_0933900) is dispensable 
and that knockout parasites have no growth defect (Bushell et al., 2017). Notably, however, 
an approximately 10% Glo1 activity was surprisingly recorded in the purified PFGLO1 
knockout strains. This residual activity might either originate from a non-canonical parasite 
enzyme or from the hGlo1 enzyme that has been taken up. The possibility that the residual 
Glo1 activity may be sufficient to prevent the lethal effects of PFGLO1 disruption, and 
therefore the presentation of a strong knockout phenotype is plausible. In the same scenario, 
the approximately 30% residual Glo2 activity recorded in purified PFcGLO2 knockout strains 
may be sufficient to prevent the lethal effects of the PFcGLO2 knockout event. A single IC50 
experiment with the Glo1 inhibitors, compound 3 and 7, for the 3D7Δglo1 and 3D7Δcglo2 
knockout strains  showed very similar IC50 values compared to wild-type parasites (data not 
shown). These results are in contrast to the possibility that hGlo1 is taken up by the parasite 
and may compensate for the loss of PFGLO1 in the 3D7Δglo1 knockout strains. If hGlo1 
were taken up, the expectation would have been altered IC50 values for the knockout strain 
because the inhibitors can also slowly inactivate the human enzyme (Wezena et al., 2016). 
With regards to PfGlo1, the dispensability of the enzyme for parasite survival may also 
explain the high IC50 values for tight-binding Glo1-inhibitors in previous cell culture 
experiments in contrast to low nanomolar inhibition constants against recombinant PfGlo1 
(Urscher et al., 2012; Wezena et al., 2016). A plausible explanation to these varying inhibitor 
outcomes is that, killing of parasites at micromolar instead of nanomolar inhibitor 
concentrations may be due to off-target effects. Concerning the dispensability of PFcGLO2 
for the blood-stage parasite development, it may be necessary to eliminate the residual 
enzyme activity recorded in the 3D7Δcglo2 knockout strains before a defective phenotype is 
observed. This feat can only be achieved by also deleting the PFtGLO2 and/or inactivating 
hGlo2 in the 3D7Δcglo2 knockout strains. In this case, a workable PfcGlo2 inhibitor will then 
also have to target not only PfcGlo2 but also PftGlo2 and/or hGlo2 to be effective. The results 
also revealed a considerable increased Glo1 activity in the 3D7cglo2 parasites in comparison 
with that of the wild-type. Though the change is statistically insignificant, it may be explained 
by an up-regulation of the Glo1 gene in the 3D7cglo2 parasites.  
A significant phenotypic difference between the wild-type and glyoxalase knockout parasites 
was observed for 3D7Δglo1 knockout parasites that were treated with external glyoxal. The 
3D7Δglo1 knockout strains were more sensitive to external glyoxal treatment than the 
3D7Δcglo2 knockout and wild-type strains. A clear relation between reduced Glo1 activity 
and susceptibility to glyoxal in the PFGLO1 knockout strains suggests that PfGlo1 plays an 
important physiological role in the parasite’s response to glyoxal. No significant differences 
in susceptibility to external methylglyoxal or phenylglyoxal were, however, observed between 
both knockout strains and the wild-type parasites. The variant levels of susceptibility 
displayed by the parasites towards the different 2-oxoaldehydes might be explained by either 
different kinetics for the transport of glyoxal, methylglyoxal and phenylglyoxal across the 
three membranes that surround the parasite cytosol or by different glyoxalase efficiencies of 
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the host-parasite unit regarding the conversion of these 2-oxoaldehydes. It would thus appear 
that glyoxal enters the unit with more ease than the other oxoaldehydes or is better converted 
than methylglyoxal and phenylglyoxal.  A third explanation could be that other enzymes of 
the host-parasite unit, such as 2-oxoaldehyde reductases or dehydrogenases, are able to 
metabolize methylglyoxal and phenylglyoxal but not glyoxal with sufficient efficiencies in 
the knockout strains. 
 
 
5.4. Loss of PFcGLO2 in the asexual blood stages increased gametocytogenesis 
 
Interestingly, the loss of PFcGLO2 in the asexual blood stages resulted in increased 
gametocyte formation.  As mentioned above, commitment to gametocytogenesis is believed 
to take place at some point before erythrocytic schizogony, when individual schizonts 
produce merozoites that develop into gametocytes after invasion of red blood cells (Bruce et 
al., 1990; Smith et al., 2000.). Results from recent studies have implicated a number of P. 
falciparum proteins in the switch between asexual blood-stage replication and gametocyte 
formation. These proteins, including P. falciparum heterochromatin protein 1 and histone 
deacetylase 2, as well as down-stream transcription factors such as Ap2G, were shown to 
epigenetically regulate the process of gametocytogenesis in P. falciparum (Kafsack et al., 
2014; A. Sinha et al., 2014; Coleman et al., 2014; Brancucci et al., 2014). A variety of 
internal and external stress factors such as high parasitemia, anemia, host immune response or 
drug treatment are also shown to influence the commitment of merozoites to gametocyte 
formation (Brancucci et al., 2014; Smalley & Brown, 1981; Schneweis et al., 1991; Trager & 
Gill, 1992; Lingnau et al., 1993; Puta & Manyando, 1997; Talman et al., 2004). S-D-
lactoylglutathione, the product of PfGlo1 catalysis which will accumulate in the parasite 
cytosol in the absence of PFcGLO2 may be the newest addition to parasite compounds that 
contribute to gametocytogenesis. Lack of functional PFGLO1, however, did not trigger 
gametocyte commitment. It is therefore plausible to speculate that the accumulation of S-D-
lactoylglutathione or another thioester substrate of PfcGlo2 (Vander Jagt et al., 1990; Urscher 
& Deponte, 2009; Urscher et al., 2011) might have caused the induction of gametocyte 
commitment. S-D-lactoylglutathione has earlier been associated with the control of 
microtubule length in human neutrophils (Thornally & Bellavite, 1987) and microtubule 
assembly (Clellan & Thornalley, 1993). Whether this control has a functional or structural 
link to gametocytogenesis is yet to be investigated. Also, altered S-D-lactoylglutathione 
concentrations were previously reported to activate E. coli potassium channels that share 
properties with cation-translocating channels in eukaryotes (Ferguson et al., 1993; Ozyama et 
al., 2010; Roosild et al., 2010). Furthermore, altered S-D-lactoylglutathione concentrations 
might also affect the uptake of glutathione into organelles as previously reported for isolated 
rat liver mitochondria (Armeni et al., 2014). Whether similar S-D-lactoylglutathione-
dependent mechanisms play a role in gametocyte commitment in P. falciparum remains to be 
studied. 
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5.5. Disruption of PftGlo2 and PfGILP genes is challenging 
 
Successful disruption of the genes encoding the cytosolic glyoxalases using the CRISPR-Cas9 
strategy confirms the robustness of this new system for genome editing in P. falciparum. It 
also exemplifies the fact that negative results from knockout attempts using traditional 
strategies in P. falciparum are difficult to interpret because of methodological limitations 
even when positive and negative selections are applied (Duraisingh et al., 2002). With this 
new strategy, some of the limitations of traditional knockout strategies as well as the peculiar 
bottle-necks presented by the P. falciparum genome (Duraisingh et al., 2002; Cowman & 
Crabb, 2005) can be overcome by the targeted introduction of DNA double-strand breaks. 
Nevertheless, four attempts to disrupt PFtGLO2 and PFGILP genes using the same CRISPR-
Cas9 system failed. It was not possible to generate 3D7Δtglo2 and 3D7Δgilp knockout 
parasites even though transfectants with resistance to both positive and negative selection 
were acquired. The most probable explanation for this outcome is off-target or unwanted 
integration of the positive selectable marker into the parasite genome. One limitation of the 
current CRIPR-Cas9 system is the use of a circular plasmid vector to deliver the homologous 
regions for double recombination. The risk associated with this limitation is the possibility of 
unwanted insertion into the genome via single crossover events (Duraisingh et al., 2002). 
Additionally, a non-specific guide sequence or the effects of the extremely AT-rich homology 
regions for PFtGLO2 and PFGILP loci are possible causes of unwanted integration.  
Methodological limitations are therefore the most probable cause of the negative outcome of 
these knockout attempts rather than essential roles of both genes. A recent study in the rodent 
parasite P. berghei, which revealed that the homologue PBtGLO2 (PBANKA_0604400) is 
dispensable and that knockout parasites have no growth defect, supports this explanation 
(Bushell et al., 2017). Going forward, the use of a linear template DNA (Crawford et al., 
2017; Ghorbal et al., 2014), which is not only acquired without cloning steps, but also avoids 
the need for negative selection may enable the disruption of the PFtGLO2 and PFGILP 
genes. The use of a linear DNA template will circumvent the episomal maintenance of 
plasmid DNA and therefore reduces the chances of off-target effects of genome-editing 
(Crawford et al., 2017). 
 
 
5.6. Standard redox agents inhibit the growth of P. falciparum in cell culture 
 
For many years, the generation of oxidative stress has been widely suggested to play an 
important role in the survival or clearance of the malaria parasite during human infection 
(Becker et al., 2004; Jortzik & Becker, 2012; Goyal et al., 2012). One of several hypotheses 
on oxidative stress and malaria is that an impaired production of external reactive oxygen 
species by host immune mechanisms in response to infection might exacerbate malaria 
infections (Becker et al., 2004; Sorci & Faivre, 2009; Clark & Hunt, 1983; Descamps-latscha 
et al., 1987; Greve et al., 1999). However, a problematic aspect of this hypothesis is that the 
host-parasite unit is packed with numerous redox enzymes such as hydroperoxidases that are 
very efficient in reducing and neutralizing H2O2 to water (Staudacher et al., 2015; Jortzik & 
Becker, 2012;  Koncarevic et al., 2009; Low et al., 2008). In addition, some redox agents such 
as the hydroxyl radical are too reactive to diffuse across several membranes or only do so in 
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limited amounts (Bienert et al., 2006; Almasalmeh et al., 2014). The very high IC50 value for 
H2O2 (~78 mM) for the P. falciparum 3D7 wild-type strain recorded in this thesis indeed 
suggests that little external H2O2 reaches the parasite to generate more detrimental redox 
species such as the hydroxyl radical in situ. Similar findings were made when 
supraphysiological doses of the strong oxidants peroxynitrite and nitric oxide were used to 
treat the mouse malaria parasite P. berghei. The results in the latter study revealed that mice 
injected with treated inoculum exhibited similar parasitemia and showed no difference in 
disease developmet compared with the control. The reasons assigned to this finding were that 
haemoglobin or other intrinsic parasite defence systems protect the parasite from external 
oxidative stress (Sobolewski et al., 2005). It is important to note, however, that the thesis IC50 
value for H2O2 was determined 72 h after a single bolus treatment. Challenging the cultures 
continuously with H2O2 might significantly alter the outcome as demonstrated previously for 
human embryonic kidney 293 cells (Sobotta et al., 2013). Furthermore, prolonged growth 
assays might also result in detrimental developmental effects for subsequent cell cycles even 
at lower H2O2 concentrations. Changing the culture or growth conditions such as oscillating 
CO2 and O2 partial pressures or replacing albumax with human serum might also influence 
the IC50 value. Earlier experiments performed by Verena Staudacher revealed that the IC50 
value for tBOOH for the 3D7 strain of P. falciparum was much lower at approximately 81.1 
µM (Wezena et al., 2017). A second study with the mouse parasite Plasmodium vinckei also 
revealed that intravenous injection of tBOOH resulted in iron-dependent hemolysis and rapid 
parasite death in vivo (Clark et al., 1984). In the P. vinckei study, free radical species 
generated as a result of the dissociation of tBOOH were suggested to cause hemolysis, lipid 
peroxidation and parasite death (Clark et al., 1984). Comparatively, the hydroperoxidase 
system of the host-parasite unit therefore seems to be much more robust against oxidative 
challenges with H2O2 than it is towards tBOOH. The inability of host catalase to reduce alkyl 
hydroperoxides might be one explanation for this situation. Another explanation for the 
higher susceptibility of P. falciparum to tBOOH compared with H2O2 might be that tBOOH is 
transported more rapidly and successfully across the erythrocyte, parasitophorous vacuole and 
parasite membranes and into the parasite cytosol. 
Ascorbic acid is a compound required by almost all vertebrate species on a daily basis in 
relatively large amounts and it is known to play vital roles including acting as an antioxidant 
in these organisms (Meister, 1994; Drouin et al., 2011). In the chloroplasts of photosynthetic 
organisms, ascorbic acid also plays, among others, a vital role of protecting against 
photoinhibition by helping detoxify reactive oxygen species such as singlet molecular oxgen 
(1O2) formed during the process of photosynthesis (Talla et al., 2011; Sano et al., 2001). Since 
malaria parasites infect vertebrates and harbor an apicoplast of algal origin (Janouškovec et 
al., 2010; Dooren & Striepen, 2013), the effect of ascorbate on the growth of P. falciparum 
was also investigated in this thesis. Previous studies have shown that ascorbate exhibits stage- 
and host-dependent growth-promoting as well as antiproliferative effects on the development 
of P. falciparum at extremely high concentrations (Marva et al., 1989; Soh et al., 2012). In 
the above study, in vitro ring-form development was promoted as ascorbate routinely acts as 
an antioxidant (Marva et al., 1989). During the trophozoite- and schizont-stages, however, 
ascorbate, probably acting as a potent prooxidant, was shown to suppress the parasite 
development (Marva et al., 1989). Results from other studies have reported inverse 
correlations between serum ascorbate concentrations and malaria for infected and uninfected 
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adults and children (Hassan et al., 2004; Venkatesh & Swamy, 2010; Onyesom et al., 2010). 
In this thesis, a 4.3 mM IC50 value for ascorbate was recorded for the P. falciparum 3D7 wild-
type strain. This value is similar to the value of 3.0 mM for the Dd2 strain that was 
determined earlier in the laboratory by Johannes Krafczyk (Wezena et al., 2017) and also in 
good agreement with a reported IC50 value of around 5.0 ± 0.7 mM for the D6 strain using a 
hypoxanthine incorporation assay (Winter et al., 1997). These values together indicate that 
physiological ascorbate concentrations, which are around 50 µM (Moeslinger et al., 1995 ), 
do not play a role for the growth or control of P. falciparum. One case supporting this 
conclusion is the fact that RPMI medium for parasite culture does not contain ascorbate, 
although trace amounts of ascorbate may remain within the washed erythrocytes used for 
growing parasites. Secondly, gene searches in PlasmoDB (Aurrecoechea et al., 2009) did not 
reveal any candidates that encode ascorbate-metabolizing enzymes such as 
monodehydroascorbate reductase (Müller & Kappes, 2007). Third, results from this thesis 
showed that a continuous treatment of P. falciparum standard cultures with physiological 
ascorbate concentrations of 50 µM did not affect parasite growth and development (Figure 4.9 
E). Therefore, if ascorbate were to really influence the development of the malaria parasite, 
the mode of action either relies on non-erythrocyte host cells or requires additional factors 
that are absent in the standard culture medium.  
In vivo experiments in Drosophila previously demonstrated that 6.1 mM NAc exhibits pro-
oxidative effects in some tissues by increasing the concentration of mitochondrial H2O2 and 
oxidized glutathione (GSSG) (Albrecht et al., 2011). In a different study in P. falciparum, 
treatment of parasite cultures with 0.9 µM and 0.9 mM concentrations of NAc alone had no 
effects on parasite development (Arreesrisom et al., 2007; Soh et al., 2012). In this thesis, the 
IC50 values for NAc were around 17 mM for the 3D7 strain which are similar to a previously 
recorded value of 12 mM for the Dd2 strain (Wezena et al., 2017). These results explain the 
lack of effects of NAc in the previous P. falciparum studies as the concentrations tested were 
much lower than the IC50 value recorded in the results of this thesis. Concerning DTT, a 
previous study reported that concentrations of between 12.5-200 µM enhanced the growth of 
the chloroquine-sensitive FC27 strain of P. falciparum with the optimum growth occurring at 
12.5 µM (Senok et al., 1997). Compared with the DTT IC50 value of 245 µM for the 3D7 
strain in this thesis and an earlier result of 389 µM for the Dd2 strain (Wezena et al., 2017), it 
would appear that lower concentrations of DTT promote parasite growth while higher 
concentrations may have antiproliferating effects on the parasites. The results also show that 
P. falciparum 3D7 strain is more sensitive to DTT than to NAc and ascorbate. In comparison 
to previous laboratory results (Wezena et al., 2017) for the chloroquine resistant Dd2 strain, 
the 3D7 strain also appears to be a little more sensitive to DTT. Generally, the antioxidants 
ascorbate, NAc and DTT all appear to exhibit non-physiological antiproliferative instead of 
growth-promoting effects to the parasite. One plausible reason for these results might be that 
these so-called antioxidants provide electrons for the Fenton reaction within the host-parasite 
system. Ascorbate, for instance, can reduce Fe (III) to Fe (II), which can then reduce H2O2 
through the Fenton reaction to OH- and a hydroxyl radical. Thus, these compounds acting as 
electron donors, might actually serve as pro-oxidants as suggested previously for ascorbate 
(Marva et al., 1989; Marva et al., 1992). Beside the detrimental Fenton reactions, ascorbate, 
NAc and DTT might also act as electron donors for the reduction of crucial disulfide bonds in 
important cellular proteins. Proteins such as albumin are vital in the host-parasite unit and are 
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actually imported into the parasite from the erythrocyte cytosol (Tahir et al., 2003). To the 
parasite, albumin is important for growth and differentiation (Tahir et al., 2003) and the 
reducted disulfide bonds in the protein might have an indirect antiproliferative effect. In 
addition, the reduction of important erythrocyte or merozoite surface proteins might directly 
alter the invasion efficiency and affect parasite proliferation. To better detect effects of 
surface protein reduction by antiproliferating agents, the use of asynchronous parasite cultures 
or the use of prolonged growth assays is more ideal. The SYBR green assay employed in this 
project does not discriminate between the DNA of growth-arrested schizonts, extracellular 
merozoites or successfully invaded merozoites. In conclusion, the results from this project 
revealed that the host-parasite unit is extremely robust towards redox challenges by H2O2, 
NAc and ascorbate, whereas a micromolar IC50 value was determined for DTT. The 
mechanisms underlying these results were not investigated in this thesis and remain to be 
unravelled. In addition, note should be taken of the background fluorescence due to gelation 
of the medium and hemolysis when studying standard reducing agents using a SYBR green 
assay. This increased fluorescence has to be taken into account when determining IC50 values. 
 
 
5.7. Conclusion 
 
For almost three decades, the glyoxalase system has gained interest as a possible target for 
antimalarial drug therapy. Results from this thesis have not only shown clearly that the two 
cytosolic glyoxalase enzymes of P. falciparum are not essential for blood-stage development 
of the parasite but also that these enzymes may not be suitable targets for the development of 
antimalarial drugs. Even though the lack of PFGLO1 increases the susceptibility of the 
parasite to the 2-oxoaldehyde glyoxal, the 3D7Δglo1 and 3D7Δcglo2 knockout parasites are 
viable with no significant morphological or growth defects.  Surprisingly, however, the results 
also show that the lack of PFcGLO2, which should result in the accumulation of S-D-
lactyoglutathione in the parasite, leads to an increase in gametocytogenesis and might actually 
contribute to the transmission of the parasite. These results again raise questions concerning 
the actual function of the glyoxalase system in the cells. The thesis also generated results that 
suggest that hGlo2 of the host-erythrocyte does not contribute to the survival of P. falciparum 
parasites at the blood-stage of development. Finally, the results from this thesis indicate that 
external H2O2 is not a strong oxidizing agent for P. falciparum parasites in culture compared 
with tBOOH. The results also show that the prooxidant H2O2 and so-called antioxidants 
ascorbate, NAc and DTT, all inhibit growth of P. falciparum in cell culture. While the host-
parasite unit is more tolerant to high levels of H2O2, ascorbate and NAc, it is more susceptible 
to DTT. 
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